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Abstract		 After	Theodor	Schwann	formulated	the	first	cell	theory	in	1839,	another	60	years	of	 histological	 advances	 passed	 by	 before	 mitochondria	 were	 discovered	 and	 the	name	 was	 phrased.	 Yet,	 120	 years	 later,	 many	 aspects	 of	 mitochondrial	 biology	remain	enigmatic	and	mitochondria	emerged	as	fundamental	organelles	of	almost	all	eukaryotes	far	beyond	the	role	as	the	powerhouses	of	the	cell.	To	 contribute	 to	 the	 continuously	 growing	 understanding	 of	 these	 multifaceted	organelles,	 the	 roles	 of	 succinate	 dehydrogenase	 subunit	 A	 (SDHA)	 and	 ATP-dependent	 Clp	 protease	 (ClpXP)	 in	 mitochondrial	 metabolism	 and	 proteostasis,	respectively,	were	investigated	in	vivo	and	in	vitro.	Conditional	 knockout	 of	 SDHA	 in	 the	 heart	 and	 striated	 muscles	 caused	 isolated	complex	II	deficiency	and	ultimately	organ	failure.	However,	metabolic	differences	of	these	 tissues	 result	 in	 varying	 adaptations	 and	 stress	 responses.	 This	 finding	emphasizes	the	significance	of	the	metabolic	background,	even	if	the	primary	defect	is	ATP	depletion.	This	is	particularly	important	for	the	treatment	of	malignant	cells	with	 SDH	 mutations,	 as	 the	 affected	 cell	 types	 can	 differ	 in	 terms	 of	 metabolic	adaptations.	In	 order	 to	 understand	 the	 role	 of	 ClpXP	 in	 mitochondrial	 proteostasis,	 diverse	proteomic	approaches	were	employed	to	 identify	novel	ClpXP	targets	as	well	as	 to	address	 the	 mode	 of	 degradation	 and	 potentially	 tissue-specific	 activity.	 The	combination	 of	 a	 classical	 in	 vitro	 substrate	 screen	 and	 the	 recently	 developed	N-terminome	quantification	identified	or	confirmed	several	bona	fide	ClpXP	substrates	and	 a	 clear	 preference	 for	 arginine	 at	 the	 P1	 position	 of	 the	 cleavage	 site.	Furthermore,	the	development	of	an	in	vivo	model	for	the	conditional	expression	of	CLPP	 in	mouse	hearts	 provided	 the	proof	 of	 principle	 for	 tissue	 specific	 substrate	screens	and	confirmed	CLPX	as	the	rate-limiting	subunit	in	vivo.		 	
			 	 	 XIV	
Zusammenfassung		 Nachdem	 Theodor	 Schwann	 die	 erste	 Zelltheorie	 im	 Jahr	 1839	 formulierte,	benötigte	 es	 weitere	 60	 Jahre	 mit	 zahlriechen	 histologischen	 Fortschritten,	 bevor	Mitochondrien	entdeckt	und	ihr	Name	geprägt	wurde.	Erstaunlicherweise	verbleiben	120	 Jahre	 später	 viele	 ihrer	 Aspekte	 rätselhaft,	 während	 sie	 sich	 als	 elementare	Organellen	für	fast	alle	Organismen	etablierten,	die	weit	mehr	als	nur	die	Kraftwerke	der	Zellen	repräsentieren.		Um	zu	dem	wachsenden	Verständnis	dieser	faszinierenden	Organellen	beizutragen,	wurde	die	Rolle	der	Succinat-Dehydrogenase	Untereinheit	A	 (SDHA)	und	der	ATP-abhängigen	 Clp	 Protease	 ClpXP	 im	 mitochondriellen	 Metabolismus	 bzw.	 in	 der	Proteostase	in	vivo	und	in	vitro	analysiert.	Dabei	stellte	sich	heraus,	dass	der	konditionelle	knockout	von	SDHA	im	Herzen	und	in	 der	 Skelettmuskulatur	 eine	 isolierte	 Komplex	 II	 Insuffizienz	 und	 letztlich	Organversagen	 auslöste.	 Allerdings	 führten	 metabolische	 Unterschiede	 dieser	Gewebe	zu	abweichenden	Adaptionen	und	Stressantworten.	Dieses	Ergebnis	betont	somit	die	Bedeutung	des	metabolischen	Hintergrunds,	auch	wenn	der	primäre	Defekt	ATP	Verlust	lautet.	Dies	ist	gerade	für	die	Behandlung	von	bösartigen	Zellen	mit	SDH	Mutationen	 von	 großer	 Bedeutung,	 da	 diese	 in	 ihren	 metabolischen	 Grundlagen	variieren	können.	Um	die	Rolle	der	ClpXP	Protease	 in	der	Proteostase	der	mitochondriellen	Proteine	besser	 zu	 verstehen,	 wurden	 diverse	 proteomische	 Ansätze	 verfolgt,	 die	 der	Identifizierung	neuer	ClpXP	Substrate,	einem	möglichen	Degradierungsmodus,	sowie	einer	 eventuellen	 Gewebespezifität	 dienen.	 Die	 Kombination	 eines	 klassischen	„Substrat-screens“	 und	 der	 kürzlich	 entwickelten	 N-Terminom	 Quantifizierung	identifizierte	oder	bestätigte	mehrere	bisher	unbekannte	ClpXP	Substrate	und	zeigte	eine	 klare	 Prävalenz	 für	 Arginin	 an	 der	 P1	 Position	 des	 Hydrolysefensters.	 Des	Weiteren	 eröffnet	 die	 Entwicklung	 eines	 Mausmodels	 für	 die	 konditionelle	Expression	von	CLPP	die	Möglichkeit	von	gewebespezifischen	Substrat-screens	und	bestätigt	die	limitierende	Rolle	von	CLPX	in	vivo.
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1 Introduction	
1.1 Succinate	dehydrogenase	and	metabolism	in	skeletal	muscles	
1.1.1 Skeletal	muscles	Skeletal	muscles	 are	 the	 sum	 of	 hundreds	 of	 individual	muscles	within	 the	human	body	and	make	up	about	40%	of	the	total	body	weight.	In	contrast	to	smooth-	or	 cardiac	 muscles,	 skeletal	 muscles	 are	 voluntarily	 controlled	 and	 harbour	 the	largest	protein	reservoir	of	the	human	body	with	a	protein	content	of	more	than	50%,	most	of	which	are	part	of	the	force-generating,	contractile	network.		Striated	 muscles	 are	 dynamic	 tissues	 with	 profound	 metabolic	 and	 structural	plasticity	that	facilitate	movement	and	posture,	but	also	serve	as	a	metabolic	storage	hub	 for	 other	 tissues	 and	 largely	maintain	 the	 core	 temperature	 of	 adult	 humans	(Wolfe	2006),	 indicating	 their	usefulness	 for	 studies	 involving	metabolism,	 energy	and	systemic	regulation	of	thereof.			
1.1.2 Skeletal	muscle	synthesis,	composition	and	basic	function	Early	 during	 development,	 mesoderm-derived	 somites	 differentiate	 into	skeletal	muscle	progenitor	cells	(myoblasts),	that	express	stem	cell	markers	(Pax3/7)	but	also	the	first	muscle	specific	genes	such	as	Myf5	and	MyoD.	These	fetal	progenitors	further	develop	into	myocytes	that	express	Acta1,	as	one	of	the	earliest	markers	for	committed	 skeletal	 muscle	 cells	 and	 are	 morphologically	 distinguishable	 through	their	 striated	 appearance.	 Adult	muscle	 cells	 (myofibers)	 are	multi-nucleated	 and	elongated	fibres	that	develop	neonatally	through	the	fusion	of	myocytes	or	through	migration	and	fusion	of	muscle	stem	cells	(satellite	cells)	with	existing	muscle	fibres.	These	 secondary	 fibres	 grow	 mostly	 through	 fusion	 with	 myoblasts,	 but	 stay	relatively	constant	in	numbers	after	birth	(Chal	and	Pourquie	2017).		Adult	muscle	fibres	can	reach	lengths	of	up	to	1cm	in	humans	and	consist	of	thousands	of	myofibrils,	the	structural	unit	of	muscle	cells,	which	themselves	contain	billions	of	muscle	 filaments.	 The	 filaments	 are	 composed	 of	 thin	 (actin)	 and	 thick	 (myosin)	elements	 that	 form	cross-bridges	 to	build	sarcomeres	and	can	contract	 the	muscle	fibres	 through	 ATP-dependent	 displacement	 of	 the	 myosin	 heads	 along	 the	 actin	filaments	(Figure	1.1).	These	contractions	occur	in	parallel	within	the	fibres	of	each	fibre	 bundle	within	 a	muscle.	 The	 fibre	 bundles,	 as	well	 as	 the	 entire	muscles	 are	
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engulfed	 by	 connective	 tissue	 called	 the	 perimysium	and	 epimysium,	 respectively,	that	 prevent	 friction	damage	during	 contractions	 (Figure	1.1).	 In	 order	 to	provide	oxygen,	nutrients	and	neuronal	stimuli	to	all	sarcomere	units	within	a	fibre,	the	cell	membrane	 (sarcolemma)	 protrudes	 into	 the	 fibres	 as	 long	 invaginations,	 or	 T	(transverse)	tubules	(Frontera	and	Ochala	2015).			
	
Figure	1.1	Structure	of	skeletal	muscles	Skeletal	muscle	 tissues	consist	of	millions	of	muscle	cells	(muscle	 fibres)	 that	are	arranged	 in	 fibre	bundles	 to	 build	 a	 muscle.	 Each	 fibre	 further	 consists	 of	 numerous	 myofibrils	 that	 are	 made	 of	sarcomeres,	 the	 contractile	 units.	 The	 cell	 membrane	 of	 a	 muscle	 fibre	 (sarcolemma)	 shows	invaginations	(T-tubules),	which	are	 in	close	contact	with	 the	sarcoplasmic	reticulum.	Figure	 taken	unmodified	from	(Listrat	et	al.	2016).		During	 a	motor	neuron	 stimulus,	 the	 arrival	 of	 an	 action	potential	 at	 the	T	 tubule	triggers	 voltage-dependent	 channels	 (RYR)	 at	 the	 terminal	 cisternae	 of	 the	sarcoplasmic	 reticulum	 (SR)	 to	 release	 calcium,	which	 is	normally	kept	 at	 a	nano-molar	concentration	within	 the	cell	 (Lanner	et	al.	2010).	The	released	calcium	can	then	bind	to	and	shift	 troponin	at	 the	actin	 filaments,	allowing	 for	myosin	 to	bind,	form	cross-bridges	and	slide	along	the	actin	filament.	The	release	of	myosin	from	actin	to	 repeat	 the	 process	 requires	 ATP	 and	 can	 reach	 up	 to	 80%	 of	 the	 total	 energy	demand	within	the	muscle	during	full	contraction	(Barclay	et	al.	2007).	Historically,	 the	 first	 classification	 of	 muscle	 fibre	 types	 regarded	 the	 colour	 of	muscles	or	 individual	 fibres.	 Strongly	 innervated	muscles	 contain	more	myoglobin	and	therefore	appear	morphologically	red,	while	less	innervated	muscles	are	pale	or	white.	Later,	physiological	experiments	with	isolated	muscles	and	fibres	marked	the	categories	fast-	and	slow	twitching	fibres,	as	well	as	their	resistance	towards	fatigue.	
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While	the	velocity	of	contraction	largely	correlates	with	the	development	of	the	SR	and	 its	 surface	 area/volume,	 the	 resistance	 towards	 fatigue	 of	 a	 fibre	 is	 mainly	determined	by	its	mitochondrial	content,	visualised	by	e.g.	succinate	dehydrogenase	(SDH)	 activity.	 The	 development	 of	 monoclonal	 antibodies	 against	 myosin	 heavy	chain	isoforms	finally	led	to	the	categorization	that	is	still	widely	used	today	(Figure	1.2):	 Type	 I	 slow	 twitching,	 highly	 oxidative	 fibres	 rich	 in	 mitochondria	 and	myoglobin,	as	well	as	fast	twitch,	oxidative/glycolytic	type	2A	fibres	and	fast	twitch,	glycolytic	type	2B	fibres	with	highly	developed	SR	structures.	Additionally,	muscles	possess	 type	2X	 fibres	with	properties	 intermediate	between	 type	2A	and	 type	2B	fibres	(Schiaffino	and	Reggiani	2011).	Notably,	type	2B	isoforms	are	not	expressed	in	human	muscles	and	result	from	miss-annotated	type	2X	fibres	(Smerdu	et	al.	1994).			
	
Figure	1.2	Different	fibre	types	expressed	in	mouse	muscles	Mouse	muscles	express	fibre	types	with	varying	amounts	of	fatigue	resistance	and	contraction	speeds	with	 type	1	 fibres	being	 the	 slowest	 and	most	 resistant	 fibres	and	 type	2B	 fibres	being	 the	 fastest	twitching	fibres	with	the	lowest	resistance	towards	fatigue.	Type	2A	and	2X	fibres	have	properties	in	between	the	other	two	types.		Most	 muscles,	 like	 for	 example	 the	 hind	 lib	 muscles,	 need	 to	 fulfil	 long-lasting	functions	such	as	posture	maintenance,	as	well	as	short,	high	intensity	movements	like	jumping.	These	muscles	therefore	have	a	heterogeneous	composition	of	oxidative	and	 glycolytic	 fibre	 types.	 Other,	 more	 specialised	 muscles	 such	 as	 the	 extensor	digitorum	 longus	 (EDL)	 and	 the	 soleus	 muscle	 contain	 almost	 exclusively	 fast	twitching-	and	slow	twitching	fibre	types,	respectively.	However,	fatigue	resistance	and	therefore	mitochondrial	content	can	vary	greatly	between	fibres	of	these	muscles	(Schiaffino	 et	 al.	 1970).	 Similar	 to	 these	 mechanical	 and	 metabolic	 properties,	different	 fibre	 types	 have	 contact	 to	 distinct	 motor	 neurons	 and	 have	 unique	responses	 towards	 electrical	 stimuli.	 Among	 major	 differences	 in	 ion	 channel	
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composition,	 the	 high	density	 of	Na+	 channels	 e.g.	 allows	 for	 the	 response	 to	 high	discharge	rates	in	fast	twitching	fibres,	to	generate	high-intensity,	albeit	short-term	force.			
1.1.3 Regulation	of	(energy-)	metabolism	in	skeletal	muscles	With	 great	 variability	 of	 mammalian	 muscles	 and	 muscle	 fibres	 comes	profound	 plasticity	 in	 terms	 of	 metabolism	 and	 energy	 homeostasis.	 However,	 a	number	of	factors	remain	in	common	for	all	fibre	types	and	are	in	stark	contrast	to	other	tissues.	Despite	skeletal	muscle’s	role	in	amino	acid	storage	and	supply,	amino	acids	only	play	a	minor	role	in	ATP	production	and	energy	homeostasis,	even	during	intense	exercise	(Lemon	and	Mullin	1980).	Similarly,	although	an	important	function	of	glycogen	in	muscle	function	and	fatigue	is	undisputed,	this	is	probably	independent	of	its	utility	as	an	energy	source	(Ortenblad	et	al.	2013).	Rather,	glycogen	has	a	non-metabolic	function	and	serves	as	an	important	factor	in	calcium	release	from	the	SR	and	fibre	contraction	(Ortenblad	et	al.	2011).	This	proposal	is	further	substantiated	by	the	fact	that	distinct	glycogen	granules	can	be	observed	close	to	the	SR	(Nielsen	and	 Ortenblad	 2013)	 and	 that	 muscle	 glycogen	 stores	 are	 not	 depleted	 during	overnight	fasting	like	hepatic	glycogen	stores	(Hearris	et	al.	2018).	At	rest	and	during	prolonged	exercise,	the	preferred	substrates	for	ATP	production	in	muscles	are	fatty	acids	 (Romijn	 et	 al.	 1993),	 however,	 short-term	 and	 intense	 exercise	 additionally	requires	the	oxidation	of	carbohydrates	(mainly	glucose).	Therefore,	glucose	uptake	is	strongly	increased	during	such	activities	and	can	reach	50-times	the	uptake	at	rest	(Katz	et	al.	1986).	Skeletal	muscles	 are	 already	 highly	 energy-demanding	 at	 rest	 (10cal/d/g	muscle)	(Wolfe	 2006)	 and	 even	 more	 so	 during	 activity.	 However,	 resting	 ATP	 levels	 are	comparably	 low	 at	 ~	 5-6mM	 and	 would	 be	 completely	 hydrolysed	 within	 a	 few	seconds	(Sahlin	et	al.	1998).	Yet,	during	exercise	with	moderate	intensity,	ATP	levels	remain	constant	due	to	the	breakdown	of	phosphocreatine	(PCr)	(Allen	et	al.	1997).	At	rest,	mitochondrial	and	cytosolic	creatine	kinase	use	ATP	produced	by	oxidative	phosphorylation	 and	 glycolysis,	 respectively,	 to	 phosphorylate	 creatine.	 The	 PCr	generated	serves	as	a	temporal	and	spatial	buffer	for	ATP	turnover	(Sweeney	1994),	as	PCr	diffuses	faster	than	ATP	(Hubley	et	al.	1995)	and	creatine	kinases	are	located	at	 the	 sites	 of	 high	 energy	 demand.	 Furthermore,	 PCr	 is	 believed	 to	 attenuate	
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oxidative	 phosphorylation	 and	 thereby	 protecting	 mitochondria	 from	 transient	disturbances	 in	ATP	demand	(Barclay	2017).	This	buffering	can	 further	extent	 the	energy	 supply	 of	 active	 muscles	 to	 several	 minutes,	 after	 which	 only	 augmented	vascular	supply	of	oxygen	and	nutrients	can	further	extent	contractility	before	fatigue	and	exhaustion	occurs.			
1.1.4 Respiratory	chain	complexes	and	oxidative	phosphorylation	Energy-demanding	tissues	such	as	skeletal	muscles	contain	large	amounts	of	mitochondria	and	these	mitochondria	are	particularly	dense	in	respiratory	chain	(RC)	complexes	to	provide	sufficient	ATP	via	oxidative	phosphorylation	(OXPHOS).		While	 the	 respiratory	 chain	 consists	 of	 four	 complexes	 (complex	 I-IV),	 the	 ATP-synthase	that	carries	out	OXPHOS,	is	also	referred	to	as	complex	V.	The	driving	force	behind	 oxidative	 phosphorylation	 is	 a	 proton	 motive	 force	 across	 the	 inner	mitochondrial	membrane	created	by	complexes	 I,	 III	and	 IV,	which	possess	proton	pumping	 activity.	 Together	 with	 the	 mobile	 electron	 carrier	 ubiquinone	 and	cytochrome	 c,	 electrons	 from	 NADH	 are	 ultimately	 used	 to	 reduce	 O2,	 which	completes	the	respiratory	chain.	While	the	exact	nature	of	respiratory	chain	complex	interaction	is	not	finally	defined	and	may	depend	on	the	cellular	environment,	 it	 is	mostly	agreed	that	these	complexes	can	act	as	isolated	entities,	as	well	as	arrange	into	higher-order	 structures	 called	 supercomplexes	 (SC).	 The	 respirasome	 (I1III2IVn)	 is	widely	considered	to	be	the	standard	model	for	respiratory	chain	SCs,	that	stabilizes	individual	complexes	and	 improves	electron	 transfer	between	them	(Schagger	and	Pfeiffer	2000,	Acin-Perez	et	al.	2008,	Enriquez	2016,	Wu	et	al.	2016).	Complex	II	of	the	respiratory	chain	 is	omitted	 from	most	 supercomplex	models,	as	 it	 is	 typically	not	observed	in	BN-PAGE	analyses	of	mitochondrial	SCs	and	behaves	like	an	individual	complex	in	flux	control	analysis	experiments	(Bianchi	et	al.	2004).	However,	recent	near-atomical	structures	of	human	RC	complexes	suggested	a	I2III2IV2	megacomplex	in	human	mitochondria,	that	is	able	to	incorporate	complex	II	units	between	complex	I	and	IV,	resulting	in	I2II2III2IV2	complexes	(Guo	et	al.	2017).	The	authors	state	that	complex	II	can	be	modelled	within	the	gaps	of	the	structure	and	that	an	overall	low	prevalence	 might	 cause	 the	 inability	 to	 confidently	 map	 complex	 II	 into	 the	megacomplex.	 In	 addition	 to	 technical	 limitations	 due	 to	 low	 stabilities,	 biological	reasons	 could	 account	 for	 this	 observation.	 It	 is	 conceivable	 that	 complex	 II	 only	
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transiently	attaches	to	the	SCs	in	certain	tissues,	or	under	circumstances	that	require	amplified	succinate	oxidation.	Further,	 it	 should	be	noted	 that	 the	 structure	of	 the	megacomplex	was	the	only	reported	structure	obtained	from	human	cells	(HEK293),	while	previous	structures	of	the	respirasome	were	generated	from	mammalian	heart	mitochondria	(Schafer	et	al.	2007,	Althoff	et	al.	2011,	Gu	et	al.	2016).	A	tissue-specific	arrangement	is	therefore	possible,	especially	since	liver	mitochondria	were	reported	to	have	partially	different	arrangements	that	can	include	complex	II	(Acin-Perez	et	al.	2008).	In	 skeletal	muscles,	 RC	 complexes	 also	 exist	 as	 both,	 individual	 complexes	 and	 in	higher-order	 structures,	 such	 as	 the	 respirasome.	 Although	 a	 fibre	 type-specific	difference	was	not	established	so	far,	it	is	nevertheless	plausible,	because	exercise	in	human	skeletal	muscles	results	not	only	in	an	increased	RC	subunit	amount,	but	also	in	the	preferential	assembly	into	supercomplex	structures	and	increased	respiration	(Greggio	et	al.	2017).		
1.1.5 Succinate	dehydrogenase	Torsten	 Thunberg	 is	 usually	 credited	 as	 the	 discoverer	 of	 succinate	dehydrogenase	(SDH;	complex	II)	in	1909,	when	he	measured	the	gas	exchange	in	frog	muscles	 (Thunberg	 1909,	 Hopkins	 and	Morgan	 1938)	 almost	 50	 years	 before	 the	isolation	 of	 its	 electron	 acceptor	 ubiquinone	 (Crane	 et	 al.	 1957,	 Crane	 1989).	 110	years	of	technological	and	intellectual	milestones	later,	the	structure	(Sun	et	al.	2005),	function	 and	 kinetic	 properties	 (Leger	 et	 al.	 2001)	 are	well	 described,	 but	 details	about	 the	 mechanics	 are	 still	 debated	 and	 its	 implication	 in	 human	 diseases	 is	continuously	explored	(Bezawork-Geleta	et	al.	2017).	SDH	 harbours	 several	 unique	 features	 among	 the	 RC	 complexes,	 making	 it	 a	particularly	interesting	object	to	study.	As	the	smallest	RC	complex,	SDH	consists	of	only	 four	subunits	(SDHA-D)	that	are	all	nuclear-encoded	 in	almost	all	eukaryotes.	Although	 it	 is	 the	only	complex	within	 the	respiratory	chain	 that	does	not	directly	shuttle	 protons	 across	 the	 inner	 mitochondrial	 membrane,	 it	 is	 yet	 indirectly	responsible	for	a	large	part	of	the	proton	motif	force	due	to	its	second	role	as	a	TCA	cycle	enzyme	in	the	oxidation	of	succinate.	 	
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SDH	consists	of	two	main	parts:	A	membrane	anchor	made	out	of	the	alpha-helical	subunits	C	and	D	and	attached	to	it	the	soluble	subunits	SDHB	and	SDHA.	SDHA	is	the	flavoprotein	with	catalytical	activity	 that	binds	and	oxidises	succinate	 to	 fumarate.	The	electrons	reduce	the	covalently	bound	FAD	moiety	and	are	further	transferred	through	three	 iron-sulphur	clusters	within	SDHB.	Finally,	 they	are	 transferred	at	a	heme	b	in	the	interface	between	SDHC	and	SDHD	onto	ubiquinone.		Currently,	there	are	four	assembly	factors	known,	that	are	required	for	the	assembly	and	integrity	of	functional	SDH.	SDHAF2	(Sdh5	in	yeast)	mediates	the	flavination	of	SDHA	and	its	absence	causes	loss	of	SDH	function	(Hao	et	al.	2009).	Flavination	is	the	initial	step	during	complex	assembly	and	essential	for	SDHB	binding	to	SDHA.	Certain	human	cell	types,	such	as	triple	negative	breast	cancer	cells	can	contain	flavinated	and	functional	SDH	even	when	SDHAF2	is	deleted	by	gene	editing	(Bezawork-Geleta	et	al.	2016).	However,	it	remains	unclear	whether	these	cells	express	proteins	redundant	to	 SDHAF2	 or	 flavination	 occurs	 spontaneously.	 SDHAF4	 (Sdh8)	 appears	 to	 exert	chaperone	 activity	 on	 flavinated	 SDHA	 to	 prevent	 unintended	 oxidative	 damage	before	complex	assembly	(Van	Vranken	et	al.	2014).	Similarly,	SDHAF1	and	SDHAF3	(Sdh6	and	Sdh7)	are	required	for	iron-sulphur	cluster	incorporation	into	SDHB	and	its	 shielding	 from	 oxidative	 damage	 (Na	 et	 al.	 2014).	 Mutations	 in	 any	 of	 these	assembly	 factors	 can	 lead	 to	 SDH	 dysfunction	 and	 the	 associated	 clinical	manifestations	described	later.	The	 activity	 of	 complex	 II	 is	 further	 regulated	 by	 reversible,	 post-translational	modifications:	The	tyrosine	kinase	FGR	phosphorylates	SDHA	at	two	distinct	residues,	a	process	that	is	stimulated	by	reactive	oxygen	species	(ROS)	(Salvi	et	al.	2007,	Acin-Perez	et	 al.	 2014).	A	possible	physiological	 relevance	 for	 the	phosphorylation	was	recently	shown	in	cells	lacking	complex	III	activity.	Impaired	complex	III	function	was	associated	 with	 increased	 ROS	 levels,	 which	 in	 turn	 lead	 to	 increased	 complex	 II	phosphorylation	and	activity	(Tropeano	et	al.	2018).	It	is	thus	plausible	that	reduced	respiratory	 chain	 activity	 mediates	 a	 compensatory	 activation	 of	 SDH-driven	respiration.	 SIRT3	 and	 SIRT5	 are	 mitochondrial	 sirtuins	 with	 deacetylation	 and	desuccinylation	 activity,	 respectively	 and	 loss	 of	 either	 protein	 is	 associated	with	increased	 SDH	 activity	 (Cimen	 et	 al.	 2010,	 Park	 et	 al.	 2013).	 However,	 a	 causal	relationship	between	acetylation/succinylation	of	SDH	and	its	activity	remains	to	be	established.	
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Finally,	the	mitochondrial	chaperone	TRAP1	of	the	HSP90	family	was	reported	to	bind	SDH	 and	 limit	 SDH-dependent	 respiration,	 particularly	 in	 cancer	 cell	 lines.	 This	inhibition	 was	 selective	 for	 complex	 II	 and	 independent	 of	 SDH	 protein	 levels	(Sciacovelli	et	al.	2013).	Surprisingly,	the	well-known	SDH	inhibitors	3-NPA	and	TTFA	only	 inhibited	 respiration	 in	 SAOS-2	 cells	 when	 TRAP1	 was	 down-regulated,	indicating	that	TRAP1	fully	inactivates	SDH-dependent	maximal	respiration	in	these	cells.		 	
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1.1.6 SDH	loss	of	function	models	and	clinical	manifestations	Mutations	in	any	SDH	subunit	or	its	assembly	factors	are	frequently	associated	with	hereditary	 or	 sporadic	malignancies	 (Laurenti	 and	Tennant	2016,	Bezawork-Geleta	 et	 al.	 2017,	 Gill	 2018).	 These	 include	 most	 commonly	 paraganglioma	 and	pheochromocytoma	(PGL/PHEO),	gastrointestinal	stromal	tumours	(GIST)	and	more	rarely,	 renal	 cell	 carcinomas	 (RCC)	 and	 pituitary	 adenomas	 (PA).	 Additionally,	(mostly)	familiar	germline	mutations	within	the	SDHA	gene	were	observed	in	several	patients	 with	 Leigh	 syndrome,	 which	 is	 sometimes	 accompanied	 by	 severe	cardiomyopathy	(Horvath	et	al.	2006,	Ghai	et	al.	2011).	Inactivation	of	both	alleles	of	the	 affected	 SDH	 gene	 in	 paraganglioma	 usually	 involves	 at	 least	 one	 germline	mutation	and	SDH	mutation-derived	tumours	are	most	commonly	defined	by	the	loss	of	SDHB	immunohistochemical	staining	(Gill	2018).		It	is	generally	agreed	upon	that	neoplasia	with	SDH	dysfunction	result	from	succinate	accumulation	within	the	affected	cells.	Increased	succinate	concentration	can	lead	to	the	 competitive	 inhibition	 of	 2-oxoglutarate	 (2-OG)-dependent	 dioxygenases.	With	over	60	family	members	in	humans,	these	enzymes	are	important	regulators	of	global	gene	expression	and	cellular	function.	Succinate	acts	as	a	product-inhibitor	of	3	major	classes	of	dioxygenases,	including	over	30	JMJC	histone	demethylases,	three	known	ten-eleven	 translocases	 (TETs)	 and	 two	 prolyl	 hydroxylases	 (PHDs)	 (Bezawork-Geleta	et	al.	2017,	Bargiela	et	al.	2018).	While	succinate-mediated	 inhibition	of	 the	former	 two	 classes	 causes	 hypermethylation	 of	 histones	 and	 DNA,	 respectively,	inhibition	of	PHDs	stabilizes	HIF1a	even	in	the	presence	of	oxygen	(pseudo-hypoxic	state).	This	hypoxic	state	was	recognized	early	on	as	an	important	factor	in	cancer	cell	transformation	 (Warburg	 et	 al.	 1927).	 Furthermore,	 other	 mutations	 leading	 to	HIF1a	 stabilization	 can	 also	 result	 in	 the	 formation	 of	 PGL/PHEO	 and	 GIST	 like	mutations	in	VHL	(Kang	et	al.	2016,	Rednam	et	al.	2017),	substantiating	that	it	is	of	central	importance	within	SDH-deficient	tumours.		 	
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Unfortunately,	most	of	the	research	on	SDH	deficiency	in	humans	is	limited	to	samples	from	these	patients,	as	there	is	currently	no	stable	cell	line	derived	from	PGL/PHEO	patients	(Bezawork-Geleta	et	al.	2017).	Additionally,	 the	analysis	of	mouse	models	with	SDH	deficiency	created	so	 far	was	limited	 to	 either	 neurodegeneration	 or	 specific	 tumour	 types	 and	 not	 expanded	towards	other	tissues	(Astuti	et	al.	2004,	Piruat	et	al.	2004,	Bayley	et	al.	2009,	Ishii	et	al.	2011,	Millan-Ucles	et	al.	2014,	Al	Khazal	et	al.	2019).		
1.1.7 Study	aim	Despite	the	profound	knowledge	about	succinate	dehydrogenase,	its	structure,	function	 and	 role	 in	 multiple	 diseases,	 fundamental	 aspects	 regarding	 its	 dual	function	in	vivo	remain	unknown.	Specifically,	it	is	still	unclear	how	SDH	function	is	regulated	 in	 tissues	 with	 large	 discrepancies	 regarding	 their	 ATP	 and	 metabolite	demands.	To	address	this	issue,	conditional	mouse	knockout	models	were	developed,	deleting	 SDHA	 in	 individual	 tissues.	 The	 main	 focus	 was	 set	 on	 metabolic	 and	energetic	 changes	 and	 the	 stress	 responses	 as	 the	 consequences	 thereof.	 A	 better	understanding	 of	 the	 tissue-specific	 role	 of	 SDH	 will	 ultimately	 also	 improve	 the	knowledge	 about	why	 some	 cell	 types	 are	 prone	 to	 generate	 neoplasia	 upon	 SDH	deficiency	and	how	these	could	be	targeted	in	the	future.		 	
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1.2 ClpXP	protease	and	mitochondrial	proteostasis	With	over	1000	soluble	and	membrane-bound	proteins	located	in	different	sub-compartments,	mammalian	as	well	as	yeast	mitochondria	face	the	challenge	to	ensure	the	functionality	and	correct	amount	of	their	proteome.	A	varying	demand	for	specific	proteins,	 as	well	 as	 fluctuating	 stress	 levels	 that	 can	 irreversibly	 damage	proteins	require	high	precision	and	plasticity	of	 the	quality	 control	 and	 regulatory	 systems	within	mitochondria.			
1.2.1 Mitochondrial	quality	control	and	mitochondrial	proteases	Quality	control	(QC)	within	a	cell	occurs	at	different	levels,	depending	on	the	severity	of	the	damage	(Tatsuta	and	Langer	2008).	On	the	molecular	level,	chaperones	and	 proteases	 regulate	 protein	 abundance,	 folding	 and	 functionality	 within	 each	organelle/compartment.	 If	 the	 damage	 exceeds	 this	 QC	 capacity,	 organellar	 QC	systems	 can	 selectively	 remove	 non-functional	 organelles.	 With	 regard	 to	mitochondria,	this	process	is	mainly	regulated	via	fusion/fission	and	mitochondrial-specific	 autophagy	 (mitophagy)	 (Pickles	 et	 al.	 2018).	 If	 this	 system	 also	 fails	 to	warrant	 functionality,	 affected	 cells	 can	undergo	 cell	 death	 in	order	 to	protect	 the	surrounding	cells	within	a	tissue	(Marino	et	al.	2014).	In	mitochondria,	regulatory	and	QC	proteostasis	is	mediated	by	ATP-dependent	protease	complexes	that	form	barrel-shaped	 catalytic	 chambers	 to	 avoid	 unintentional	 activity.	 The	 membrane-bound	mAAA	and	 iAAA	proteases	 face	 the	matrix	and	 intermembrane	space,	respectively,	and	are	able	to	extract	and	degrade	other	membrane	proteins.	Mitochondrial	matrix	proteostasis	 on	 the	 other	 hand	 is	 mostly	 regulated	 by	 the	 two	 soluble	 protease	complexes,	 ClpXP	 and	 LonP1.	 These	 proteases	 are	 structurally	 different	 and	 not	(fully)	redundant,	as	they	cannot	compensate	for	the	loss	of	the	other	(Gispert	et	al.	2013,	 Venkatesh	 et	 al.	 2019).	 Most	 of	 the	 QC	 within	 the	 mitochondrial	 matrix	 is	performed	by	LonP1,	particularly	with	regard	to	oxidatively	damaged	proteins	(Bota	and	Davies	 2002,	 Ngo	 et	 al.	 2013,	 Bezawork-Geleta	 et	 al.	 2015,	 Pinti	 et	 al.	 2016),	although	several	regulatory	substrates	such	as	TFAM	or	COX4I1	have	been	described	(Fukuda	et	al.	2007,	Matsushima	et	al.	2010).		Though	substantial	evidence	for	a	role	of	ClpXP	in	the	regulation	of	the	mitochondrial	unfolded	protein	response	(mtUPR)	exists	in	C.	elegans	(Haynes	et	al.	2007,	Haynes	et	al.	2010),	 this	was	 recently	disputed	 in	a	mammalian	background	 (Seiferling	et	 al.	
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2016),	 indicating	 that	 ClpXP	 adopted	 different	 substrates	 and	 functions	 during	evolution	and	may	rather	be	a	part	of	-	than	a	trigger	of	the	mtUPR	in	mammals.	Only	recently,	 the	 first	 substrates	 and	 in	 vivo	 functions	were	 described	 for	mammalian	ClpXP	and	many	open	questions	remain	about	other	substrates,	tissue-specificity	and	the	regulation	of	its	activity	(Cole	et	al.	2015,	Fischer	et	al.	2015,	Szczepanowska	et	al.	2016,	Matsushima	et	al.	2017,	Becker	et	al.	2018).		
1.2.2 ATP-dependent	Clp	protease	ClpXP	ClpXP	 is	a	highly	conserved	protease	complex	 found	 in	bacteria	 (Baker	and	Sauer	 2012),	 mitochondria	 (Glynn	 2017)	 and	 chloroplasts	 (Olinares	 et	 al.	 2011),	consisting	of	a	catalytic	subunit	(CLPP,	ClpP)	and	an	unfoldase	subunit	(CLPX,	ClpX)	(Figure	1.3).			
	
Figure	1.3	Structure	of	the	functional	ClpXP	protease	complex	The	ClpXP	protease	is	composed	of	two	heptameric	CLPP	rings	that	form	the	catalytic	core	(CLPP14n)	and	two	hexameric	CLPX	rings	(CLPX6n)	that	attach	to	either	site	of	the	CLPP	chamber	and	perform	substrate	recognition,	unfolding	and	translocation.		 	
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While	plants	like	Arabidopsis	thaliana	have	multiple	gene	duplications	for	ClpP	and	ClpX,	with	partially	dual	DNA	origin	(Adam	et	al.	2001),	bacteria	and	mitochondria	have	one	gene	 for	 each	 subunit	 that	 is	nuclear	 encoded.	 Structurally,	 the	protease	resembles	 the	 cytosolic	 26S	 proteasome	 with	 a	 catalytic	 core	 consisting	 of	 two	stacked	 CLPP	 heptameric	 rings	 forming	 a	 chamber.	 Within	 this	 chamber,	 14	serine/histidine/aspartate	residues	form	catalytic	triads,	which	perform	the	peptide	cleavage	(Kang	et	al.	2005).	This	chamber	is	only	stable	in	the	presence	of	hexameric	CLPX	 rings	 and	 ATP.	 The	 CLPX	 rings	 attach	 to	 the	 chamber	 and	 block	 unspecific	peptide	entry.	 In	mitochondria,	CLPX	 is	 the	only	unfoldase	 isoform	responsible	 for	substrate	recognition,	unfolding	and	translocation	into	the	CLPP	chamber	(Lowth	et	al.	 2012).	Mitochondrial	CLPX	was	additionally	 suggested	 to	play	a	 chaperone-like	role	 in	heme	biosynthesis	 independent	of	CLPP	(Kardon	et	al.	2015),	which	 is	also	supported	by	 the	 fact	 that	 the	yeast	 strain	S.	 cerevisiae	possesses	a	homologue	 for	CLPX	but	none	for	CLPP.	Substrate	unfolding	and	translocation	can	occur	at	both	termini	and	is	dependent	on	the	 location	 of	 the	 recognition	 site	 (Olivares	 et	 al.	 2017).	 In	 bacteria,	 known	degradation	motifs	(degrons)	such	as	the	ssrA-tag	are	recognized	by	adaptor	proteins	like	ClpS,	SspB	or	TrfA	(Flynn	et	al.	2004,	Donegan	et	al.	2014).	Fusion	proteins	of	the	ssrA-tag	 and	 fluorescent	 proteins	 are	 commonly	 used	 to	 study	 bacterial	 ClpXP	activity,	however	this	system	cannot	be	translated	to	the	mitochondrial	homologue,	as	human	and	mouse	CLPX	cannot	recognize	the	tag	(Martin	et	al.	2008).	In	bacteria,	ribosomes	stalled	on	mRNAs	are	recycled	using	transfer-messenger	RNAs	(tmRNAs).	These	 mRNAs	 are	 short	 RNA	 species	 that	 structurally	 resemble	 tRNAs.	 They	 are	therefore	able	to	enter	stalled	ribosomes,	where	they	are	translated	into	the	ssrA-tags,	resulting	in	fusion	proteins	of	the	aberrant	protein	and	the	tag	(Janssen	and	Hayes	2012).	The	inability	of	human/mouse	CLPX	to	recognize	the	tag	might	stem	from	the	lack	of	known	adaptors,	however	no	tmRNA/ssrA	system	has	yet	been	described	in	mammalian	mitochondria.		 	
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1.2.3 Mammalian	ClpXP	substrates,	interactors	and	tissue	specificity	As	mentioned	before,	mammalian	ClpXP	shows	profound	differences	in	terms	of	substrates	in	comparison	to	its	bacterial	homologue,	although	both	proteases	share	strong	structural	and	functional	homology.	The	difference	can	be	largely	attributed	to	the	CLPX-mediated	substrate	recognition,	as	hybrid	proteases	made	of	human	CLPP	and	E.	coli	ClpX	are	able	to	degrade	ssrA-tagged	fusion	proteins	in	vitro	(Kang	et	al.	2002).	The	differences	 in	substrates	may	have	resulted	during	 the	development	of	multicellular	organisms	that	demanded	cell	type-specific	substrate	regulations.	The	almost	inevitable	presence	of	adaptor	proteins	also	in	eukaryotic	mitochondria	would	allow	even	further	diversification	of	protease	function	and	could	account	for	some	of	the	 differences	 observed	 between	 cell	 types	 and	 organisms	 and	 explain	 why	individual	approaches	towards	the	identification	of	mitochondrial	ClpXP	substrates	resulted	in	(partially)	different	proposed	candidates.		A	particular	useful	model	for	the	study	of	mammalian	ClpXP	was	the	Clpp-/-	knockout	mouse	 that	 largely	 recapitulates	 the	 symptoms	 observed	 in	 Perrault	 syndrome	patients	 (Gispert	et	al.	2013,	Szczepanowska	et	al.	2016).	Accordingly,	Clpp-/-	mice	show	growth	retardation,	infertility	and	hearing	loss.	In	addition	to	the	tissue-specific	phenotypes,	 these	 mice	 show	 systemic	 aberrations,	 such	 as	 augmented	 glucose	homeostasis,	 impaired	 adaptive	 thermogenesis	 and	 protection	 from	 diet-induced	obesity	and	insulin	resistance	(Becker	et	al.	2018,	Bhaskaran	et	al.	2018).	To	date,	mitochondrial	ClpXP	 substrate	 screens	using	 inactive	CLPP	variants	were	performed	in	MEFs	(Szczepanowska	et	al.	2016)	and	Podospora	anserina	(Fischer	et	al.	2015),	and	a	mitochondrial	ClpXP	 interactome	screen	using	BioID	 labelling	was	performed	in	human	HEK293	cells	(Cole	et	al.	2015).	While	all	three	highlight	the	role	of	ClpXP	in	regulating	respiratory	chain	subunits	and	metabolic	enzymes,	the	screen	in	MEFs	 also	 generated	ERAL1	 as	 a	 potential	 substrate,	 that	 affects	mitoribosome	biogenesis,	primarily	 in	 the	heart.	The	effect	was	 less	pronounced	 in	 cells	 and	not	observed	 in	 hepatocytes	 (Becker	 et	 al.	 2018),	 which	 strongly	 insinuates	 the	importance	 of	 tissue-specific	 substrates	 and	 the	 careful	 consideration	 of	 any	substrate	 screen	 system.	 Non-screen	 approaches	 with	 knockout	 or	 knockdown	models	 have	 further	 suggested	 LRPPRC1	 as	 a	 substrate	 in	 D.	 melanogaster	(Matsushima	et	al.	2017),	EFG1,	VLCAD,	PNPT1	and	CLPX	in	mice	(Szczepanowska	et	al.	2016,	Becker	et	al.	2018),	and	NOA1	in	mouse	C2C12	cells	(Al-Furoukh	et	al.	2014).	
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Notably,	only	NOA1	was	verified	in	an	in	vitro	degradation	assay	with	recombinant	proteins.	This	or	other	confirmation	experiments	 lower	the	chances	that	 increased	steady	 state	 levels	 in	 the	 absence	 of	 the	 protease	 result	 as	 a	 secondary	 effect.	However,	negative	in	vitro	degradation	experiments	might	also	arise	due	to	the	lack	of	mandatory	adaptors.	Furthermore,	C1QBP	was	suggested	as	a	mitochondrial	adaptor	protein	because	of	its	strong	binding	to	ClpXP	and	the	fact	that	it	is	not	degraded	by	ClpXP	in	vitro	or	in	vivo	(Lowth	et	al.	2012,	Szczepanowska	et	al.	2016).	However,	its	“promiscuous”	affinity	towards	 many	 proteins	 under	 standard	 purification	 conditions	 raises	 further	questions	as	to	which	of	the	interactions	have	biological	meaning	(Ghebrehiwet	et	al.	1994,	Mcgee	and	Baines	2011,	Zhang	et	al.	2013,	Szczepanowska	et	al.	2016,	Kim	et	al.	2017,	Hong	et	al.	2018).	Despite	this	controversy	and	the	uncertainty	about	the	exact	function	of	the	protein,	C1QBP	can	still	be	utilized	as	a	control	for	non-substrate	interactors	in	ClpXP	substrate	screens.		
1.2.4 Study	aim	The	understanding	of	a	given	protease	is	inevitably	linked	to	the	discovery	of	its	substrates	and	the	regulation	of	their	degradation.	The	most	useful	tools	to	identify	these	substrates	are	undoubtedly	loss	of	function	models	and	screens	with	inactive	proteases	in	combination	with	proteomic	quantitation	approaches.	Surprisingly,	only	few	substrates	for	mammalian	ClpXP	were	confidently	identified	so	far	and	it	remains	unclear	as	to	why	mutations	in	the	CLPP	gene	manifest	as	particular	tissue	 deficiencies	 in	 patients	 with	 the	 Perrault	 syndrome.	 To	 identify	 further	substrates,	 two	 independent	 proteomic	 screens	 were	 employed	 to	 quantitatively	address	the	issue.	Additionally,	a	mouse	model	conditionally	expressing	tagged	CLPP	was	developed	to	enable	purification	studies	in	vivo	that	could	shed	light	on	the	tissue-specificity	of	the	protease.
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2 Materials	and	Methods	
2.1 Materials	
Table	2.1:	Materials	and	suppliers	used	in	the	study	
Name	 Supplier	2-Propanol	 AppliChem	35S-methionine	 Hartmann	Analytic	Acetyl-CoA	 Sigma	Aldrich	40%	Acrylamid	(37.5:1)	 Carl	Roth	4-16%	Acrylamide	gels	 Life	Technologies	ADP	 Sigma	Aldrich	Agarose	 Carl	Roth	6-Aminohexanoic	acid	 Carl	Roth	Antimycin	A	 Sigma	Aldrich	APS	 Sigma	Aldrich	Bradford	Reagent	 Sigma	Aldrich	BSA	 Sigma	Aldrich	BSA	(FA-free)	 Sigma	Aldrich	Cas9	mRNA	 Tebu-bio	Cas9	protein	 IDT	Catalase	 Sigma	Aldrich	cDNA	synthesis	kit	 Applied	Biosystems	Coomassie	Brillian	Blue	G-250	 AppliChem	Cytochrome	c	 Sigma	Aldrich	Detection	screen	 Fuji	Diaminobenzidine	 Sigma	Aldrich	Digitonin	 Merck	DMEM	medium	 Life	Technologies	Dulbeco	PBS	 Life	Technologies	Dried	milk	powder	 AppliChem	DTT	 Sigma	Aldrich	EDTA	 Sigma	Aldrich	
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EGTA	 Sigma	Aldrich	Ethanol	 Applichem	Ethidium	bromide	 Sigma	Aldrich	FBS	Superior	 Merck	FCCP	 Sigma	Aldrich	GoTaq	polymerase/buffer	 Promega	Glutamate	 Sigma	Aldrich	Glycine	 Applichem	H2O2	 Sigma	Aldrich	HCl	 VWR	HRP	 Sigma	Aldrich	KCl	 AppliChem	KCN	 Sigma	Aldrich	Klenow	polymerase	 Invitrogen	Malate	 Sigma	Aldrich	Malonate	 Sigma	Aldrich	Mannitol	 AppliChem	Mayer’s	hematoxylin	 AppliChem	MeOH	 AppliChem	MgCl2	 Sigma	Aldrich	NaCl	 Sigma	Aldrich	NADH	 Sigma	Aldrich	NaF	 AppliChem	NaOH	 Sigma	Aldrich	Na	orthovanadat	 AppliChem	Na3PO4	 AppliChem	NaN3	 Sigma	Aldrich	4x	native	sample	buffer	 Life	Technologies	Nucleofector	electroporation	kit	 Lonza	Oligomycin	 Sigma	Aldrich	Oxaloacetate	 Sigma	Aldrich	Paraformaldehyde	 Sigma	Aldrich	
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PBS	 Life	Technologies	Penicillin/Streptomycin	 Life	Technologies	Periodic	acid	 Sigma	Aldrich	2-Propanol	 Aplichem	Protaese	Inhibitor	Cocktail	 Sigma	Aldrich	Proteinase	K	 Applichem	Pyruvate	 Sigma	Aldrich	Random	primer	mix	 Invitrogen	RNase-free	water	 Life	Technologies	Rotenone	 Sigma	Aldrich	Schiff	reagent	 Sigma	Aldrich	SDS	 AppliChem	Succinate	 Sigma	Aldrich	Sucrose	 Sigma	Aldrich	SYBR	Green	qPCR	Master	Mix		 Agilent		TBE	 AppliChem	TEMED	 Sigma	Aldrich	Tris	 Sigma	Aldrich	Triton	X-100	 Sigma	Aldrich	Trizol	 Life	Technologies	0.05%	Trypsin	 Life	Technologies	Tween20	 VWR	Ubiquinone	 Sigma	Aldrich			 	
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2.2 Transgenic	mouse	models	
2.2.1 Sdhatm2a	
Sdhatm2a	mice	were	obtained	 from	the	KOMP	repository	(Project	 ID:	CSD48939)	as	cryo-conserved	 sperm.	The	Sdhatm2a	 allele	harbours	 an	FRT-flanked	knockout-first	cassette	(Skarnes	et	al.	2011)	between	exon	5	and	exon	6	of	the	Sdha	gene	and	two	loxP	sites	surrounding	exon	6	outside	of	the	cassette.		
2.2.2 Sdhafl/fl		
Sdhafl/fl	 were	 generated	 via	 intercrossing	 of	 Sdhatm2a	 mice	 with	 FLP	 deleter	 mice	(ROSA26::FLPe)	 that	 deletes	 the	 FRT-flanked	 sequence.	Mice	were	 further	 bred	 to	
Sdhafl/fl	homozygosity	without	the	ROSA26::FLPe	allele.		
2.2.3 SdhaMKO	Conditional	 striated	 muscle-specific	 knockout	 (SdhaMKO)	 mice	 were	 generated	 via	intercrossing	of	Sdhafl/fl	mice	with	heterozygous	ACTA-Cre	transgenic	mice	(provided	by	Prof.	Dr.	Thomas	Langer),	harbouring	one	Sdhafl	allele.	Matings	were	set	up	in	both	combinations	and	both	male	and	female	mice	were	used	for	the	experiments.	Mice	were	 sacrificed	 at	 3	 or	 4	 weeks	 of	 age	 and	 skeletal	 muscles	 (quadriceps,	gastrocnemius,	 triceps	 and	 soleus)	 and	 livers	 were	 isolated	 for	 the	 experiments.	
Sdhafl/fl	mice	of	the	same	sex	and	age	were	used	as	controls.		
2.2.4 SdhaHKO	Conditional	 heart	 and	 skeletal	 muscle-specific	 knockout	 (SdhaHKO)	 mice	 were	generated	 via	 intercrossing	 of	 Sdhafl/fl	 mice	 with	 heterozygous	 Ckmm-NLS-Cre	transgenic	mice	 (provided	by	Prof.	Dr.	Nils-Göran	 Larsson),	 harbouring	 one	Sdhafl	allele.	Matings	were	set	up	in	both	combinations	and	both	male	and	female	mice	were	used	for	the	experiments.	Mice	were	sacrificed	between	11	and	21	days	of	age	and	hearts	were	extracted	for	the	experiments.	Sdhafl/fl	mice	of	the	same	age	were	used	as	controls.		 	
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2.2.5 SdhaLKO	Conditional	 hepatocyte-specific	 knockout	 (SdhaLKO)	 mice	 were	 intended	 via	intercrossing	 of	 Sdhafl/fl	 mice	 with	 heterozygous	 Albumin-Cre	 transgenic	 mice	(provided	by	Prof.	Dr.	Elena	Rugarli),	harbouring	one	Sdhafl	allele.	Matings	were	set	up	 in	 both	 combinations	 and	 >60	 pups	 were	 genotyped	 without	 positive	 SdhaLKO	offspring.		
2.2.6 Clpp-/-	The	generation	and	breeding	of	Clpp-/-	mice	was	performed	as	previously	published	(Szczepanowska	 et	 al.	 2016).	Mice	were	 sacrificed	 at	 the	 age	 of	 15-20	weeks	 and	hearts	were	extracted	for	further	experiments.	Clpp+/+	mice	of	the	same	sex	and	age	were	used	as	controls.		
2.2.7 R26-Clpp-Flag	Conditional	 Rosa26	 (R26)-Clpp-Flag	 knockin	mice	 were	 generated	 as	 described	 in	(Chu	et	 al.	2016)	using	pR26	CAG/GFP	Dest	as	 the	 targeting	vector.	The	Clpp-Flag	sequence	 (Szczepanowska	 et	 al.	 2016)	 was	 cloned	 between	 the	 attB	 sites	 of	 the	targeting	vector	using	gateway	cloning	to	create	pR26	CAG/CLPP/GFP	Dest.	crRNA	(5’-ACUCCAGUCUUUCUAGAAGAGUUUUAGAGCUAUGCU-3’)	annealing	to	the	ROSA26-
1	 locus	 and	 tracrRNA	 were	 obtained	 from	 IDT	 and	 annealed	 according	 to	 the	manufacturer’s	instructions.	pR26	CAG/CLPP/GFP	Dest	targeting	vector	(20ng/µL),	sgRNA	 (15ng/µL),	Cas9	mRNA	 (30ng/µL)	 and	Cas9	protein	 (30ng/µL)	 in	 injection	buffer	 (Tris-HCl	 10mM,	 EDTA	 0.1mM,	 pH	 7.5)	 was	 injected	 into	 pro-nuclei	 in	 the	transgenic	core	facility	of	the	CECAD	institute	and	the	offspring	was	genotyped	for	positive	insertion	as	described	in	(Chu	et	al.	2016)	with	PCRs	amplifying	within	the	targeting	vector	(Neo)	and	throughout	targeting	vector	and	locus	(R26).	Positive	mice	were	back-crossed	for	3	generations	before	analysis.	Targeting	with	R26-Clpp-Trap-
Flag	did	not	result	in	positive	offspring.		
2.2.8 R26-Clpp-Flag	Ckmm-Cre	CLPP-FLAG	expression	was	induced	in	the	heart	by	crossing	R26-Clpp-Flag	mice	with	
Ckmm-Cre	mice.	Mice	heterozygous	for	each	allele	were	sacrificed	at	10	weeks	of	age	and	R26-Clpp-Flag	mice	without	Ckmm-Cre	were	used	as	controls.	
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2.3 Mouse	housing	conditions	and	sacrifice	All	mice	were	kept	in	single-ventilated	cages	at	22-24°C	in	groups	of	2-5	per	cage	in	the	CECAD	animal	facility.	Mice	were	fed	a	ssniff	chow	diet	(v1554-330)	consisting	of	10	kJ%	fat,	23	kJ%	protein	and	67	kJ%	carbohydrates,	as	well	as	drinking	water	ad	libitum.	The	 animals	were	kept	under	 a	12h	 light/dark	 cycle	 starting	 at	6	 am	and	killed	by	cervical	dislocation	or	decapitation	(pups	at	11	days	of	age)	at	12pm.	All	experiments	were	approved	and	permitted	by	the	Animal	Ethics	Committee	of	North-Rhein-Westphalia	(Landesamt	für	Natur,	Umwelt	und	Verbraucherschutz	Nordrhein-Westfalen;	 LANUV)	 following	German	 and	European	Union	 regulations.	 All	 animal	work	 was	 performed	 in	 accordance	 with	 recommendations	 and	 guidelines	 of	 the	Federation	of	European	Laboratory	Animal	Science	Associations	(FELASA).		
2.4 Blood	glucose	measurement	Immediately	 following	 sacrifice,	 tail	 vain	 blood	 was	 collected	 and	 used	 for	 blood	glucose	 measurement	 with	 an	 ACCU-Check	 Aviva	 (Roche)	 according	 to	 the	manufacturer	instructions.		
2.5 Cell	culture	models	For	 the	 substrate	 trapping	 screen,	 previously	 published	 Clpp-/-	 MEFs	 were	 used	(Szczepanowska	et	al.	2016).		
2.5.1 Cell	culture	Cells	were	grown	at	37°C,	21%	O2	and	5%	CO2	conditions	in	full	DMEM	high	glucose	medium	 with	 10%	 FBS	 added	 and	 split	 before	 cells	 reached	 80%	 confluency	 for	maintenance.	Cells	were	detached	from	culture	dishes	with	1	min	incubation	in	0.05%	trypsin	solution,	following	quenching	with	3x	the	volume	of	culture	medium.		
2.5.2 Transfection	of	CLPP-FLAG	constructs		
Clpp-/-	cells	were	transfected	with	previously	published	constructs	(Szczepanowska	et	al.	 2016)	 using	 the	 Nucleofector	 electroporation	 kit	 (Lonza)	 according	 to	 the	manufacturer	instructions.	4	times	106	MEF	cells	were	transfected	per	condition	and	replicate	and	transferred	to	10cm	culture	dishes.	24h	post	transfection,	the	medium	
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was	exchanged	and	72h	post	transfection	cells	were	harvested	with	trypsin	and	the	four	dished	per	condition	were	pooled.	Cell	pellets	were	washed	twice	with	cold	PBS	and	immediately	used	for	lysis.		
2.6 Biochemistry	
2.6.1 Isolation	of	proteins	from	tissues	For	 tissue	protein	 isolations,	heart	or	skeletal	muscle	 tissue	was	 taken	up	 in	heart	protein	 isolation	buffer	(50mM	HEPES,	0.1M	NaF,	10mM	Na	orthovanadate,	10mM	EDTA,	100mM	NaCl,	1%	Triton	X-100,	0.2%	SDS,	pH	7.4)	or	skeletal	muscle	protein	isolation	 buffer	 (50mM	 Tris-HCl,	 150mM	 NaCl,	 1mM	 EDTA,	 1%	 NP-40,	 pH	 7.5),	respectively	 with	 protease	 and	 phosphatase	 inhibitor	 cocktails	 and	 lysed	 with	ceramic	beads	in	a	FastPrep	homogenizer	(MP	Biomedicals,	Santa	Ana,	CA,	USA).	After	30	 min	 incubation	 on	 ice,	 insoluble	 material	 was	 removed	 by	 centrifugation	 at	20,000x	g	for	30	min	and	the	supernatant	was	stored	at	-80°C	until	further	use.			
2.6.2 Isolation	of	mitochondria	from	skeletal	muscles	Mitochondria	from	skeletal	muscles	were	isolated	as	described	previously	(Frezza	et	al.	 2007).	 In	 summary,	 freshly	 isolated	muscle	 tissue	 was	 isolated,	 stripped	 from	visible	connective	tissue,	minced	and	incubated	in	0.05%	trypsin	and	10mM	EDTA	for	30	min.	 The	 trypsin	 solution	was	 removed	 and	 the	 tissue	 resuspended	 in	 skeletal	muscle	isolation	buffer	1	(150mM	sucrose,	10mM	EDTA,	50mM	KCl,	50mM	Tris-HCl,	0.2%	 FA-free	 BSA	 pH	 7.7).	 Using	 a	 Teflon	 potter	 at	 1600	 rpm,	 the	 tissue	 was	homogenized	on	ice	and	un-lysed	fragments	were	removed	at	700x	g	centrifugation.	The	mitochondria	were	collected	from	the	supernatant	with	8000x	g	centrifugation	and	resuspended	in	skeletal	muscle	isolation	buffer	2	(250mM	sucrose,	3.3mM	EGTA,	10mM	 Tris-HCl	 pH	 7.7).	 Mitochondria	 were	 collected	 again	 with	 8000x	 g	centrifugation	and	resuspended	in	75µL	isolation	buffer	2.	Protein	concentration	was	determined	 with	 Bradford	 reagent	 and	 mitochondria	 were	 used	 immediately	 for	respiration	measurement	and	frozen	once	for	BN-PAGE	analysis.			
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2.6.3 Isolation	of	mitochondria	from	hearts	To	isolate	mitochondria,	fresh	heart	tissue	was	homogenized	with	a	Teflon	potter	at	1000	rpm	in	5mL	heart	mitochondria	isolation	buffer	(100mM	sucrose,	50mM	KCl,	1mM	EDTA,	20mM	TES,	pH	7.2)	with	the	addition	of	subtilisin	A	(1mg/g	heart)	and	0.2%	BSA	 (FA-free).	Fat	was	 removed	with	 the	 supernatant	after	 centrifugation	at	8500x	g	at	4°C	and	the	homogenate	was	resuspended	in	30mL	isolation	buffer.	Un-lysed	material	was	 removed	 by	 centrifugation	 at	 800x	 g	 and	 the	 supernatant	was	centrifugated	at	8500x	g	to	collect	the	crude	mitochondrial	fraction.	The	pellet	was	resuspended	 in	 100µL	 isolation	 buffer	 and	 used	 immediately	 for	 respiration	measurements	or	stored	at	-80°C.			
2.6.4 SDS-PAGE	and	western	blot	To	 separate	 proteins	 via	 polyacrylamide	 gel	 electrophoresis	 under	 denaturating	conditions,	proteins	were	incubated	with	Laemmli	buffer	(final:	50	mM	Tris-HCl,	2%	SDS,	10%	Glycerol,	1%	2-mercaptoethanol,	12.5	mM	EDTA,	0.02%	Bromphenol	Blue,	pH	6.8)	at	95	°C	for	5	minutes.	Chilled	samples	were	than	loaded	on	10%	or	12%	Tris-Glycine	acrylamide	gels	in	a	Mini-PROTEAN	Tetra	Cell	(BioRad,	München,	Germany).	Separation	gel	(10-12%	acrylamide-bisacrylamide	(37.5:1),	37.5	mM	Tris-HCl,	0.1%	SDS,	pH	8.8)	and	stacking	gel	(5%	acrylamide-bisacrylamide	(37.5:1),	12.5	mM	Tris-HCl,	 0.1%	 SDS,	 pH	 6.8)	 were	 casted	 and	 used	 when	 completely	 polymerized.	 To	catalyse	polymerization,	0.1%	APS	and	TEMED	were	added	to	the	separation	gel	and	0.25%	APS	and	TEMED	to	the	stacking	gel.	Electrophoresis	was	performed	at	constant	85	V	in	running	buffer	(25	mM	Tris-HCl,	250	mM	Glycine,	0.1%	SDS,	pH	8.3)	until	the	loading	dye	reached	the	separating	gel	and	at	constant	150	V	until	it	reached	the	end	of	the	gel.	After	electrophoresis,	the	gels	were	shortly	washed	and	the	transfer	was	assembled	in	a	BioRad	Criterion	Blotter:	 	
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• Black	sieve	
• Sponge	
• 2	layers	of	Whatman	paper	
• Gel	
• Nitrocellulose	membrane	
• 2	layers	of	Whatman	paper	
• Sponge	
• Red	sieve		Proteins	 were	 transferred	 in	 transfer	 buffer	 (30	 mM	 Tris-HCl,	 240	 mM	 Glycine,	0.037%	SDS,	20%	methanol)	at	constant	400	mA	and	4	°C	for	2	hours.	After	transfer,	the	membranes	were	shortly	washed	in	dH2O	and	successful	transfer	was	evaluated	by	Ponceau	S	staining.	Afterwards,	 the	Ponceau	S	staining	was	removed	with	PBST	and	membranes	were	blocked	for	60	minutes	in	5%	Milk-PBST.	Primary	 and	 secondary	 antibody	 incubation	 has	 been	 performed	 according	 to	 the	manufacturer’s	instructions,	each	following	3	rounds	of	5	minutes	washing	in	PBST.	After	the	last	washing,	ECL	solution	was	applied	to	the	membranes,	which	were	then	exposed	to	Fujifilm	Super	RX	films.		 	
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Table	2.2:	Antibodies,	suppliers	and	identifiers	used	for	western	blots	
Name	 Supplier	 Cat.	Nr.	4-HNE	 Abcam	 ab46545	AcK	 Abcam	 21623	ACTIN	 Sigma	 A5441	AKT	 CST	 9272	pAKT	 CST	 4060	ALDH18A1	 Sigma	 HPA01260	AMPK	 CST	 2532	pAMPK	 CST	 2535	ATF4	 Proteintech	 10835-1-AP	ATP5A1	 Abcam	 ab14748	C1QBP	 Millipore	 AB2991	Citrate	Synthase	 Santa	Cruz	 sc-515640	CLPP	 Sigma	 WH0008192M1	CLPX	 Sigma	 HPA040262	COXI	 Molecular	Probes	 459600	COXIV	 Molecular	Probes	 A21348	EIF2a	 Abcam	 ab26197	pEIF2a	 Abcam	 ab32157	pERK1/2	 CST	 9102	ETFDH	 Santa	Cruz	 sc-515202	FLAG	M2	 Sigma	 F1804	HSC70	 Santa	Cruz	 sc-7298	HSP60	 ATCC	 HSP60	MCAD	 Santa	Cruz	 sc-49047	MHC	Type	I	 Sigma	 M8421	MHC	Type	IIa	 ATCC	 sc-71	MHC	Type	IIb	 ATCC	 BF-F3	MTHFD2	 Abcam	 ab56772	mTOR	 CST	 2972	pmTOR	 CST	 2971	NDUFA9	 Molecular	Probes	 459100	NDUFB8	 Abcam	 ab110413	OAT	 Abcam	 ab137679	P62	 Abnova	 H00008878-M01	PYCR1	 Abcam	 ab94780	RPS6	 Biomol	 A300-557A-M	pRPS6	 CST	 2211	SDHA	 Mitosciences	 MS204	SDHB	 Abcam	 ab110413	SHMT2	 Abcam	 ab224428	TOMM20	 Santa	Cruz	 sc-17764	TUBULIN	 Calbiochem	 CP06	UQCRC1	 Molecular	Probes	 459140	UQCRC2	 Abcam	 ab110413	VDAC1	 Abcam	 ab14734	
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2.6.5 BN-PAGE	Blue	native	gel	electrophoresis	(BN-PAGE)	was	performed	according	to	the	guidelines	published	previously	(Wittig	et	al.	2006).		Isolated	mitochondria	(50-100µg)	were	lysed	in	50µL	BN-PAGE	lysis	buffer	(50mM	NaCl,	 50mM	 imidazole,	 2mM	 6-aminohexanoic	 acid,	 1mM	 EDTA,	 pH	 7.0)	 with	 6g	digitonin/g	 mitochondrial	 protein	 for	 15	 min	 on	 ice.	 Insolubilized	 material	 was	removed	by	centrifugation	at	20,000x	g	for	20	min	and	the	supernatant	was	mixed	with	10x	Loading	dye	(50%	glycerol,	5%	Coomassie)	for	a	final	detergent/dye	ratio	of	 8g/g.	 10-20µL	 of	 samples	 were	 loaded	 on	 4-16%	 native	 acrylamide	 gels	 (Life	Technologies)	and	electrophoresis	was	performed	at	4°C	for	30	min	at	150V	and	4h	at	250V	in	an	electrophoresis	chamber	(Invitrogen).	After	 completed	 electrophoresis,	 proteins	 were	 transferred	 onto	 an	 equilibrated	PVDF	membrane	in	western	blot	transfer	buffer	without	SDS	and	methanol	at	4°C	for	16h	at	constant	120mA	current.	After	completed	transfer,	the	membrane	was	shortly	de-stained	in	methanol,	blocked	for	 1h	 in	 5%	 milk	 PBST	 and	 incubated	 with	 specific	 antibodies	 for	 2h	 at	 room	temperature.	 Further	 incubations/washes	 and	 signal	detection	were	performed	as	described	for	SDS-PAGEs.		
2.6.6 In	gel	complex	IV	activity	assay	
In-gel	 complex	 IV	 activity	 assays	 were	 performed	 as	 to	 the	 guidelines	 published	previously	 (Wittig	 et	 al.	 2007).	 After	 completed	 BN-PAGE,	 the	 gels	 were	 shortly	washed	 and	 incubated	 in	 complex	 IV	 activity	 buffer	 (50mM	 Na3PO4,	 25mM	 3,3’-diaminobenzidine,	50µL	cytochrome	c,	pH	7.2)	for	30	min	at	room	temperature.	The	gel	was	cleared	with	water	and	documented	with	a	transparency	scanner.		
2.6.7 Whole	tissue	proteomics	For	label-free	protein	quantification,	tissues	were	harvested,	frozen	in	liquid	nitrogen	and	ground	to	fine	powder.	The	tissue	was	resuspended	in	protein	extraction	buffer	(Heart:	50mM	HEPES,	0.1M	NaF,	10mM	Na	orthovanadate,	10mM	EDTA,	100mM	NaCl,	1%	Triton	X-100,	0.2%	SDS,	pH	7.4,	Skeletal	muscle:	50mM	Tris-HCl,	150mM	NaCl,	1%	NP-40,	1mM	EDTA,	0.1%	Na	deoxycholate)	with	protease	inhibitor	cocktail	and	lysed	 for	 30	 min	 on	 ice	 with	 protease	 inhibitors	 present.	 Proteins	 were	 further	
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acetone-precipitated	at	-20°C	overnight	and	resuspended	in	8M	urea	(in	50mM	TEAB)	using	a	Bioruptor	(Diagenode).	Protein	concentration	was	determined	using	Bradford	reagent	and	50µg	of	protein	was	used	for	in-solution	digestion.	Protein	reduction	was	performed	with	DTT	at	a	final	concentration	of	5mM	and	incubation	for	1h	at	room	temperature.	For	alkylation,	CAA	was	added	to	40mM	and	incubated	for	30	min	in	the	dark.	Lys-C	protease	was	then	added	at	1:75	ratio	to	protein	content	and	incubated	for	4h	at	room	temperature.	Final	protein	digestion	was	achieved	with	 trypsin	at	1:75	 ratio	 in	≤2M	urea	TEAB	buffer	at	room	temperature	overnight.	Following	 protein	 digestion,	 samples	 were	 loaded	 onto	 SDB	 RP	 StageTips	 using	standard	 procedure	 and	 submitted	 to	 the	 CECAD	 proteomics	 facility	 for	 mass-spectrometry	measurement	and	MaxQuant	analysis	of	the	data.		
2.6.8 N-terminome	profiling		Terminal	 amine	 isotope	 labelling	 of	 substrates	 (TAILS)	 was	 performed	 at	 the	Forschungszentrum	 Jülich	 in	 collaboration	 with	 Dr.	 Fatih	 Demir	 and	 Dr.	 Pitter	 F.	Huesgen	as	described	previously	(Demir	et	al.	2017).	In	short,	1mg	of	isolated	heart	mitochondrial	 proteins	 were	 denaturated	 in	 6M	 GuaHCl	 and	 purified	 with	MeOH/CHCl3	extraction.	Samples	were	reduced	with	DTT	(10mM)	and	alkylated	with	IAA	 (30mM)	 and	 labelled	with	 light	 formaldehyde	 (12CH2O	 for	Clpp+/+)	 and	 heavy	formaldehyde	(13CD2O	for	Clpp-/-)	in	20mM	cyanoborohybride	overnight	at	37°C.	The	labelling	was	quenched	with	Tris-HCl	(100mM)	and	the	pH	was	adjusted	to	6-7.	Three	WT/KO	pairs	were	pooled	at	 equal	protein	 amounts.	Proteins	were	 again	purified	with	 MeOH/CHCl3	 extraction	 and	 dissolved	 in	 100mM	 HEPES	 pH	 7.5.	 Trypsin	digestion	was	performed	overnight	at	1:100	ratio	to	the	protein	mixtures.	Dialyzed	HPG-ALD	II	polymer	was	added	to	bind	non-labelled	amines	that	result	from	trypsin	digestion,	which	were	removed	through	a	10	kDa	cut-off	spin	filter	column.	The	flow-through	was	collected	(TAILS)	and	loaded	onto	C18	Stage-Tips	as	described	in	section	2.6.7.	A	small	amount	of	collected	samples	was	subjected	to	SDS-PAGE	and	silver	staining	for	validation.		
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2.6.9 Cell	lysis	and	co-immunoprecipitation	of	CLPP-FLAG	fusion	proteins	The	transfected	cells	were	lysed	for	45	min	each	in	300µL	IP	buffer	(Thermo)	on	ice	and	incubated	with	30µL	equilibrated	α-FLAG	M2	magnetic	beads	(Sigma)	over	night	at	4°C	on	a	rotating	wheel.	On	the	next	day,	the	beads	were	collected	with	a	magnetic	tube	rack	and	washed	4	times	with	IP	buffer.	Unbound	proteins	(flow-through,	FT)	and	 the	 first	 washing	 solution	 (W1)	were	 collected	 for	 the	 validation	 experiment.	Proteins	 bound	 to	 the	 beads	were	 eluted	with	 70µL	 Elution	 buffer	 (Thermo)	 and	neutralized	with	10µl	1M	Tris/HCl	pH	7.5.	All	collected	samples	were	frozen	in	liquid	nitrogen	and	stored	at	-80°C	until	further	processing.		
2.6.10 Co-IP	eluate	proteomics/verification	For	the	validation	of	the	immune-purification,	1%	of	lysate	(L),	1%	of	flow-through	(FT),	1%	of	washing	buffer	(W1)	and	10%	of	the	elution	(E)	were	subjected	to	SDS-PAGE	and	western	blot	as	described	in	section	2.6.4.	For	western	blot	detection,	α-FLAG	M2,	-CLPX,	-C1QBP,	-TOMM20	and	-ACTIN	antibodies	were	used.		
2.6.11 In	organello	translation	assay	
In	 organello	 translation	 assays	 were	 performed	 as	 described	 previously	(Szczepanowska	 et	 al.	 2016).	 1.5mg	 freshly	 isolated	 heart	 mitochondria	 were	resuspended	in	1mL	translation	buffer	(60µg/mL	amino	acids	[Ala,	Arg,	Asp,	Asn,	Glu,	Gln,	Gly,	His,	 Ile,	Leu,	Lys,	Phe,	Pro,	Thr,	Trp,	Val],	25mM	HEPES,	100mM	mannitol,	10mM	succinate,	80mM	KCl,	5mM	MgCl2,	1mM	KH2PO4,	5mM	ATP,	20µM	GTP,	6mM	creatine	phosphate,	60µg/mL	creatine	kinase,	60µg/mL	cysteine,	60µg/mL	tyrosine	pH	7.4)	with	7µL	35S-methionine	and	rotated	for	1h	at	37°C.	35S-translation	buffer	was	removed	 by	 centrifugation	 at	 12000x	 g	 and	 mitochondria	 were	 resuspended	 in	translation	buffer	without	35S-methionine.	The	samples	were	divided	into	two	parts	(pulse	 and	 chase)	 and	 centrifugated	 again.	 The	 pulse	 sample	was	 resuspended	 in	100µL	Laemmli	buffer	and	kept	for	30	min	at	room	temperature.	The	chase	sample	was	resuspended	again	in	500µL	translation	buffer	and	rotated	for	3h	at	37°C	before	it	was	resuspended	in	Laemmli	buffer	as	well.	10µL	of	each	sample	was	loaded	on	a	15cm	long	15%	acrylamide	SDS	gel	and	run	at	constant	 80V	 in	 a	 Hofer	 electrophoresis	 chamber	 overnight.	 The	 gel	 was	 shortly	washed,	 fixed	 in	 50%	 methanol,	 10%	 acetic	 acid	 for	 30	 min	 and	 stained	 with	
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Coomassie	solution.	De-staining	of	the	background	with	20%	methanol,	10%	acetic	acid	was	performed	until	 the	background	was	 clear	but	 loaded	proteins	were	 still	visible.	The	gel	was	further	placed	on	whatman	paper	and	dried	for	2h	at	80°C	in	a	gel	dryer	before	it	was	documented	as	the	loading	control	of	the	assay.	A	hyper-screen	film	was	put	directly	onto	the	gel	and	incubated	at	-80°C	in	a	film	cassette	for	12h	to	one	week	with	several	image	acquisitions	in	between.		
2.6.12 In	vitro	enzyme	activity	assays	Enzyme	activities	were	measured	as	described	previously	(Spinazzi	et	al.	2012).	In	short,	frozen	heart	samples	were	homogenized	in	10mM	potassium	phosphate	buffer	(pH	7.4)	using	a	glass	douncer	and	subjected	to	3	cycles	of	freezing	in	liquid	nitrogen	and	 thawing	 at	 37°C	 to	 break	 the	 cells	 and	 mitochondrial	 membranes.	 Protein	concentration	of	the	homogenate	was	determined	with	Bradford	solution	and	50µg	of	protein	was	used	for	the	assay.		For	 complex	 I	 activity,	 the	 decrease	 in	 NADH	 absorbance	 (340nm)	was	 followed.	Heart	 homogenate	 in	 assay	 buffer	 (20mM	 K2HPO4,	 0.2mM	 NADH,	 1mM	 NaN3,	1mg/mL	BSA,	pH	8.0)	was	incubated	at	30°C	for	10	min,	followed	by	base-line	activity	measurement	for	2	min.	Maximal	complex	I	activity	was	initiated	by	the	addition	of	CoQ1	 (50µM)	and	 the	 absorbance	was	 recorded	 for	2	min.	Complex	 I-independent	NADH	oxidation	was	recorded	after	the	addition	of	rotenone	(5µM)	for	2	min.	Relative	activity	 was	 determined	 by	 calculating	 the	 slope	 (10	 measuring	 points)	 during	maximal	activity	and	subtracting	the	slope	after	rotenone	addition.	For	 complex	 II	 activity,	 the	 decrease	 of	 oxidised	 DCPIP	 absorbance	 (600nm)	was	followed.	DCPIP	is	an	artificial	electron	acceptor,	which	oxidises	CoQ1H2	and	loses	its	blue	 colour	 when	 reduced.	 Heart	 homogenate	 was	 pre-incubated	 in	 assay	 buffer	(50mM	K2HPO4,	1.5mM	KCN,	0.1mM	DCPIP,	pH	7.0)	and	succinate	for	30	min.	Base-line	activity	was	recorded	for	2	min	at	30°C	and	the	assay	was	started	by	the	addition	of	 CoQ1	 (50µM).	 Complex	 II-independent	 activity	 was	 determined	 with	 malonate	(10mM).	The	relative	activity	was	calculated	as	for	complex	I.		 	
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Both	complex	activities	were	 further	normalized	to	the	activity	of	citrate	synthase.	Citrate	synthase	activity	was	determined	by	coupling	the	production	of	CoA-SH	to	the	reduction	of	DTNB	and	recording	the	absorbance	of	the	product	TNB	(412nm).	Heart	homogenate	was	 incubated	 in	 assay	buffer	 (75mM	Tris-HCl,	 0.1mM	DTNB,	 0.4mM	Acetyl-CoA,	0.1%	Triton	X-100,	pH	8.0)	at	30°C	for	2	min	and	the	assay	was	started	by	the	addition	of	oxaloacetate	(0.5mM).	The	relative	activity	was	calculated	as	for	the	complexes,	 except	 for	 the	 normalization	 that	 used	 the	 baseline	 activity	 instead	 of	specific	inhibitors.		
2.6.13 Respirometry	Respiration	measurements	were	 performed	 as	 described	 previously	 (Becker	 et	 al.	2018).	 50µg	 of	 freshly	 isolated	 heart	 mitochondria	 or	 30µg	 of	 skeletal	 muscle	mitochondria	 were	 added	 to	 calibrated	 oxygraphy	 chambers	 (OROBOROS	instruments)	filled	with	respiration	medium	(120mM	sucrose,	50mM	KCl,	20mM	Tris-HCl,	 1mM	 EGTA,	 4mM	 KH2PO4,	 2mM	 MgCl2,	 0.1%	 BSA	 pH	 7.2).	 For	 parallel	 ROS	measurements,	20µM	AmR,	1	U/mL	HRP,	5	U/mL	SOD	and	0.1µM	H2O2	was	added	to	the	chambers	as	well.	For	complex	I-dependent	respiration,	pyruvate	(2mM),	malate	(0.8mM)	 and	 glutamate	 (4mM)	 was	 added	 to	 the	 chambers	 and	 respiration	 was	started	by	the	addition	of	ADP	(2mM).	Complex	II-dependent	respiration	was	started	by	the	addition	of	succinate	(4mM),	 followed	by	the	 inactivation	of	complex	I	with	rotenone	(0.2µM).	Leak	respiration	was	measured	by	the	inhibition	of	ATP-synthase	with	oligomycin	(1µM)	and	complex	II-driven	maximal	respiration	was	achieved	via	the	 titration	 of	 FCCP	 (0.05µM	 increments)	 until	 no	 more	 uncoupling	 could	 be	observed.	Residual	oxygen	capacity	respiration	(ROX)	was	measured	by	the	addition	of	antimycin	A	(1µM)	and	resulted	in	non-detectable	respiration	(not	shown).		
2.6.14 NAD+/NADH	quantification	For	NAD+/NADH	quantification,	the	“Total	NAD	and	NADH	Assay	Kit	(Colorimetric)”	(Abcam)	 was	 used	 according	 to	 manufacturer	 instructions.	 For	 heart	 and	 muscle	tissue,	10µg	of	protein	lysates	were	de-proteinized	with	10kDa	cut-off	spin	columns	(Abcam)	and	used	for	the	assay.		 	
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2.6.15 Amino	acid	quantification	Amino	acid	quantification	of	skeletal	muscle	samples	was	performed	at	the	CECAD	Lipidomics	facility	as	described	before	(Murru	et	al.	2019).	In	summary,	frozen	tissue	was	lyophilized	and	homogenized	in	acetonitrile,	0.3%	formic	acid	solution	and	mixed	with	 internal	 standards	 of	 isotope-labelled	 amino	 acids.	 Amino	 acids	 were	 then	derivatized	with	6-aminoquinolyl-N-hydroxysuccinimidyl	carbamate	using	the	AccQ-Tag	Ultra	Derivatization	kit	and	quantified	using	a	Core-Shell	Kinetex	C18	column	and	a	 QTRAP	 6500	 triple	 quadrupole/linear	 ion	 trap	 mass	 spectrometer	 (SCIEX)	 and	normalized	to	protein	content.		
2.6.16 Metabolomic	quantification	Anionic	metabolite	quantification	of	skeletal	muscle	samples	was	performed	at	the	CECAD	Lipidomics	facility	as	described	in	(Schwaiger	et	al.	2017).	In	summary,	frozen	tissue	was	 lyophilized	 and	homogenized	 in	75%	MeOH,	 0.2%	 formic	 acid	 solution	mixed	 with	 internal	 standards	 (D4-SUC,	 13C-ATP	 and	 13C-G6P	 for	 TCA-cycle	metabolites,	nucleotides	and	sugars,	respectively).	A	Dionex	Integrion	HPIC	system	(Thermo	 Scientific)	was	 used	 for	 anion-exchange	 chromatography	 and	 separation	was	 conducted	 on	 a	 Dionex	 IonPac	 AS11-HC	 column	 at	 30°C	 with	 a	 potassium	hydroxide	gradient.	High-resolution	mass	spectrometry	was	conducted	on	a	high	field	Thermo	 Scientific	 Q	 Exactive	 HF	 quadrupole-Orbitrap	 mass	 spectrometer	 and	metabolite	quantities	were	normalized	to	the	protein	content.		
2.7 Molecular	Biology	
2.7.1 Isolation	of	DNA	from	tissues	For	genotyping,	ear	biopsies	were	lysed	in	500µL	tail	DNA	lysis	buffer	(100mM	Tris-HCl,	5mM	EDTA,	200mM	NaCl,	0.2%	SDS,	0.2	mg/mL	Proteinase	K,	pH	7.4)	at	55°C	with	constant	shaking	until	all	tissue	was	dissolved.	DNA	was	precipitated	with	500µL	2-propanol	and	washed	once	with	70%	ethanol.	The	DNA	was	resolved	in	150µL	dH2O	and	stored	at	4°C	until	used.	For	high	purity	DNA	isolation	of	skeletal	muscles,	a	small	piece	of	tissue	was	lysed	in	600µL	DNA	isolation	buffer	(100mM	NaCl,	10mM	EDTA,	20mM	Tris-HCl,	 0.5%SDS,	 0.2	mg/mL	Proteinase	K	 pH	 7.4)	 at	 55°C	with	 constant	shaking	until	all	tissue	was	dissolved.	RNA	was	degraded	with	RNase	A	(100µg/mL)	at	37°C	for	30	min	and	phenol-chloroform	extraction	of	DNA	was	performed	with	the	
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addition	of	600µL	PCI.	The	aqueous	phase	was	collected	and	DNA	was	precipitated	with	250µL	of	8M	ammonium	acetate	and	600µL	2-propanol.	After	centrifugation	at	15000x	g	for	15	min	at	4°C	the	pellet	was	washed	with	70%	ethanol	and	the	dry	pellet	was	 resuspended	 in	100µL	ultra-pure	water.	For	 complete	dissolving,	 the	 samples	were	stored	at	4°C	overnight	and	the	DNA	concentration	was	adjusted	to	10ng/µL.		
2.7.2 Genotyping		For	genotyping	PCRs,	the	following	PCR	mix	was	prepared:	1µL	DNA	1µL	Fw	primer	(10mM)	1µL	Rv	primer	(10mM)	1.2µL	MgCl2	(25mM)	2µL	dNTP	mix	(1.25mM	each)	4µL	5x	Polymerase	Buffer		0.05µL	GoTaq	Polymerase	10µL	ddH2O	All	PCRs	were	run	at	the	following	program:	
• 5	min	95°C	For	30	cycles:	
• 30	sec	95°C	
• 15	sec	annealing	[°C]	
• 60	sec	72°C	Final	extension:	
• 10	min	72°C	
• Cool-down	to	4°C		 	
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The	following	primer	were	used	(Cre	was	used	independent	of	the	driving	promoter):		
Table	2.3:	Primer	sequences	and	annealing	temperatures	for	genotyping	PCRs	
PCR	 Fw	Primer	[5’-3’]	 Rv	Primer	[5’-3’]	 Annealing		Cre	 CACGACCAAGTGACAGCAAT	 AGAGACGGAAATCCATCGCT	 52°C	Sdha	 TGAAGGACAGTAGTCACTAGATCAG	 TAAAGGAACCTACTGGTGCTCTAAT	 52°C	Clpp	 GTGGATGATGGTCAGTAGAATCC	 CCCAGACATGATTCCTAGCAC	 58°C	R26	 CTGCCCGAGCGGAAACGCCACTGAC	 CCTGGACTACTGCGCCCTACAGA	 60°C	Neo	 GCTAACCATGTTCATGCCTTC	 CGTTGGCTACCCGTGATATT	 52°C		
2.7.3 mtDNA	quantification	mtDNA	levels	in	skeletal	muscles	were	determined	as	described	previously	(Quiros	et	al.	2017).	 In	summary,	RNA-free	DNA	 from	skeletal	muscles	was	used	 for	qPCR	as	described	 in	 section	2.7.5.	For	quantification,	ND1	and	16S	 rRNA	DNA	 levels	were	quantified	and	normalized	to	HK2	DNA	levels	(nDNA	control).		
2.7.4 Isolation	of	RNA	from	tissues	and	cDNA	synthesis	For	RNA	 isolation,	 an	approximal	3	mm3	piece	of	 tissue	was	homogenized	 in	1mL	Trizol	reagent	with	a	FastPrep	homogenizer	(MP	Biomedicals)	and	ceramic	beads	and	incubated	 for	5	min	at	 room	temperature.	After	addition	of	200µL	chloroform	and	centrifugation	at	12000x	g	for	15	min	at	4°C,	the	aqueous	phase	containing	the	RNA	was	 collected	and	precipitated	with	500µL	2-propanol.	The	RNA	was	pelleted	and	washed	with	75%	ethanol	and	shortly	dried	before	resuspending	it	in	50µL	ultra-pure	water	and	 incubation	at	60°C	 for	10	min.	The	RNA	concentration	and	purity	were	determined	with	a	NanoDrop	spectrophotometer	and	samples	were	stored	at	-80°C.	 	
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For	 cDNA	 synthesis,	 10µg	 RNA	 was	 treated	 with	 DNase	 according	 to	 the	manufacturers	 instruction	 and	 the	 RNA	 concentration	 was	 adjusted	 to	 200ng/µL.	Using	the	reverse	transcription	kit,	2µg	RNA	was	used	for	cDNA	synthesis	in	a	PCR	machine	with	the	following	program:	
• 10	min	25°C	
• 120	min	37°C	
• 5	sec	85°C	
• Cooldown	to	4°C	The	cDNA	was	adjusted	to	a	final	concentration	of	25ng/µL	and	50ng	were	used	for	a	test	PCR	for	the	endogenous	control	HPRT	(not	shown).		
2.7.5 mRNA	quantification	via	qPCR	For	mRNA	quantification,	50ng	cDNA	and	the	Brilliant	III	Ultra-Fast	SYBR	Green	qPCR	Master	 Mix	 kit	 (Agilent	 technologies)	 were	 used	 according	 to	 the	 manufacturer’s	instruction.	The	following	program	was	run	on	a	96well	qPCR	thermocycler	(ABI):	
• 3	min	95°C	For	40	cycles:	
• 5	sec	95°C	
• 15	sec	60°C	dissociation	curve:	
• 15	sec	95°C	
• 1	min	60°C	
• 15	sec	95°C	2–∆∆Ct	was	used	 to	 calculate	 foldchanges	 and	mRNA	 levels	were	normalized	 to	 the	endogenous	controls.			 	
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Table	2.4:	Primer	sequences	for	qPCRs	
PCR	 Fw	Primer	[5’-3’]	 Rv	Primer	[5’-3’]	ND1	 CTAGCAGAAACAAACCGGGC	 CCGGCTGCGTATTCTACGTT	16S	rRNA	 CCGCAAGGGAAAGATGAAAGAC	 TCGTTTGGTTTCGGGGTTTC	HK2	 GCCAGCCTCTCCTGATTTTAGTGT	 GGGAACACAAAAGACCTCTTCTGG	4Ebp1	 GGGGACTACAGCACCACTC	 CTCATCGCTGGTAGGGCTA	Afg3L2	 GTTGATGGGCAATACGTCTGG	 GACCCGGTTCTCCCCTTCT	Atf4	 GCAAGGAGGATGCCTTTTC	 GTTTCCAGGTCATCCATTCG	Chop	 TGCCTTTCACCTTGGAGAGACGG	 CGCAGGGTCAAGAGTAGTGAAGG	Cdkn1a	 CCTGGTGATGTCCGACCTG	 CCATGAGCGCATCGCAATC	ClpX	 CTTCGCTGTCCTAAATGTGGT	 CCAACAACATACTTGTCGAGGT	Cox4i2	 CTGCCCGGAGTCTGGTAATG	 CAGTCAACGTAGGGGGTCATC	Fbxo32	 CAGCTTCGTGAGCGACCTC	 GGCAGTCGAGAAGTCCAGTC	Fgf21	 GTGTCAAAGCCTCTAGGTTTCTT	 GGTACACATTGTAACCGTCCTC	Fh1	 GGTCATCAAAATTGGGCGAAC	 CTTGCTGAACGTAACCACTGAA	Gadd45a	 CCGAAAGGATGGACACGGTG	 TTATCGGGGTCTACGTTGAGC	Gdf15	 GAGCTACGGGGTCGCTTC	 GGGACCCCAATCTCACCT	Glut1	 TCAGGCGGAAGCTAAC	 GGAGGAAACATGCAGTCATC	Gpd2	 CACTAGATGCCGTCACCAGAG	 GAAGGGCTTCTTTCACCATCC	Hprt	 GCCCAAAATGGTTAAGGTT	 TTGCGCTCATCTTAGGCTTT	Hsp60	 GCCTTAATGCTTCAAGGTGTAGA	 CCCCATCTTTTGTTACTTTGGGA	Klf15	 CCATTGCCGCCAAACCTATTG	 AACTCATCTGAGCGGGAAAAC	Lars	 GAAAGCAGTGCTAAACCTGGA	 CACTATGTCGTCATCAGAGAGC	Lias	 CCTGGGGTCCCGGATATTTG	 GAAGGTCTGGTCCATTATGCAA	Lonp1	 ATGACCGTCCCGGATGTGT	 CCTCCACGATCTTGATAAAGCG	Mthfd2	 CTGAAGTGGGAATCAACAGTGAG	 GTCAGGAGAAACGGCATTGC	Nars	 GAGCTGTATGTATCTGACCGAGA	 AAATGGTGGGAAATGGCTCTTT	Ogdh	 GTTTCTTCAAACGTGGGGTTCT	 GCATGATTCCAGGGGTCTCAAA	Pgc1a	 TATGGAGTGACATAGAGTGTGCT	 CCACTTCAATCCACCCAGAAAG	Trim63	 GTGTGAGGTGCCTACTTGCTC	 GCTCAGTCTTCTGTCCTTGGA	Vdac1	 CCCACATACGCCGATCTTGG	 GCTGCCGTTCACTTTGGTG	Vdac2	 CTCCACCCTATGCTGACCTC	 CCCGCTAACTTTACCAGTGTCT	
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2.8 Histology	and	Imaging	
2.8.1 Formaldehyde	fixation	and	paraffin	embedding	of	tissues	Liver	 and	 skeletal	 muscle	 tissues	 were	 fixated	 overnight	 in	 4%	 PBS-buffered	formaldehyde	 solution	 at	 4°C.	 Dehydration	 was	 performed	 automated	 using	 the	following	gradient:	2h	50%	EtOH,	2h	75%	EtOH,	1h	96%	EtOH,	2x	2h	100%	EtOH,	2x	2h	in	100%	xylol.	Tissues	were	embedded	in	paraffin	wax	(Paraplast)	for	1h,	2h	and	1h.		5µm	histological	 sections	were	 produced	 using	 a	microtome	 and	 transferred	 onto	poly-L-lysine	glass	slides	for	the	following	staining	procedures:		
2.8.2 Hematoxylin	and	Eosin	(H&E)	staining	For	morphological	analysis,	5µm	formaldehyde-fixated	paraffin	tissue	sections	were	deparaffinized	 and	 hydrated.	 Sections	 were	 incubated	 for	 4	 min	 in	 Mayer’s	hematoxylin	solution	and	washed	for	15	min	in	running	water.	Counterstaining	was	performed	with	 eosin	 solution	 for	1	min,	washed	with	water	 and	 sections	 in	95%	EtOH	 and	 100%	 EtOH	 for	 2	 min	 each.	 Section	 were	 further	 cleared	 in	 xylol	 and	mounted	with	Entallan.		
2.8.3 PAS	staining	for	glycogen	detection	For	 glycogen	 content	 determination,	 5µm	 formaldehyde-fixated	 paraffin	 tissue	sections	were	 deparaffinized	 and	 hydrated.	 The	 sections	were	 further	 oxidised	 in	0.5%	 periodic	 acid	 for	 5	 min	 and	 incubated	 in	 Schiff	 reagent	 for	 15	 min.	 Excess	solution	 was	 removed	 with	 running	 water	 for	 5	 min	 and	 the	 sections	 were	counterstained	with	Mayer’s	 hematoxylin	 solution	 for	 1	min.	 Excess	 solution	was	again	 removed	 with	 running	 water	 for	 5	 min	 and	 sections	 were	 dehydrated	 and	mounted	as	described	for	the	H&E	staining	procedure.	Glycogen	is	stained	in	a	deep	red/purple	colour,	while	the	background	is	stained	blue.		 	
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2.8.4 Tissue	fixation	and	transmission	electron	microscopy	(TEM)	Freshly	isolated	skeletal	muscle	tissue	was	minced	into	5-10	small	pieces	and	fixated	in	 glutaraldehyde	 buffer.	 Sample	 preparation,	 contrasting	 and	 cutting	 have	 been	performed	at	the	CECAD	imaging	facility	and	image	acquisition	has	been	performed	together	with	the	facility.		
2.9 Image	processing	and	data	analysis		Western	 blot	 films	 were	 scanned	 using	 an	 Epson	 V800	 transparency	 scanner	 at	800dpi	 16Bit	 colour	 depth.	Histology	 sections	were	 imaged	with	 an	 SCN400	 slide	scanner	 (Leica)	 at	 40x	 magnification	 and	 TEM	 images	 were	 taken	 with	 a	 JEOL	JEM2100PLUS	microscope	and	a	OneVew	 (GATAN)	 camera.	Adobe	Photoshop	was	used	 to	 crop	 pictures,	 adjust	 contrast	 (globally	 to	 the	 entire	 scan)	 and	 remove	remaining	 inscriptions	 from	 scanned	 films.	 Adobe	 Illustrator	 was	 used	 for	 figure	arrangement	and	model	illustrations.	Graphpad	Prism	8	was	used	for	graphs	and	charts	and	statistical	analyses	as	indicated	in	 the	 figures.	 Instant	 clue	 (University	 of	 Cologne)	 was	 used	 for	 the	 heatmap	illustration	of	the	hierarchical	clustering.
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3 Results	
3.1 Role	of	succinate	dehydrogenase	in	muscle	metabolism			 Many	(mouse)	models	with	loss	of	functions	of	mitochondrial	proteins	directly	or	 indirectly	 affect	 the	 respiratory	 chain	 and	 thus	 ATP	 production.	 Typically,	 the	pathological	phenotype	was	therefore	prematurely	also	ascribed	to	the	lack	of	ATP	in	the	 past.	 Recently,	 however,	 it	 became	 obvious	 that	 other	 incidents	 such	 as	 the	shortage	of	essential	metabolites	or	an	overactive	stress	response	can	substantially	contribute	to	the	progression	of	the	phenotype	or	the	patient	outcome	(Birsoy	et	al.	2015,	Sullivan	et	al.	2015,	Wang	et	al.	2018).	To	further	elucidate	the	intertwined	role	of	 mitochondrial	 metabolism	 and	 energy	 homeostasis,	 a	 striated	 muscle-specific	deletion	 of	 the	 catalytically	 active	 complex	 II	 subunit	 SDHA	 was	 developed	 in	C57BL6N	mice	using	ACTA-Cre-mediated	recombination.		
3.1.1 SDHAMKO	mice	exhibit	multisystemic	phenotypes		 SDHA	 was	 deleted	 in	 embryonic	 and	 adult	 myocytes	 and	 knockout	 mice	(SdhaMKO)	survived	until	4.5	weeks	of	age	(Figure	3.1	B)	with	severe	muscle	loss	and	growth	retardation	(Figure	3.1	A	and	C).	From	3	weeks	of	age,	SdhaMKO	mice	exhibited	markedly	less	voluntary	movement,	loss	of	white	adipose	tissue,	as	well	as	clear	signs	of	 hypoglycaemia	 (Figure	 3.1	 D).	 Glycogen	 storages	 in	muscles,	 evidenced	 by	 PAS	staining	of	quadriceps	sections,	revealed	no	difference	between	the	two	genotypes,	confirming	that	glycogen	does	not	primarily	serve	as	a	source	for	ATP	production	in	
vivo	(Figure	3.1	E)	(Ortenblad	et	al.	2013).	
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Figure	3.1	SdhaMKO	mice	have	reduced	body	and	muscle	mass	with	low	blood	glucose	levels	(A)	Photograph	of	wild	type	and	SdhaMKO	mice	at	the	age	of	4	weeks.	(B)	Survival	rate	of	SdhaMKO	mice.	(C)	Photograph	of	wild	type	and	SdhaMKO	femur	bones	at	the	age	of	3	weeks	on	1mm2	squares.	(D)	Blood	glucose	concentration	and	bodyweight	of	3	weeks	old	mice.	(E)	PAS	staining	of	wild	type	and	SdhaMKO	quadriceps	muscle	sections	at	the	age	of	3	weeks.	Data	presented	as	individual	points.		
3.1.2 Loss	of	SDHA	only	affects	complex	II	of	the	respiratory	chain		 Surprisingly,	 isolated	 muscle	 mitochondria	 had	 normal	 levels	 of	 respiratory	chain	 proteins	 and	 complexes	 (Figure	 3.2	 A	 and	 B)	 and	 showed	 comparable	respiratory	capacity	when	supplemented	with	pyruvate,	malate	and	glutamate	in	the	respiration	medium	 (Figure	 3.2	 C).	 Despite	 residual	 levels	 of	 SDHA	protein	 in	 the	
SdhaMKO	 knockout	 muscles	 (Figure	 3.2	 A),	 no	 SDH	 complexes	 or	 succinate-driven	respiration	(Figure	3.2	C)	was	detected	in	SdhaMKO	muscle	mitochondria.	In	line	with	unaltered	 complex	 I-dependent	 respiratory	 function	 and	normal	 respiratory	 chain	subunit	 abundance,	 mtDNA	 levels	 were	 also	 comparable	 between	 wild	 type	 and	
SdhaMKO	muscles	(Figure	3.2	D).		
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Figure	3.2	Loss	of	SDHA	in	skeletal	muscle	tissue	only	affects	SDH	levels	and	function	(A)	Western	blot	analysis	of	quadriceps	muscle	lysates.	(B)	BN-PAGE	analysis	of	muscle	mitochondria.	Antibodies	against	SDHA	and	respiratory	chain	subunits	were	used	as	indicated.	HSC70,	VDAC1	and	HSP607n	were	used	as	loading	controls.	(C)	Respirometry	of	muscle	mitochondria	(n=1).	(D)	mtDNA	quantification	with	qPCR	of	quadriceps	muscles	at	the	age	of	4	weeks	(n=5).	HK2	DNA	was	used	for	normalisation.	Data	presented	as	individual	bars	or	points	with	mean	±	SD.		
3.1.3 SDHAMKO	muscle	fibres	show	increased	atrophy	at	early	stages		 To	 investigate	 the	 physiological	 consequences	 of	 the	 complex	 II	 deficit	 in	muscles	in	an	unbiased	way,	label-free	protein	quantification	of	muscle	lysates	was	performed	at	3	weeks	of	age.	Gene	ontology	enrichment	analysis	revealed	a	profound	down	 regulation	 of	 processes	 related	 to	 cytosolic	 translation	 and	 an	 increase	 of	(stress	 related)	 mRNA	 processing	 and	 extracellular	 matrix	 proteins.	 Additionally,	lysosomal	proteases	and	proteins	associated	with	cell	death	were	among	the	highest	up-regulated	proteins	in	SdhaMKO	quadriceps	muscles	(Table	3.1).		 	
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Table	3.1:	GO-Term	analysis	of	3	weeks	old	quadriceps	muscle	proteomics	
GO	Term	 Mean	FC	log2(KO/WT)	aminoacyl-tRNA	synthetase	multienzyme	complex	 -1.02726	cytosolic	large	ribosomal	subunit	 -0.883524	polysomal	ribosome	 -0.821117	cytoplasmic	translation	 -0.816493	small	ribosomal	subunit	 -0.677551	rRNA	processing	 -0.662523	cytosolic	small	ribosomal	subunit	 -0.59881	chaperonin-containing	T-complex	 -0.595175	endoplasmic	reticulum	lumen	 -0.550944	structural	constituent	of	ribosome	 -0.458166	chaperone-mediated	protein	folding	 -0.457449	translation	 -0.435888	ribosome	 -0.423367	ER	to	Golgi	vesicle-mediated	transport	 -0.412481	endoplasmic	reticulum-Golgi	intermediate	compartment	 -0.394036	vesicle-mediated	transport	 -0.303095	endoplasmic	reticulum	membrane	 -0.274995	actin	cytoskeleton	 0.268035	chromosome	 0.274773	focal	adhesion	 0.309418	basolateral	plasma	membrane	 0.34969	extracellular	matrix	 0.389771	cell	adhesion	 0.392051	mRNA	processing	 0.393653	catalytic	step	2	spliceosome	 0.399639	nuclear	matrix	 0.402953	caveola	 0.411069	RNA	splicing	 0.433265	stress	fiber	 0.469216	spliceosomal	complex	 0.481776	nuclear	inner	membrane	 0.567994	microvillus	 0.616359	myosin	complex	 0.646945	collagen	trimer	 0.769881			 	
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In	 order	 to	 further	 investigate	 the	 responses	 elicited	 from	 affected	muscles,	 gene	expression	of	classical	stress	markers	and	muscle	homeostasis	were	investigated	in	muscles	 of	 3	 weeks	 old	 mice.	 In	 line	 with	 an	 increased	 abundance	 of	 lysosomal	proteases,	SdhaMKO	muscles	strongly	induced	the	expression	of	ATF4-	and	FOXO3A-dependent	 atrophy	 markers	 (Figure	 3.3	 A),	 but	 surprisingly	 only	 increased	 Atf4	mRNA	 expression	 as	 a	 stress	 response.	 Other	 members	 of	 the	 integrated	 stress	response,	 such	 as	 Chop,	 Fgf21,	Gdf15	 or	Mthfd2	 were	 unchanged	 or	 even	 showed	reduced	 expression	 in	 SdhaMKO	 muscles	 (Figure	 3.3	 B).	 Histologically,	 SdhaMKO	quadriceps	muscle	fibres	were	comparable	in	size	and	did	not	show	any	signs	of	tissue	damage	(Figure	3.3	C).	The	absence	of	centralised	nuclei	further	indicated	that	at	least	no	tissue	regeneration,	which	is	commonly	associated	with	mitochondrial	defects	in	muscles,	occurred	in	SdhaMKO	muscles.	In	line	with	this	observation,	ultrastructure	of	knockout	muscle	fibres	and	mitochondria	was	unaltered	as	well.	The	swollen	and	or	cristae-lacking	mitochondria	 frequently	 observed	 in	 e.g.	 complex	 I	 (Civiletto	 et	 al.	2015)	or	complex	IV	(Viscomi	et	al.	2011)	mutant	muscles	could	not	be	seen	(Figure	3.3	D).	While	a	clear	fibre	type	switch	was	not	observed,	SdhaMKO	quadriceps	muscles	had	 increased	 protein	 levels	 of	 both,	 fast	 and	 slow	 twitching	myosin	 heavy	 chain	isoforms	(Figure	3.3	E).	This	increase	was	not	recapitulated	by	skeletal	alpha	actin	(ACTA1)	and	the	effects	of	this	imbalance	are	currently	unknown.	
	 	 3	Results	
		 	 	 43	
	
Figure	3.3	SdhaMKO	muscles	display	normal	morphology	and	initiate	an	atrophic	response	at	3	
weeks	of	age	(A)	Relative	expression	levels	of	atrophy	related	genes	with	qPCR	(n=5).	(B)	Relative	expression	levels	of	 integrated	 stress	 response	 genes	with	 qPCR	 (n=5).	 (C)	H&E	 staining	 of	 3	weeks	 old	 quadriceps	muscle	sections	fixated	in	formaldehyde	and	embedded	in	paraffin.	Scale	bars	25µm.	(D)	Ultrastructure	analysis	of	3	weeks	old	quadriceps	muscles	using	transmission	electron	microscopy.	Scale	bars:	top	1µm,	bottom	500nm.	(E)	Western	blot	analysis	of	skeletal	muscle	lysates	for	fibre	type	compositions.	Antibodies	were	uses	as	indicated	and	TUBULIN	was	used	as	loading	control.	Data	presented	as	mean	±	SD	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).				 	
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3.1.4 Increased	mitobiogenesis	in	SDHAMKO	muscle	fibres	at	late	stages		 Due	to	the	possibility	of	a	delayed	stress	response,	animals	were	additionally	analysed	at	4	weeks	of	age,	at	which	all	animals	displayed	strongly	reduced	movement	and	 signs	 of	 tremor	 as	 well	 as	 piloerection.	 Surprisingly,	 at	 this	 timepoint	 the	expression	of	atrophy	markers	and	Atf4	were	blunted	(Figure	3.4	A).	Furthermore,	an	isolated	induction	of	Chop	and	Gdf15	expression	was	observed	at	this	age	(Figure	3.4	B).	Despite	the	extended	time	of	observable	phenotype,	no	increased	expression	of	
Fgf21,	Mthfd2	or	Klf15	could	be	detected	(Figure	3.4	B).	This	absence	of	an	integrated	stress	response	was	further	confirmed	on	protein	level,	were	also	other	markers	such	as	 SHMT2	 or	 ALDH18A1	 were	 unaltered	 in	 the	 SdhaMKO	 knockout	 (Figure	 3.4	 C).	Despite	the	severe	muscle	loss	at	this	age,	no	changes	in	P62	levels	were	observed,	arguing	against	autophagy	as	a	main	driver	of	atrophy.	Fasting	is	a	known	trigger	of	autophagy-mediated	muscle	wasting	 (Bujak	et	al.	2015),	however,	muscles	 lacking	complex	IV	activity	were	reported	to	have	inhibited	autophagy	(Civiletto	et	al.	2018).	Unlike	 the	before	mentioned	markers,	 both	MTHFD2	and	PYCR1	 levels	were	 even	strongly	decreased	compared	to	wild	type	tissue	(Figure	3.4	C).	To	identify	the	main	pathways	affected	at	this	age,	label-free	quantification	of	muscle	proteins	was	again	performed.	 While	 cytosolic	 translation	 was	 still	 the	 main	 overall	 down-regulated	pathway,	 at	 this	 age,	 SdhaMKO	 muscles	 displayed	 a	 strong	 accumulation	 of	mitochondrial	and	peroxisomal	proteins,	 especially	 regarding	enzymes	 involved	 in	fatty	acid	oxidation	(FAO)	(Figure	3.4	D	and	E).	Although	the	sarcomere	structure	of	muscle	fibres	was	still	not	affected	in	SdhaMKO	muscles,	the	increased	mitochondrial	mass	 can	 be	 attributed	 to	 large	 accumulations	 of	 intermyofibrillar	 mitochondrial	aggregations	observed	in	SdhaMKO	muscle	TEM	sections	(Figure	3.4	F).	These	clusters	sporadically	 appeared	within	 the	 fibres	 and	 seemed	 to	 be	 unfused	 congestions	 of	mitochondrial	entities	that	still	displayed	morphologically	correct	cristae	structures.	Increased	mitochondrial	mass	was	further	confirmed	by	the	accumulation	of	soluble	and	membrane	bound	mitochondrial	proteins	on	western	blots	(Figure	3.4	G).		
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Figure	3.4	SdhaMKO	muscles	have	increased	mitobiogenesis	at	4	weeks	of	age	(A)	Relative	expression	levels	of	atrophy	related	genes	with	qPCR	(n=5).	(B)	Relative	expression	levels	of	integrated	stress	response	genes	and	Klf15	with	qPCR	(n=5).	(C)	Western	blot	analysis	of	skeletal	muscle	lysates	for	proteins	of	the	integrated	stress	response.	HSC70	was	used	as	loading	control.	(D)	GO-Term	analysis	of	label-free	quantifications	of	quadriceps	lysates	at	4	weeks	of	age.	(E)	Hierarchical	clustering	 of	 mitochondria	 annotated	 proteins	 from	 label-free	 quantifications.	 GOBP:	 Fatty	 acid	oxidation	annotated	proteins	are	depicted	on	the	right	site.	(F)	Ultrastructure	analysis	of	4	weeks	old	
SdhaMKO	 quadriceps	muscles	 using	 transmission	 electron	microscopy.	 Scale	 bars:	 top	 1µm,	 bottom	500nm.	(G)	Western	blot	analysis	of	skeletal	muscle	 lysates	 for	mitochondrial	proteins.	HSC70	was	used	as	loading	control.			
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3.1.5 Metabolic	 changes	 drive	 AMPK-dependent	 NAD+	 accumulation	 in	
SDHAMKO	muscles		 To	understand	the	underlying	deficits	of	SdhaMKO	animals,	isolated	muscles	were	subjected	 to	 metabolic	 and	 energetic	 analyses.	 Typically,	 in	 tissues	 or	 cells	 with	compromised	respiratory	chain	activity,	such	as	those	of	Dars2HKO	or	mutator	mice,	NAD+/NADH	ratios	drop	due	 to	 the	 inability	 to	oxidise	NADH	via	 complex	 I	of	 the	respiratory	chain	(unpublished	data).	SdhaMKO	muscles,	however,	displayed	increased	NAD+	 levels	 (Figure	 3.5	 A),	 which	 is	 in	 line	with	 unaffected	 complex	 I-dependent	respiration	 in	 vitro	 (Figure	 3.2	 C).	 No	 changes	 in	 NADH	 levels	 were	 detected	 in	
SdhaMKO	muscles,	 arguing	 for	 an	 increase	 of	de	 novo	 synthesis	 or	 salvage	 of	 NAD+	rather	than	the	inability	to	reduce	NAD+.	A	key	enzyme	of	the	NAD+	synthesis	pathway	is	nicotinamide	phosphoribosyl	transferase	(NAMPT),	which	was	more	abundant	in	the	 knockout	 (3	 weeks	 LFQ	 log2(KO/WT):	 0.59).	 A	 well	 described	 pathway	 that	regulates	NAD+	synthesis	via	NAMPT	is	dependent	on	the	activity	of	5’	AMP-activated	protein	 kinase	 (AMPK).	 AMPK	 is	 an	 important	 regulator	 of	 skeletal	 muscle	homeostasis	 and	 fully	 active	 when	 phosphorylated	 (pAMPK)	 and	 bound	 to	 AMP.	
SdhaMKO	animals	had	increased	levels	of	pAMPK	at	both	3	and	4	weeks	of	age	(Figure	3.5	B)	and	a	decreased	energy	charge	displayed	by	 lower	ADP	and	ATP	 levels	and	increased	AMP	content	(Figure	3.5	C),	indicating	the	induction	of	AMPK	activity.	All	other	 detected	 mono-phosphorylated	 nucleotides	 were	 less	 abundant	 in	 SdhaMKO	muscles	(Figure	3.5	D).	De	novo	 synthesis	of	any	nucleotide	 is	ATP-consuming	and	dependent	on	the	amino	acids	glutamine	and	aspartate,	which	were	among	the	most	severely	depleted	amino	acids	in	SdhaMKO	muscles	(Figure	3.5	E).	Overall	amino	acid	abundance	 was	 decreased	 in	 SdhaMKO	 muscles	 (Figure	 3.5	 E),	 pointing	 towards	 a	change	in	their	metabolic	usage	since	they	typically	do	not	notably	contribute	to	ATP	production	(Romijn	et	al.	1993).		
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Figure	3.5	Loss	of	SDHA	in	muscles	causes	ATP	and	amino	acid	depletion	and	activates	AMPK	
signalling	(A)	Colorimetric	quantification	of	NAD+/NADH	levels	in	deproteinised	skeletal	muscle	lysates	(n=4);	NADt	 =	 total	 NAD++NADH.	 (B)	 Western	 blot	 analysis	 of	 skeletal	 muscle	 lysates	 for	 AMPK	 and	phosphorylated	AMPK	levels	at	3	and	4	weeks.	HSC70	was	used	as	loading	control.	(C)	Metabolomic	quantification	of	AMP,	ADP	and	ATP	in	3	weeks	old	muscles	(n=9-10).	Protein	concentration	was	used	for	normalisation.	(D)	Metabolomic	quantification	of	other	nucleotides	in	3	weeks	old	muscles	(n=9-10).	Protein	 concentration	was	used	 for	normalisation.	 (E)	Quantification	of	 amino	acid	 levels	 in	4	weeks	old	muscles	(n=4).	Protein	concentration	was	used	for	normalisation.	Data	presented	as	mean	±	SD	for	nucleotides	and	log2	FC(KO/WT)	for	amino	acids	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).			
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3.1.6 AKT	and	ERK1/2	signalling	intensifies	the	atrophy	program	in	SDHAMKO	
muscles		 Excessive	AMPK	activation	in	skeletal	muscles,	such	as	during	prolonged	fasting,	is	a	known	contributor	to	muscle	wasting	due	to	the	phosphorylation	and	activation	of	FOXO3A	(Thomson	2018),	which	might	be	contributing	to	the	atrophy	observed	in	
SdhaMKO	muscles	(Figure	3.3	A).	To	further	elaborate	on	the	regulation	of	atrophy	and	myogenesis,	other	implicated	kinase	pathways	were	investigated	as	well.	AKT	(also	known	 as	 protein	 kinase	 B)	 is	 a	 growth	 hormone-regulated	 kinase	 implicated	 in	numerous	 biological	 pathways	 such	 as	 cell	 cycle/survival,	 protein	 synthesis	 and	metabolism	(Yu	and	Cui	2016).	Phosphorylated	and	activated	by	phosphoinositide	3-kinase	 (PI3K),	 AKT	 phosphorylates	 FOXO3A,	 which	 is	 also	 one	 of	 AMPK’s	 direct	targets.	Unlike	AMPK,	however,	 phosphorylation	by	AKT	 inhibits	 FOXO3A	activity.	
SdhaMKO	mice	displayed	reduced	AKT	phosphorylation	(Figure	3.6	A),	which	in	turn	would	 further	 strengthen	 FOXO3A	 activation	 by	 AMPK.	 In	 line	with	 reduced	 AKT	activity	was	also	the	lack	of	consistent	mTOR	activation	(Figure	3.6	C),	which	has	been	observed	in	muscles	of	other	mitochondrial	dysfunction	models	(Khan	et	al.	2017).	Myostatin-driven	 myogenesis	 in	 adult	 muscles	 is	 in	 part	 mediated	 by	 a	 mitogen-activated	 protein	 kinase	 (MAPK)	 cascade	 with	 the	 extracellular	 signal-regulated	kinases	 ERK1/2	 as	 the	 final	 kinases.	 SdhaMKO	 muscles	 had	 less	 phosphorylated	ERK1/2	 (pERK1/2)	 independent	 of	 their	 age	 (Figure	 3.6	 B),	 indicating	 that	additionally	 to	 increased	muscle	 wasting,	 hormone	 induced	myogenesis	might	 be	repressed.	As	reported	before,	ERK2	was	the	primarily	expressed	isoform	in	skeletal	muscles	 (Figure	 3.6	 B).	 Similar	 to	 mTOR	 phosphorylation	 and	 signalling,	 eIF2a	phosphorylation	 was	 unaltered	 in	 SdhaMKO	 muscles	 (Figure	 3.6	 C),	 potentially	explaining	 the	 lack	 of	 an	 integrated	 stress	 response	 signature.	 At	 both	 timepoints	
SdhaMKO	 muscles	 had	 no	 signs	 of	 oxidative	 damage,	 however,	 increasingly	accumulated	proteins	with	lysine-acetylation	with	age	(Figure	3.6	D).			
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Figure	3.6	SdhaMKO	muscles	have	decreased	ERK/AKT	signalling	without	affecting	mTOR	targets	(A)	Western	blot	analysis	of	skeletal	muscle	lysates	for	AKT	and	phosphorylated	AKT	levels	at	3	and	4	weeks	and	pAKT/AKT	ratio	determination	with	densitometric	quantification	(n=3).	(B)	Western	blot	analysis	 of	 skeletal	 muscle	 lysates	 for	 phosphorylated	 ERK1/2	 levels	 at	 3	 and	 4	 weeks	 and	densitometric	quantification	(n=3).	HSC70	was	used	as	loading	control.	(C)	Western	blot	analysis	of	skeletal	muscle	lysates	for	(phosphorylated)	eIF2a,	mTOR	and	RPS6	levels	at	3	and	4	weeks	of	age.	HSC70	was	used	as	loading	control.	(D)	Western	blot	analysis	of	skeletal	muscle	lysates	for	proteins	with	HNE	modification	(4-HNE)	and	lysine	acetylation	(AcK).	HSC70	was	used	as	loading	control.	Data	presented	as	mean	±	SD	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).			 	
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3.1.7 SDHAMKO	 muscles	 have	 no	 hypoxic	 response	 despite	 succinate	
accumulation		 Most	SDHx	mutation-derived	tumours,	as	well	as	cultured	cells	with	impaired	SDH	function	display	succinate	accumulation	due	to	the	inability	to	actively	export	the	metabolite	from	the	cells.	In	3	weeks	old	SdhaMKO	muscles,	succinate	accumulated	to	around	800	times	the	wild	type	level	(Figure	3.7	A),	whereas	most	other	detected	TCA	cycle	metabolites	were	 unchanged	 (Figure	 3.7	 C).	 Reportedly,	 increased	 succinate	concentrations	inhibit	2-oxoglutarate	(2-OG)-dependent	dioxygenases	such	as	prolyl	hydroxylases	 (PHDs)	 that	 regulate	 HIF1a	 stability	 or	 the	 activity	 of	 DNA	 methyl	transferases	 (Bargiela	 et	 al.	 2018).	 Therefore,	 SDHx	 mutations	 are	 commonly	associated	with	a	“pseudo-hypoxic”	state	and	hyper-methylated	DNA.	However,	the	HIF1a	target	genes	most	commonly	induced	during	hypoxia	LonP1,	Glut1	and	Cox4i2	were	all	expressed	to	lesser	extend	SdhaMKO	muscles	(Figure	3.7	B).		
	
Figure	 3.7	 Loss	 of	 SDHA	 in	muscles	 causes	 succinate	 accumulation	without	 affecting	 HIF1a	
targets		(A)	 Metabolomic	 quantification	 of	 succinate	 levels	 in	 3	 weeks	 old	 muscles	 (n=9-10).	 (B)	 Relative	expression	 levels	of	HIF1a	 target	 genes	with	qPCR	 (n=5).	Metabolomic	quantification	of	TCA	cycle	metabolite	levels	in	3	weeks	old	muscles	(n=9-10).	Data	presented	as	mean	±	SD	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).		
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3.1.8 SDHAMKO	livers	are	depleted	of	glycogen	storages		 During	 starvation	 or	 an	 energetic	 crisis,	 the	 glucose	 demand	 of	 muscles	 is	initially	supplied	by	the	liver	and	after	prolonged	time	further	amended	by	fatty	acid	complementation	from	adipose	tissue.	To	investigate	how	a	skeletal	muscle-specific	loss	of	SDHA	affects	whole	body	metabolism,	liver	sections	from	knockout	and	control	animals	were	analysed.	Similar	to	muscle	fibres,	hepatocytes	from	SdhaMKO	livers	were	comparable	 in	 size	with	 the	overall	 tissue	 size	being	much	 smaller	 (Figure	3.8	A).	Additionally,	these	hepatocytes	contained	less	glycogen,	indicated	by	the	fainter	PAS	staining	(Figure	3.8	B).	Together	with	the	severe	loss	of	white	adipose	tissue	mass,	it	is	 apparent	 that	 SdhaMKO	 animals	 show	 systemic	 adaptations	 to	 supply	 the	compromised	muscles	with	available	energy	carriers.		
	
Figure	3.8	Loss	of	SDHA	in	skeletal	muscles	systemically	affects	hepatic	glycogen	storage	(A)	H&E	staining	of	3	weeks	old	liver	sections	fixated	in	formaldehyde	and	embedded	in	paraffin.	Scale	bars	 100µm.	 PAS	 staining	 of	 3	weeks	 old	 liver	 sections	 fixated	 in	 formaldehyde	 and	 embedded	 in	paraffin.	Scale	bars	100µm.			In	 summary,	 loss	 of	 skeletal	 muscle	 SDHA	 had	 a	 profound	 impact	 on	 local	 ATP	production,	 which	 triggered	 a	 cascade	 of	 responses	 to	 alleviate	 the	 energy	 crisis,	peaking	in	the	complete	depletion	of	all	fat	reserves.	Additionally,	systemic	alterations	of	glucose	homeostasis	and	body	size,	as	well	as	a	unique	stress	response	signature	could	be	observed	in	SdhaMKO	animals.		 	
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3.1.9 SDHAHKO	hearts	lose	complex	II	early	in	life	and	develop	cardiomyopathy		 Although	the	physiological	consequences	of	a	succinate	dehydrogenase	defect	in	striated	muscles	was	in	part	comparable	to	those	caused	by	other	respiratory	chain	deficiencies,	the	metabolic	and	molecular	consequences	were	repeatedly	different	or	in	 the	opposite	direction.	To	understand	whether	 these	discrepancies	stem	 from	a	difference	in	the	investigated	tissue,	the	affected	protein,	or	the	combination	of	both,	SDHA	was	also	deleted	specifically	in	heart	and	skeletal	muscles	with	Ckmm-NLS-Cre-mediated	recombination.	Using	the	Ckmm	promoter,	the	primary	and	eventually	fatal	defect	originates	from	the	heart,	allowing	it	to	be	used	as	a	model	for	cardiomyocyte	specific	 gene	 deletions.	 Deletion	 of	 SDHA	 in	 the	 heart	 (SdhaHKO)	 caused	 lethality	between	 16	 and	 21	 days	 of	 age	 (Figure	 3.9	 A)	 with	 a	 suddenly	 occurring,	 severe	cardiomyopathy.	SdhaHKO	animals	had	increased	heart	to	bodyweight	ratios	early	on	(Figure	 3.9	 B	 and	 C)	 but	 did	 not	 exhibit	 hypoglycaemia	 as	 it	was	 observed	 in	 the	
SdhaMKO	 line	 (Figure	3.9	D).	By	 the	age	of	11	days,	 animals	 almost	 completely	 lost	succinate	dehydrogenase	activity,	whereas	complex	I	activity	was	not	affected	in	the	heart	 (Figure	3.9	F).	This	 loss	occurred	although	SDHA	protein	 levels	 remained	at	around	50%	of	control	animals,	possibly	due	to	a	faster	loss	of	the	anchoring	subunit	SDHB	(Figure	3.9	E).			
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Figure	3.9	Loss	of	SDHA	in	cardiomyocytes	abolishes	SDH	levels	and	function		(A)	Survival	rate	of	SdhaHKO	mice.	(B)	Heart	to	body	weight	ratio	of	20	days	old	SdhaHKO	mice.	(C)	Heart	to	 body	weight	 ratio	 of	 11	 days	 old	SdhaHKO	mice.	 (D)	Blood	 glucose	 concentration	 of	 20	 days	 old	
SdhaHKO	mice.	(E)	Densiometric	quantification	of	respiratory	chain	subunits	(n=3).	Enzyme	activities	of	respiratory	chain	complex	I,	complex	II	and	citrate	synthase	(CS)	(n=4).	Data	presented	as	individual	points	or	mean	±	SD	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).			 	
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3.1.10 SDHAHKO	heart	mitochondria	lack	complex	II	activity	and	lose	complex	IV	
at	late	stages		 Similar	 to	 muscle	 mitochondria,	 mitochondria	 isolated	 from	 SdhaHKO	 hearts	showed	 normal	 complex	 I-dependent	 respiration,	 whereas	 succinate	 driven	respiration	 was	 largely	 abolished	 (Figure	 3.10	 A).	 Accompanied	 with	 lower	respiration	 levels	 was	 also	 a	 reduced	 ROS	 production	 during	 the	 respiration	measurements	 (Figure	 3.10	 B).	 Surprisingly,	 some	 SdhaHKO	 hearts	 at	 21	 days	 lost	complex	IV	subunits,	complexes	and	complex	activity	(Figure	3.10	C-E),	an	effect	that	could	 not	 be	 observed	 in	 younger	 animals,	 even	 when	 the	 cardiomyopathy	 has	progressed	severely.			
	
Figure	3.10	SdhaHKO	heart	mitochondria	show	normal	respiration	but	sporadically	lose	complex	
IV	at	late	stages	(A)	Respirometry	of	19	days	old	heart	mitochondria	(n=3).	(B)	ROS	production	of	19	days	old	heart	mitochondria	 determined	 by	 AmpR	 oxidation	 (n=3).	 (C)	 BN-PAGE	 analysis	 of	 19	 days	 old	 heart	mitochondria	with	Coomassie	staining	(left)	and	complex	 IV	 in	gel	activity	staining	(right).	 (D)	BN-PAGE	analysis	of	heart	mitochondria.	(E)	Western	blot	analysis	of	21	days	old	heart	mitochondria	for	respiratory	chain	subunits.	Antibodies	were	used	as	indicated.	Data	presented	as	mean	±	SD	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).	
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This	 loss	 of	 complex	 IV	 subunits	 was	 also	 confirmed	 with	 label-free	 protein	quantifications,	that	showed	a	clear	loss	of	almost	all	detected	subunits	(Figure	3.11	A).	Loss	of	complex	IV	and	the	other	complex	II	subunits	likely	resulted	from	changes	in	protein	stability	or	proteolysis,	as	their	mRNA	levels	were	not	affected	(Figure	3.11	B).		
	
Figure	3.11	SdhaHKO	heart	proteomics	and	respiratory	chain	gene	expression	(A)	 Volcano	 plot	 of	 label-free	 quantification	 of	 21	 days	 old	 heart	 lysates.	 Individual	 proteins	 are	annotated	and	the	implicated	function	is	noted	(bottom)	in	the	same	colour.	(B)	Relative	expression	levels	of	respiratory	chain	subunits	with	qPCR	(n=5).		Data	presented	as	mean	±	SD	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).		To	 exclude	 a	 potential	 role	 of	mitochondrial	 translation	 in	 the	 loss	 of	 complex	 IV	subunits,	freshly	isolated	heart	mitochondria	were	used	for	in	organello	translation	assays,	 that	 revealed	 a	 mild	 reduction	 of	 translation	 rates	 in	 SdhaHKO	 heart	mitochondria	for	all	mitochondria-encoded	peptides	(Figure	3.12).		 	
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Figure	3.12	Loss	of	SDHA	in	the	heart	mildly	disturbs	mitochondrial	translation	
In	organello	analysis	of	heart	mitochondrial	translation	from	20	days	old	wild	type	and	SdhaHKO	mice.	30	min	pulse	labelling	and	2h	chase	are	presented	on	an	autoradiography	screen	(top).	Mitochondrial	encoded	 peptides	 run	 as	 indicated.	 Photograph	 of	 the	 Coomassie	 stained	 gel	 as	 loading	 control	(bottom).		
3.1.11 SDHAHKO	hearts	exhibit	the	classical	integrated	stress	response		 Since	SdhaHKO	mice	also	developed	cardiomyopathy	when	only	complex	II	of	the	respiratory	 chain	 was	 affected,	 those	 animals	 were	 also	 analysed	 regarding	 their	mitochondrial	stress	response.	Unlike	SdhaMKO	muscles,	SdhaHKO	hearts	elicited	a	clear	integrated	stress	response	with	Fgf21,	Gdf15	and	Mthfd2	being	among	the	highest	up-regulated	genes	analysed	in	the	SdhaHKO	hearts	(Figure	3.13	A).	No	changes	in	gene	expression	 were	 observed	 for	 other	 genes	 related	 to	 mitochondrial	 membrane-,	translation-	or	metabolism-associated	proteins	(Figure	3.13	B).	These	changes	were	also	reflected	on	the	protein	level,	where	MTHFD2/PYCR1	levels	increased	in	SdhaHKO	hearts	 (Figure	3.13	C)	but	enzymes	related	 to	 fatty	acid	oxidation	(MCAD/ETFDH)	remained	unchanged	(Figure	3.13	D).		
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Figure	3.13	SdhaHKO	hearts	exhibit	canonical	ISR	gene	expression	(A)	Relative	expression	 levels	of	atrophy	related	genes	with	qPCR	(n=5)	 in	20	days	old	hearts.	 (B)	Relative	expression	levels	of	metabolic	genes	with	qPCR	(n=5)	in	20	days	old	hearts.	(C)	Western	blot	analysis	of	20	days	old	heart	lysates	for	proteins	of	the	integrated	stress	response.	HSC70	was	used	as	loading	control.	 (D)	Western	blot	analysis	of	20	days	old	heart	 lysates	 for	metabolic	proteins.	Data	presented	as	mean	±	SD	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).			
3.1.12 SDHAHKO	hearts	do	not	display	AMPK-dependent	accumulation	of	NAD+	One	 of	 the	 most	 striking	 molecular	 changes	 within	 SdhaMKO	 muscles	 was	 the	increased	NAD+/NADH	ratio.	To	determine	if	this	ratio	might	influence	the	observed	differences	in	stress	response	gene	expression,	SdhaHKO	hearts	were	also	analysed	for	these	metabolites.	Indeed,	no	increase	in	NAD+	levels	could	be	observed	in	SdhaHKO	hearts	(Figure	3.14	A),	in	line	with	unchanged	AMPK	phosphorylation	(Figure	3.14	B).	Thus,	the	AMPK-dependent	increase	in	NAD+	levels	is	potentially	a	modulator	of	the	integrated	stress	response	and	only	the	loss	of	SDHA	in	skeletal	muscles	elicited	the	combination	of	the	physiological	phenotype	and	the	non-canonical	stress	response.	Furthermore,	 unlike	 SdhaMKO	 skeletal	 muscles,	 SdhaHKO	 hearts	 had	 increased	expression	of	HIF1a	target	genes	(Figure	3.14	C),	indicating	a	pseudo-hypoxic	state.			
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Figure	3.14	Loss	of	SDHA	in	the	heart	does	not	affect	AMPK	phosphorylation	and	NAD+/NADH	
ratios	(A)	Colorimetric	quantification	of	NAD+/NADH	levels	in	deproteinised	heart	lysates	(n=4).	(B)	Western	blot	analysis	of	heart	lysates	for	phosphorylated	AMPK	levels	at	20	days	of	age.	(C)	Relative	expression	levels	of	HIF1a	 target	genes	(n=5).	Data	presented	as	mean	±	SD	(*	P<0.05,	**	P<0.01,	***	P<0.001;	multiple	t-tests	corrected	with	the	Holm-Sidak	method).		Despite	the	similarity	between	heart	and	skeletal	muscle	tissue,	the	adaptations	to	the	loss	 of	 SDHA,	 as	 well	 as	 the	 resulting	 stress	 responses	 were	 markedly	 different.	Whereas	 the	 increased	 AMP/ATP	 and	 NAD+/NADH	 ratios	 crystalized	 as	 the	main	driver	of	AMPK-dependent	gene	expression	changes	in	myocytes,	no	such	alterations	were	 observed	 in	 cardiomyocytes	 with	 the	 same	 underlying	 deficiency.	 Further	analysis	 of	 the	 cardiomyocyte	 metabolome	 is	 thus	 necessary	 to	 determine	 which	metabolites	or	ratios	evoke	the	diverse	stress	responses	observed.		 	
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3.2 Identification	of	novel	ClpXP	substrates	in	vitro	and	in	vivo		 Mammalian	mitochondria	harbour	>1000	proteins	(Calvo	et	al.	2016),	most	of	which	 are	 physically	 separated	 from	 the	 cytosol	 and	 cannot	 be	 accessed	 by	 its	proteostasis	 machinery.	 They	 are	 thus	 mostly	 relying	 on	 intrinsic	 proteases	 and	peptidases	to	ensure	correct	processing	of	imported	proteins,	removal	of	damaged	or	incorrectly	 folded	 proteins	 and	 adjusting	 the	 abundance	 of	 proteins	 with	 varying	necessities.	 In	 the	mitochondrial	matrix,	 three	ATP-dependent	protease	complexes	are	in	charge	of	the	degradation	of	non-functional	or	superfluous	proteins.	The	mAAA	and	 LonP1	 proteases	 were	 implicated	 in	 the	 removal	 of	 membrane-bound	 and	oxidatively	damaged	proteins,	respectively	(Bota	and	Davies	2002,	Lee	et	al.	2017),	however,	 little	 despite	 structure	 and	 few	 potential	 substrates	 is	 known	 about	 the	ClpXP	protease.	Previously,	ClpP	 knockout	mice	 (Clpp-/-)	were	 generated	 and	 a	 classical	 substrate-trapping	screen	was	used	to	identify	some	of	the	first	mammalian	ClpXP	substrates	(Szczepanowska	et	al.	2016),	however,	many	others	are	likely	still	unidentified	and	no	 recognition	mechanism	 or	 mode	 of	 degradation	 has	 been	 proposed	 so	 far.	 To	further	elaborate	on	these	shortages,	the	substrate	screen	was	repeated	in	triplicates	and	 an	 independent,	 unbiased	 approach	 was	 performed	 to	 identify	 N-terminal	degradation	 products	 and	 provide	 further	 evidence	 for	 putative	 ClpXP	 substrates.	Finally,	 conditional	 knockin	 mice	 were	 generated	 to	 enable	 substrate	 trapping	screens	in	vivo.			 	
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3.2.1 Bona	 fide	 ClpXP	 substrate	 identification	 with	 N-terminome	
quantification		 Terminal	 amine	 isotope	 labelling	 of	 substrates	 (TAILS)	 was	 used	 to	differentially	 label	 and	 quantify	 N-termini	 of	 wild	 type	 and	 Clpp-/-	 mitochondrial	proteins	 (Figure	3.15	A).	 In	 total,	1058	 termini	 from	215	mitochondrial-annotated	proteins	could	be	detected.	154	of	these	peptides	corresponded	to	the	“expected”	N-termini	 that	 are	predicted	 to	be	 generated	after	 the	 cleavage	of	 the	mitochondrial	targeting	signal	(MTS).	The	abundance	of	the	expected	N-termini	correlated	well	with	the	 previously	 published	 label-free	 quantification	 of	 wild	 type	 and	 CLPP-deficient	heart	mitochondrial	proteomes	(Szczepanowska	et	al.	2016)	(Pearson	correlation	=	0.76),	allowing	for	their	use	as	protein	abundance	measures.	All	other	N-termini	are	considered	 as	 “unexpected”	 and	 reflect	 degradation	 products	 and	 intermediates.	These	do	not	correlate	well	with	total	protein	abundance	(Pearson	correlation	=	0.31),	indicating	 that	 mitochondrial	 protein	 processing	 is	 indeed	 affected	 by	 the	 loss	 of	CLPP.	Whereas	increased	abundance	in	total	protein	content	(LFQ)	or	expected	N-termini	in	the	Clpp-/-	knockout	can	be	indicative	of	putative	ClpXP	substrates,	unexpected	N-termini	have	to	be	interpreted	in	the	opposite	direction.	If	unexpected	N-termini	are	less	 abundant	 in	 the	 absence	 of	 CLPP,	 they	 are	 potentially	 generated	 by	 ClpXP-mediated	proteolysis.	Sequence	logo	analysis	of	these	N-termini,	revealed	a	surprising	congestion	of	Arg	at	the	P1	position	(Figure	3.15	C).	On	the	other	hand,	unexpected	N-termini	that	were	less	abundant	in	Clpp-/-	knockout	mitochondria	did	not	show	any	amino	acid	preference	within	the	cleavage	window.		Using	differentially	abundant	N-termini,	potential	ClpXP	substrates	can	be	identified.	This	 approach	 is	 not	 restricted	 to	 expected	N-termini,	 however,	 as	 unexpected	N-termini	 without	 the	 Arg	 motif	 can	 represent	 ClpXP-independent	 quality	 control	proteolysis	 and	 thus	 indicate	 total	 protein	 abundance.	 In	 agreement	with	 the	 LFQ	approach,	increased	N-termini	abundance	of	HSPA9,	LONP1,	MRPS22	and	OAT	were	detected	 in	 CLPP-deficient	mitochondria	 (Figure	 3.15	 B).	 To	 verify	 these	 putative	ClpXP	substrates,	steady	state	protein	abundance	and	stability	were	analysed	with	western	 blots	 and	 cycloheximide	 chase	 experiments,	 respectively.	 Whereas	 three	proteins	showed	strong	accumulation	in	the	knockout	background	on	western	blots	(HSPA9,	LONP1	and	OAT)	(Figure	3.15	D),	HSPA9	was	also	clearly	stabilised	when	
	 	 3	Results	
		 	 	 61	
protein	 synthesis	 was	 interrupted,	 making	 it	 the	 best	 candidate	 for	 a	 bona	 fide	substrate.	LonP1	was	not	consistently	stabilised	in	these	experiments	and	is	mildly	induced	on	mRNA	levels	(data	not	shown).	Although	this	does	not	rule	out	a	protease-substrate	relationship,	the	finding	merits	further	investigation.	Mitochondrial	LonP1	(Rendon	and	Shoubridge	2018),	as	well	as	bacterial	homologues	of	ClpXP	(Vass	and	Chien	2013)	can	process	certain	substrates	at	the	N-terminus.	The	suggested	mechanisms	vary	greatly,	however,	 the	TAILS	dataset	was	examined	 for	potential	 signs	 of	 substrate	 processing.	No	 large-scale	 loss	 of	 processed	N-termini	were	 detected	 in	 CLPP-deficient	 mitochondria,	 although	 PDHA1	 N-termini	 are	 a	promising	 indication.	 The	 expected	 N-terminus-	 (like	 the	 LFQ)	 abundance	 was	unaltered	 in	 the	 absence	 of	 CLPP,	 however	 a	 second	 N-terminus	 15	 amino	 acids	further	into	the	protein	was	almost	absent	in	the	Clpp-/-	knockout	(FC	log2(KO/WT):	-2.42)	 (Figure	3.15	E).	Unfortunately,	 the	 resulting	 truncated	protein	 could	not	be	detected	on	western	blots,	as	the	size	difference	is	likely	too	small	to	be	distinguished	from	the	full-length	proteoform.	Nevertheless,	the	strong	difference	in	its	fold-change	suggests	 that	more	 of	 low-abundant,	 and	 thus	 undetected	mitochondrial	 proteins	could	be	processed	in	a	ClpXP-dependent	manner.		 	
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Figure	3.15	TAILS	identifies	novel	ClpXP	substrates	and	a	possible	cleavage	motif	(A)	Strategy	for	TAILS	in	CLPP-deficient	mitochondria.	Wild	type	and	knockout	mitochondrial	proteins	were	 labelled	with	 light	 and	 heavy	 formaldehyde,	 respectively	 and	 digested	with	 trypsin.	 Internal	peptides	 were	 removed	 with	 an	 ALD-polymer	 and	 labelled	 peptides	 were	 prepared	 for	 mass	spectrometry	 quantification.	 (B)	 N-termini	 spectrum	 of	 potential	 ClpXP	 substrates	 with	 increased	(green)	N-termini.	The	approximate	position	within	the	proteins	are	indicated	by	amino	acid	numbers.	The	 yellow	 bar	 represents	 the	 MTS	 and	 the	 blue	 bar	 the	 mature	 protein.	 Cleavage	 windows	 are	described	for	all	N-termini	detected,	with	the	P1	position	highlighted	in	red	and	the	detected	sequence	being	underlined.	Fold-changes	(KO/WT)	are	indicated	next	to	the	sequences.	(C)	Ice-logo	of	cleavage	windows	from	N-termini	significantly	less	abundant	in	Clpp-/-	mitochondria.	(D)	Western	blot	analysis	of	 CLPP-deficient	 heart	 lysates.	 Antibodies	 against	 CLPP	 and	 putative	 substrates	 were	 used	 as	indicated.	HSC70	was	used	as	loading	control.	(E)	PDHA1	N-termini	spectrum	with	unchanged	(grey)	and	decreased	N-termini	(red)	in	CLPP-deficient	mitochondria.		
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3.2.2 Quantitative	substrate	trapping	in	Clpp-/-	MEFs		 The	initial	substrate	trapping	screen	in	mouse	embryonic	fibroblasts	served	as	a	proof	of	concept	for	the	approach	and	already	resulted	in	several	confirmed	ClpXP	substrates	 (Szczepanowska	 et	 al.	 2016).	 To	 further	 limit	 the	 proteins	 to	 the	most	promising	substrates	candidates,	the	screen	was	repeated	in	triplicates	that	allowed	for	a	quantitative	evaluation	(Figure	3.16).			
	
Figure	3.16	Substrate	trapping	strategy	with	FLAG-tagged	CLPP	variants	Three	replicates	of	Clpp-/-	MEFs	were	each	transfected	with	plasmids	containing	control,	CLPP-FLAG	or	TRAP-FLAG	for	transient	expression.	Cells	were	lysed	and	CLPP-FLAG	was	affinity	purified	with	a-FLAG	M2	bound	magnetic	beads.	Samples	were	digested	with	trypsin	and	prepared	for	mass	spectrometry	quantification.		1-10%	of	 the	 lysate	 (L),	washing	 (W),	 flow-through	 (FT)	 and	 elution	 (E)	 fractions	were	 pooled	 and	 used	 for	 evaluation	 on	western	 blots.	 As	 expected,	 the	 only	 two	reported	 interacting	proteins	CLPX	and	C1QBP	were	co-purified	with	 the	protease	(Figure	 3.17	 B),	 while	 no	 contamination	 with	 cytosolic	 (ACTIN	 and	 HSC70)	 or	mitochondrial	(TOMM20)	proteins	that	do	not	share	the	same	compartment	could	be	detected	(Figure	3.17	A	and	B).	This	allowed	for	mass-spectrometry	analysis	of	the	elution	 replicates	 that	 resulted	 in	14	proteins	 significantly	 enriched	 in	 the	 affinity	purification	of	 inactive	CLPP	 (CLPP-TRAP)	over	wild	 type	CLPP	 (CLPP-WT)	 (Table	3.2).	As	indicated	on	the	control	western	blots,	CLPX	also	belongs	to	this	substrate-enrichment	category.	CLPX	steady	state	protein	levels	were	increased	in	the	absence	of	CLPP,	which	was	independent	of	gene	expression	(Szczepanowska	et	al.	2016)	and	the	 nature	 of	 this	 accumulation	 is	 currently	 unclear.	 Other	 potential	 substrates	enriched	with	CLPP-TRAP	include	the	proteins	POLDIP2	and	CHCHD2,	which	were	reported	to	interact	with	CLPP/CLPX	but	were	not	further	verified	in	this	work.			 	
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Table	3.2	Proteins	significantly	enriched	in	CLPP-TRAP	over	CLPP-WT	elutions	
Protein	name	NDUFV2	CCRN4l	FPGS	MRPL13	MRPL18	MRPL39	SDHB	CLPX	UQCRC1	C1QBP	POLDIP2	CHCHD2	NDUFV1	MRPS22		Excluding	the	proteins	that	were	not	detected	in	CLPP-WT	elutions,	UQCRC1	showed	the	 highest	 enrichment	 in	 CLPP-TRAP	 elutions	 (FC	 log2(TRAP/WT):	 8.23).	 This	enrichment	suggests	that	UQCRC1	is	a	strong	substrate	candidate,	however,	previous	LFQ	data	showed	no	changes	in	protein	abundance	in	the	absence	of	CLPP.	This	came	as	 a	 surprise,	 since	 increased	 protein	 abundance	 in	 the	 absence	 of	 the	 respective	protease	is	the	strongest	criterium	for	bona	fide	substrates.		 	
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Figure	3.17	CLPP-FLAG	is	successfully	purified	from	cell	lysates	along	with	known	interactors	(A)	Western	 blot	 analysis	 and	Coomassie	 gel	 staining	 of	 substrate	 trapping	 fractions	 to	 determine	purity	and	efficiency.	(B)	Western	blot	analysis	of	substrate	trapping	fractions	to	determine	successful	co-purification	of	CLPP-interacting	proteins.	Antibodies	against	CLPP,	CLPX	and	C1QBP	were	used	as	indicated.	 TOMM20,	 HSC70	 and	 ACTIN	 were	 used	 as	 controls	 for	 mitochondria	 and	 cytosolic	contaminations,	respectively.	<-	indicates	correct	protein	bands	and	*	represents	unspecific	staining	of	IgH	from	the	FLAG	M2	antibody	in	(A)	or	unspecific	bands	from	CLPX/C1QBP	antibodies	in	(B).		
3.2.3 Cooperative	proteolysis	of	UQCRC1		 To	better	understand	the	underlying	interaction	between	CLPP	and	UQCRC1,	its	N-termini	abundance	was	closely	analysed	in	the	TAILS	dataset.	Not	uncommon	for	highly	abundant	proteins	such	as	subunits	of	the	respiratory	chain,	2	expected	and	20	unexpected	N-termini	from	UQCRC1	were	detected.	These	can	represent	degradation	intermediates	as	the	abundance	of	the	protein	has	a	direct	influence	on	the	abundance	of	the	intermediates	and	therefore	the	likelihood	of	their	detection.	However,	upon	close	 inspection,	 UQCRC1	 N-termini	 revealed	 a	 non-random	 distribution.	 In	agreement	with	LFQ	data,	the	abundance	of	the	expected	N-termini	was	not	affected	by	the	absence	of	CLPP.	Around	the	40	aa,	150	aa	and	190	aa	position	of	UQCRC1,	three	groups	of	closely	congested	N-termini	with	mostly	increased	abundance	were	detected	in	CLPP-deficient	mitochondria.	These	were	followed	by	5	N-termini	with	decreased	 abundance	 in	Clpp-/-	 knockout	mitochondria.	While	 the	 up-regulated	N-termini	cleavage	windows	showed	no	preferences	for	certain	amino	acids,	all	5	down-regulated	 termini	 resulted	 from	 cleavage	 after	 Arg,	 as	 it	 was	 proposed	 for	 ClpXP	earlier	(Figure	3.18	A).		
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The	 accumulation	 of	 a	 truncated	 UQCRC1	 proteoform	 in	Clpp-/-	mitochondria	was	further	confirmed	on	western	blots,	proving	that	the	detected	N-termini	exist	in	vivo	(Figure	3.18	B).	Additionally,	UQCRC1	protein	levels	in	Clpp-/-	cells	were	stabilised	in	cycloheximide	chase	experiments,	as	it	is	expected	for	ClpXP	substrates	(Figure	3.18	C).		
	
Figure	3.18	Truncated	UQCRC1	becomes	a	substrate	for	ClpXP-mediated	degradation	(A)	UQCRC1	N-termini	spectrum	with	increased	(green),	unchanged	(grey)	and	decreased	N-termini	(red)	in	CLPP-deficient	mitochondria.	The	approximate	positions	within	the	proteins	are	indicated	by	amino	acid	numbers.	The	yellow	bar	represents	the	MTS	and	the	blue	bar	the	mature	protein.	Cleavage	windows	 are	 described	 for	 all	N-termini	 detected,	with	 the	 P1	 position	 highlighted	 in	 red	 and	 the	detected	sequence	being	underlined.	(B)	Western	blot	analysis	of	Clpp-/-	mitochondria	performed	by	Dr.	 Karolina	 Szczepanowksa.	 (C)	 CHX-chase	 experiment	 for	 UQCRC1	 stability	 performed	 by	 Dr.	Karolina	Szczepanowksa.	Antibodies	against	CLPP	and	UQCRC1	were	used	as	indicated.	CS	and	ACTIN	were	used	as	loading	controls	for	mitochondria	and	cell	lysates,	respectively.			 	
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3.2.4 Generation	of	conditional	ROSA26-CAG::CLPP-FLAG	mice		 Surprisingly,	 the	 analysis	 of	 Clpp-/-	 livers	 revealed	 that	 not	 all	 substrates	discovered	in	the	heart	had	increased	abundance	in	the	liver	and	phenotypes	such	as	the	compromised	mitoribosome	assembly	were	not	conserved	across	tissues	(Becker	et	al.	2018).	Thus,	using	MEFs	or	any	other	cell	model	for	substrate	trapping	screens	for	the	identification	of	ClpXP	substrates	is	limited	in	terms	of	substrate	expression	in	the	 investigated	 cell	 type	 and	 in	 its	 transferability	 to	 other	 cells	 or	 tissues.	 To	overcome	this	obstacle,	an	in	vivo	model	for	substrate	screens	is	axiomatic.	To	that	matter,	 recent	 advances	 in	 CRIPSPR/Cas9	 technologies	 were	 utilised	 for	 the	generation	of	mice	conditionally	expressing	CLPP-FLAG	from	the	ROSA26	locus	under	the	 strong	 CAG	 promoter	 (Figure	 3.19	 A).	 A	 conditional	 approach	 was	 chosen	 to	overcome	 the	 possibility	 of	 detrimental	 effects	 due	 to	 the	 over-expression	 of	 the	protease	subunit.	As	a	proof	of	 concept,	 the	Ckmm-Cre	 line	was	chosen	 to	express	CLPP-FLAG	 in	 the	 heart	 and	 the	 resulting	 mice	 showed	 a	 strong	 expression	 of	endogenous	CLPP	and	CLPP-FLAG	protein.	However,	no	phenotype	could	be	observed	in	 these	mice	at	 the	age	of	10	weeks	and	known	substrates	were	unaltered	by	 the	expression	 of	 CLPP-FLAG	 (Figure	 3.19	 B).	 To	 investigate	 whether	 CLPP-FLAG	 is	functionally	active	 in	vivo,	mitochondria	were	isolated	and	functional	import	of	the	protein	 was	 confirmed	 (Figure	 3.19	 C).	 Furthermore,	 BN-PAGE	 analysis	 of	 these	mitochondria	revealed	that	oligomers	corresponding	to	the	tetradecameric	chamber	CLPP14n	 assembled	 in	 vivo	 (Figure	 3.19	 D).	 Further	 experiments,	 however,	 are	necessary	to	confirm	activity	and	to	identify	the	underlying	mechanism	for	the	lack	of	substrate	processing	in	the	heart.	
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Figure	3.19	Conditional	CLPP-FLAG	expression	in	vivo	(A)	Knockin	of	a	CAG::CLPP-FLAG-IRES-eGFP	cassette	into	the	ROSA26	locus	for	the	generation	of	mice	conditionally	expressing	CLPP-FLAG.	(B)	Western	blot	analysis	of	heart	lysates	expressing	CLPP-FLAG.	(C)	Western	blot	analysis	of	heart	mitochondrial	extracts	expressing	CLPP-FLAG.	(D)	BN-PAGE	analysis	of	heart	mitochondrial	extracts	expressing	CLPP-FLAG.	Antibodies	against	CLPP/FLAG,	known	ClpXP	substrates	and	respiratory	chain	subunits	were	used	as	indicated.	<-	indicates	endogenous	CLPP/CLPX,	#	represents	CLPP-FLAG	fusion	protein	and	*	indicates	unspecific	CLPX	signal.		Together,	 the	proteomic	approaches	performed	 further	verified	multiple	 substrate	candidates	 suggested	 before	 and	 provided	 several	 novel	 putative	 substrates	 of	mammalian	 ClpXP.	 Additionally,	 ClpXP	 was	 found	 to	 participate	 in	 cooperative	degradation	in	vivo	and	a	novel	cleavage	site	was	proposed	for	mouse	CLPP.	Finally,	the	generation	of	a	mouse	model	conditionally	expressing	CLPP-FLAG	proved	the	concept	of	a	potential	in	vivo	substrate	screen	to	elaborate	on	tissue-specific	ClpXP	function.	
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4 Discussion	
4.1 Loss	of	 SDHA	causes	energy	 crisis	and	 triggers	 tissue-specific	
stress	responses		Mitochondrial	(energy)	metabolism	is	essential	for	almost	all	eukaryotic	cells.	
Monocercomonoides	sp.	is	the	only	discovered	species	that	adopted	a	cytosolic	iron-sulphur	cluster	 (ISC)	synthesis	pathway	and	 therefore	can	also	 lack	mitochondria-related	 organelles	 (Karnkowska	 et	 al.	 2016).	 All	multi-cellular	 organisms,	 though,	contain	some	form	of	mitochondrial	organelles,	highlighting	their	importance,	even	if	ATP	production	 is	 of	 secondary	 function.	 In	most	 cells	 and	especially	 in	 tissues	of	mammalian	 organisms,	 these	 functions	 cannot	 be	 considered	 independent	 of	 each	other	 and	 mitochondrial	 disorders	 may	 affect	 metabolic	 pathways	 or	 respiration	alike.	To	further	understand	how	perturbations	in	mitochondrial	energy	metabolism	affect	 tissues	 with	 different	 metabolism,	 conditional	 knockouts	 of	 the	 succinate	dehydrogenase	subunit	A	were	developed	and	analysed	with	regard	to	mitochondrial	function	 and	 stress	 adaptations/responses.	 Numerous	 mouse	 models	 that	 affect	different	mitochondrial	proteins	 in	multiple	 tissues	have	been	developed	 in	recent	years.	However,	in	most	cases	secondary	effects	of	altered	respiration	on	metabolism	and	vice	versa	cannot	be	ruled	out	and	are	therefore	indistinguishable.	As	a	TCA	cycle	enzyme	and	part	of	 the	respiratory	chain,	SDHA	 is	 intimately	connected	with	both	respiration	 and	 metabolism.	 If	 these	 processes	 cannot	 be	 fully	 uncoupled,	 a	simultaneous	loss	of	both	and	its	consequences	on	tissue	function	is	left	as	the	most	promising	approach	to	address	the	issue.		
4.1.1 Loss	of	SDHA	causes	muscle	energy	crisis	without	triggering	the	ISR	Phenotypically,	 SdhaMKO	 mice	 show	 the	 expected	 signs	 of	 mitochondrial	dysfunction	in	skeletal	muscles	with	muscle	loss,	growth	retardation	and	eventually	lethality	 that	 was	 described	 for	 many	 mouse	 models	 using	 muscle-specific	mitochondrial	 perturbations.	 These	 include	 muscle-specific	 knockouts	 of	 COX10,	COX15	and	TFAM	(Wredenberg	et	 al.	 2002,	Viscomi	et	 al.	 2011,	Tezze	et	 al.	 2017,	Peralta	et	al.	2018).	With	the	exception	of	muscle-specific	OPA1	deletion,	that	is	lethal	within	 10	 days	 after	 birth,	 SdhaMKO	 mice	 die	 earlier	 than	 the	 aforementioned	cytochrome	c	oxidase-	or	TFAM-depleting	models.	The	poor	survival	of	Opa1MKO	mice,	
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however,	might	stem	from	a	much	shorter	protein	half-life,	as	SDHA	protein	levels	are	never	completely	lost	even	at	death.	This	indicates	that	the	loss	of	SDHA	cannot	be	compensated	for	as	long	as	the	loss	of	complex	IV,	possibly	due	to	a	quicker	depletion	of	ATP	and	energy-storages.	An	even	longer	half-life	of	cytochrome	c	oxidase	subunits	seems	unlikely,	however,	 cannot	be	 fully	excluded	as	no	data	at	4	weeks	of	age	or	younger	were	presented	for	these	knockout	mice.	The	 induction	 of	 muscle	 atrophy	 is	 very	 common	 in	 all	 of	 these	 mouse	 models,	independent	of	 the	studied	protein.	 It	was	observed	upon	 loss	of	COX10	or	COX15	(Diaz	 et	 al.	 2005,	 Civiletto	 et	 al.	 2015),	 other	 mitochondrial	 proteins	 such	 as	 the	mitochondrial	calcium	uniporter	(MCU)	(Gherardi	et	al.	2019)	and	cytosolic	proteins	without	a	direct	relevance	to	mitochondria	like	in	Titin-deficient	muscles	(Peng	et	al.	2005).	Furthermore,	muscle	atrophy	is	also	induced	by	prolonged	starvation	in	the	absence	of	genetic	manipulation	(Bonaldo	and	Sandri	2013).	Markedly	different,	however,	is	the	absence	of	centralized	nuclei	in	SdhaMKO	muscles.	Centralized	 nuclei	 are	 a	 hallmark	 of	 myopathies	 and	 result	 from	 satellite	 cell	activation	and	subsequent	fusion	of	myoblasts	with	damaged	fibres.	Central	nuclei	are	thus	strictly	speaking	a	sign	of	muscle	regeneration,	which	is	induced	by	degenerating	muscle	fibres.	This	process,	however,	requires	extensive	protein	translation	and	cell	proliferation	 (Karalaki	 et	 al.	 2009),	 both	 of	 which	 are	 very	 energy-demanding	processes	and	attenuated	in	SdhaMKO	muscles.	Thus,	muscle	regeneration	might	not	be	 initiated	 in	 these	mice.	Acta1,	 the	gene	of	which	the	promoter	was	used	 for	 the	muscle-specific	SDHA	 knockout,	 is	 expressed	early	during	development,	but	not	 in	satellite	 cells	 (Chal	 and	Pourquie	 2017).	 The	muscle	 stem	 cells	 themselves	 should	therefore	not	be	directly	affected	in	SdhaMKO	mice.	Nevertheless,	a	secondary	loss	of	satellite	 cells	 was	 also	 observed	 in	 Pax7	 mutant	 mice,	 which	 lack	 an	 important	myocyte	differentiation	marker	that	is	not	expressed	in	satellite	cells	(Oustanina	et	al.	2004).		A	 role	 for	 inflammation	 in	 the	 suppression	of	muscle	 regeneration	 (Mourkioti	 and	Rosenthal	2005)	cannot	be	excluded	as	well,	however,	no	signs	of	increased	immune	cell	infiltration	was	observed	during	histological	examination.			 	
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Additionally,	it	is	possible	that	the	prolonged	hypoglycaemia	in	SdhaMKO	mice	causes	changes	in	IGF-1	signalling,	which	is	known	to	restrict	muscle	regeneration	(Winn	et	al.	2002).		Upon	various	cellular	stresses	like	ER-stress,	mitochondrial	stress,	or	nutrient	stress,	eukaryotic	 cells	 elicit	 the	 integrated	 stress	 response	 (ISR),	 a	 common	 signalling	cascade	 that	 leads	 to	 global	 changes	 in	 gene	 expression	 in	 favour	 of	 cell	 survival	(Figure	4.1).			
	
Figure	4.1	Simplified	model	of	the	integrated	stress	response	(ISR)	Various	stresses,	such	as	nutrient	or	unfolded	protein	stress	causes	the	phosphorylation	of	eIF2a	by	multiple	kinases	(not	shown).	Phosphorylated	eIF2a	inhibits	5’Cap-dependent	protein	translation	and	favours	 the	 translation	 of	 ATF4.	 Together	 with	 co-activators	 (not	 shown),	 ATF4	 mediates	 the	transcription	 of	 pro-survival	 genes.	 The	 induction	 of	 the	 ISR	 is	 self-regulated	 via	 GADD34,	 which	inhibits	eIF2a	phosphorylation	together	with	PP1.	Pathway	adopted	from	(Pakos-Zebrucka	et	al.	2016)		At	the	core	of	the	ISR	is	the	eukaryotic	initiation	factor	eIF2	with	eIF2a	as	the	main	regulatory	subunit.	Under	normal	conditions,	eIF2	plays	a	main	role	in	the	initiation	of	 cytosolic	 translation.	 Upon	 stress,	 however,	 eIF2a	 phosphorylation	 by	 various	kinases	hinders	 the	 formation	of	 the	 initiation	 complex	 and	 therefore	halts	 5‘Cap-dependent	 translation,	while	 in	 turn	 favouring	5‘Cap-independent	 translation.	This	translation	initiation	depends	on	short	open	reading	frames	within	the	5’UTR	that	are	also	present	in	the	mRNAs	of	the	transcription	factor	ATF4	and	one	of	its	co-activators	CHOP	 (Hinnebusch	 2011,	 Palam	 et	 al.	 2011).	 These	 transcription	 factors	 in	 turn	
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regulate	 many	 pro-survival	 processes	 like	 autophagy	 (B'chir	 et	 al.	 2013)	 and	proteostasis	(Harding	et	al.	2000).	Although	it	 is	currently	unclear	which	kinase(s)	are	responsible	for	the	transmission	of	mitochondrial	stresses,	the	phosphorylation	of	eIF2a	and	the	downstream	consequences	are	typically	observed	in	mouse-	and	cell	models	 that	 affect	 mitochondrial	 function.	 An	 increased	 expression	 of	 Fgf21,	 for	example,	was	observed	in	DARS2-	or	CLPP-deficient	cardiomyocytes	and	in	skeletal	muscles	of	Twinkle-	or	OPA1-deficent	mice.	Furthermore,	the	induction	appears	to	be	independent	of	cell	type,	age	of	the	animal	or	severity	of	the	phenotype	(Dogan	et	al.	2014,	Khan	et	al.	2017,	Kuhl	et	al.	2017,	Tezze	et	al.	2017)	and	it	is	possible	that	an	overactive	or	unstopped	ISR	plays	a	role	in	the	described	pathologies.		Surprisingly,	levels	of	phosphorylated	eIF2a	were	unaltered	in	SdhaMKO	muscles	and	consequently,	ATF4	protein	amount	was	unchanged	as	well.	A	possible	explanation	for	the	lack	of	eIF2a	phosphorylation	might	be	that	the	inherent	negative	feedback	loop	 through	GADD34	and	the	protein	phosphatase	1	complex	(Novoa	et	al.	2001)	favours	its	de-phosphorylation	in	SdhaMKO	muscles.	Nevertheless,	it	would	still	remain	unclear	 as	 to	why	 this	 feedback	 loop	 does	 not	 stop	 eIF2a	 phosphorylation	 in	 e.g.	DARS2-	(Dogan	et	al.	2014)	and	SDHA-deficient	hearts	or	skeletal	muscles	with	OPA1-	or	Twinkle	deficiency	(Khan	et	al.	2017,	Tezze	et	al.	2017).	While	this	part	of	the	integrated	stress	response	cannot	be	explained	without	further	data,	the	decreased	expression	of	Mthfd2	and	especially	Pycr1	might	be	the	result	of	altered	c-MYC	activity	and	will	be	discussed	further	in	section	4.1.2.			 	
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4.1.2 The	AMPK-SIRT	axis	possibly	drives	adaptations	in	SdhaMKO	muscles	
SdhaMKO	muscles	show	clear	signs	of	energy	crisis	already	at	the	age	of	3	weeks.	Although	detailed	metabolic	analyses	of	other	time	points	are	lacking	at	the	moment,	it	can	be	assumed	that	the	observed	depletion	of	ATP	and	amino	acids	is	progressing	with	age	and	peaks	at	death.	The	low	energy	charge	causes	the	activation	of	AMPK	allosterically	 through	AMP-binding,	 as	well	 as	 via	 increased	phosphorylation	of	 α-Thr172	of	the	g	subunit,	an	adaptation	to	low	nutrient	supply	and	energy	deficits	that	is	almost	universal	to	eukaryotic	cells	(Hardie	2011).	Despite	its	ubiquitous	presence,	the	 activity	 of	 the	 hetero-trimer	 is	 in	 part	 regulated	 by	 the	 expression	 of	 tissue-specific	isoforms	and	phosphatase/kinase	activities	(Mounier	et	al.	2015).		In	skeletal	muscles,	AMPK	activation,	e.g.	during	starvation,	triggers	a	chain	of	events	to	increase	the	energy	status	and	restore	muscle	function.	Notably,	one	of	the	earliest	responses	 is	 the	 phosphorylation	 of	 TBC1D1	 by	 AMPK,	 which	 causes	 GLUT4	translocation	to	the	sarcolemma	in	order	to	increase	glucose	uptake	in	muscle	fibres	(Chavez	et	al.	2008).	Continued	glucose	supply	into	muscles	is	provided	by	hepatic	gluconeogenesis	 through	 glycogenolysis	 and	 the	 glucose-alanine	 cycle.	 However,	during	prolonged	fasting,	this	supply	is	not	able	to	cover	the	requirements	of	muscle	cells,	leading	to	hypoglycaemia	(Bujak	et	al.	2015).	This	is	a	possible	explanation	for	the	reduced	blood	glucose	and	liver	glycogen	levels	 in	SdhaMKO	mice,	as	these	mice	most	likely	have	a	continuous	lack	of	ATP	in	the	muscles.	In	 order	 for	 the	 liver	 to	 provide	 enough	 glucose,	 AMPK-activated	muscle	 atrophy	further	 generates	 alanine	 that	 is	 deaminated	 in	 the	 liver	 (glucose-alanine	 cycle).	During	 muscle	 atrophy,	 AMPK	 phosphorylates	 the	 transcription	 factor	 FOXO3A,	which	in	turn	increases	the	expression	of	the	ubiquitin	ligases	Atrogin-1	(FBXO32)	(Sandri	 et	 al.	 2004)	 and	 MuRF-1	 (TRIM63)	 (Senf	 et	 al.	 2010)	 that	 target	 muscle	proteins	 for	proteasomal	degradation.	Both	genes	are	highly	expressed	 in	SdhaMKO	muscles	and	could	be	the	main	drivers	of	muscle	atrophy	(Figure	4.2).	 	
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Figure	4.2	AMPK/SIRT1-regulated	activation	of	FOXO3A	and	PGC1a	Energy	crisis	in	cells	is	sensed	through	AMPK	phosphorylation	and	its	binding	to	AMP.	These	processes	activate	AMPK,	which	in	turn	phosphorylates	the	transcription	factor	FOXO3A	and	the	transcriptional	co-activator	PGC1a.	Additionally,	AMPK	increases	the	expression	of	NAMPT,	a	key	enzyme	of	de	novo	NAD+	 synthesis.	 NAD+	 is	 as	 mandatory	 cofactor	 of	 SIRT1,	 that	 preferentially	 deacetylates	phosphorylated	 FOXO3A/PGC1a.	 This	 fully	 activates	 their	 transcriptional	 activity,	 causing	 the	induction	of	atrophy	and	mitochondrial	biogenesis,	respectively.	Pathway	adopted	from	(Canto	et	al.	2009).		In	addition,	an	ATF4-mediated	atrophy	program	(Adams	et	al.	2017)	is	also	activated	despite	 the	 absence	 of	 Eif2a	 phosphorylation	 or	 an	 increase	 in	ATF4	 steady	 state	levels.	The	observed	expression	of	 the	ATF4	 targets	4Ebp1	 and	Cdkn1a	 in	SdhaMKO	muscles	are	milder	in	comparison	to	the	expression	of	Atrogin-1/	MuRF-1	and	could	result	 from	 increased	 nuclear	 ATF4	 localization	 that	 does	 not	 require	 increased	protein	levels.		At	4	weeks	of	age,	the	expression	of	all	analysed	atrophy-related	genes	was	blunted,	although	the	underlying	defect	was	ongoing	and	the	energy	deficit	likely	worsened.	This	 could	be	 a	 safe-guard	mechanism	within	muscle	 tissue,	 as	 continued	atrophy	would	result	in	the	complete	loss	of	muscles	at	this	point.	However,	a	more	detailed	analysis	of	FOXO3A	and	AMPK	activity	at	this	age	is	required	to	understand	whether	the	induction	is	no	longer	maintained	or	if	other	signals	interfere	with	it.		 	
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In	 addition	 to	 the	 activating	 phosphorylation	 by	 AMPK	 (S412),	 FOXO3A	 can	 be	phosphorylated	by	ERK1/2	(S7,	S12,	S283,	S293,	S424)	and	AKT	(T32,	S252,	S314),	resulting	 in	 the	 inhibition	 and	degradation	 of	 the	 protein	 (Wang	 et	 al.	 2017).	 The	phosphorylation	(and	activation)	of	these	two	kinases	is	reduced	at	the	age	of	3	weeks	in	 SdhaMKO	 muscles,	 which	 should	 even	 further	 stabilize	 FOXO3A	 and	 therefore	increase	muscle	 atrophy	 in	 the	 knockout.	 Both	AKT	 and	ERK1/2	 are	 regulated	 by	growth	 hormones	 like	 IGF1	 or	 myostatin	 and	 decreased	 blood	 levels	 of	 these	hormones	might	be	adding	to	the	observed	muscle	wasting.	Lower	levels	of	IGF-1	in	
SdhaMKO	mice	would	also	be	in	line	with	the	whole-body	growth	retardation	and	the	sustained	hypoglycaemia.	In	addition	to	the	effect	on	FOXO3A,	AKT	and	ERK1/2	are	known	to	increase	protein	translation,	proliferation	and	cell	survival	(Miyazaki	and	Takemasa	 2017,	 Kjobsted	 et	 al.	 2018,	 Zou	 et	 al.	 2019),	 which	 are	 all	 inhibited	pathways	in	SdhaMKO	muscles.		Another	 important	 regulator	 of	 translation	 and	 proliferation	within	 the	 cell	 is	 the	mammalian	 target	 of	 rapamycin	 (mTOR).	 mTOR	 is	 present	 in	 two	 multi-protein	complexes	 (mTORC1	 and	mTORC2)	with	mTORC1	 acting	 as	 a	master	 regulator	 of	metabolism	and	protein	synthesis	(Laplante	and	Sabatini	2009).	Furthermore,	mTOR	activity	can	be	regulated	by	AMPK	and	AKT,	resulting	 in	a	complex	web	of	cellular	signalling	 pathways.	 However,	 no	 clear	 effect	 on	 the	 activity	 of	 mTOR	 could	 be	detected	in	SdhaMKO	muscles	as	target	protein	phosphorylation	was	unchanged	in	the	knockout.	Multiple	 feedback	 loops	 could	be	 responsible	 for	 this	 observation,	 since	amino	acid	starvation-induced	mTOR	inhibition	has	been	described	in	great	detail	and	overall	amino	acid	levels	were	decreased	in	SdhaMKO	muscles.	It	is	also	possible	that	mTOR	inhibition	precedes	the	chosen	time	points	and	resumed	to	normal	activity	by	3	weeks	of	age.	On	 the	 other	 hand,	 mTOR	 activation	 was	 also	 observed	 in	 skeletal	 muscles	 with	mitochondrial	defects	along	with	the	integrated	stress	response	(Khan	et	al.	2017).	It	is	thus	possible	that	opposite	stimuli	act	upon	mTOR,	which	reciprocally	extenuate	each	other.	A	closer	inspection	of	multiple	mTOR	targets	at	different	time	points	might	therefore	be	helpful	to	understand	its	role	in	SdhaMKO	muscles.		 	
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In	the	late	stages	of	SdhaMKO	mice,	an	increase	in	mitochondrial	proteins	and	especially	proteins	involved	in	FAO	was	observed	as	the	third	response.	This	is	also	reminiscent	of	 the	 classical	 starvation	 response,	 as	 fatty	 acid	 oxidation	 is	 augmented	 during	prolonged	exercise	or	starvation	(Goodman	et	al.	1974).	An	 increase	 in	mitobiogenesis	 is	often	caused	by	 the	activation	of	 the	peroxisome-proliferator-activated	 receptor	 gamma	 coactivator	 1	 alpha	 (PGC1a),	 which	 can	increase	PPAR/NRF-mediated	expression	of	mitochondrial	genes.	PGC1a	mRNA	as	well	as	the	protein	are	generally	upregulated	through	the	activity	of	AMPK	(Lee	et	al.	2006,	Jager	et	al.	2007,	Lira	et	al.	2010)	and	its	phosphorylation	at	T177	and	S538	is	essential	 for	 the	 activation	 of	 PGC1a.	 It	 is	 currently	 unclear	why	 the	 induction	 of	PGC1a-mediated	mitobiogenesis	occurs	only	at	the	very	late	stages.	Mitobiogenesis	is	clearly	more	time-consuming	than	the	fusion	of	GLUT4	vesicles	with	the	membrane	or	the	targeted	degradation	of	skeletal	muscle	proteins.	However,	a	correlation	to	the	severity	of	the	phenotype	is	also	possible.	In	addition	to	its	role	in	muscle	atrophy,	AMPK	activity	was	reported	to	augment	NAD+	
de	novo	synthesis.	Together	with	the	inhibition	of	the	TCA	cycle,	these	processes	could	be	 responsible	 for	 the	 increased	 the	 NAD+/NADH	 ratio	 in	 SdhaMKO	 muscles.	 An	important	role	for	AMPK	in	the	SdhaMKO	muscle	NAD+/NADH	ratio	can	be	assumed,	because	 the	 increase	 in	 the	NAD+/NADH	 ratio	was	 largely	 due	 to	 increased	NAD+	levels	(Figure	4.2).	Increased	NAD+	levels	in	turn	activate	sirtuins	(Canto	et	al.	2009),	that	 use	NAD+	 as	 a	 cofactor	 for	 the	 deacetylation	 of	 numerous	 proteins	 to	 change	cellular	activity	and	gene	expression.		Although	 no	 direct	 evidence	 for	 enhanced	 sirtuin	 activity	 in	 SdhaMKO	muscles	was	provided,	it	is	most	likely	the	case,	since	SIRT1-mediated	deacetylation	is	important	for	 the	 full	 activation	 and	 stabilization	 of	 PGC1a	 and	 FOXO3A.	 It	 is	 further	 a	coordinated	 activation,	 as	 the	 AMPK-mediated	 phosphorylation	 primes	 these	proteins	for	the	subsequent	deacetylation	by	SIRT1	(Canto	and	Auwerx	2009,	Canto	et	al.	2009)	(Figure	4.2).	The	use	of	antibodies	specific	for	acetylated/phosphorylated	forms	of	PGC1a	and	FOXO3A	could	additionally	substantiate	 the	role	of	sirtuins	 in	
SdhaMKO	muscles	at	this	point.		 	
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Further	indirect	evidence	for	sirtuin	activation	due	to	increased	NAD+	levels	comes	from	the	absence	of	HIF1a	and	c-MYC	signalling	in	SdhaMKO	muscles.	HIF1a	activity	is	inhibited	 directly	 through	 deacetylation	 via	 SIRT1	 and	 indirectly	 through	 the	deacetylation	 of	 histone	 H3	 via	 SIRT6,	 which	 affects	 HIF1a-dependent	 gene	expression	 (Zhong	 et	 al.	 2010)	 (Figure	 4.3).	 Sirtuin-dependend	 deacetylation	additionally	attenuates	AKT	signalling	(Sundaresan	et	al.	2012)	and	might	therefore	further	inhibit	protein	translation	and	increase	FOXO3A-mediated	atrophy	in	SdhaMKO	muscles.			
	
Figure	4.3	Model	for	sirtuin-mediated	adaptations	in	SdhaMKO	muscles	Various	cytosolic	and	nuclear	sirtuins	possibly	regulate	four	main	transcriptional	pathways	in	SDHA-deficient	muscles	due	to	increased	NAD+	levels.	Direct	deacetylation	of	PGC1a	and	FOXO3A	causes	their	activation	 and	 the	 induction	 of	 mitochondrial	 biogenesis	 and	 atrophy,	 respectively.	 Directly	 and	indirectly,	multiple	 sirtuins	deacetylate	HIF1a,	 c-MYC	as	well	 as	histones	at	 their	 respective	 target	genes.	These	reactions	cause	the	overall	repression	of	HIF1a	and	c-MYC	activity	as	observed	in	SdhaMKO	muscles.		c-MYC	is	an	oncoprotein	transcription	factor	that	drives	tumour	transformation	and	induces	 the	 eIF2a/ATF4	 arm	 of	 the	 integrated	 stress	 response	 (Hart	 et	 al.	 2012).	Additionally,	it	shares	some	of	its	target	genes	with	ATF4,	impeding	the	attribution	of	these	genes	to	specific	transcription	factors	(Kuhl	et	al.	2017).		The	transcription	of	two	of	these	genes,	Pycr1	and	Mthfd2,	is	induced	by	both	c-MYC	and	ATF4.	This	induction	is	observed	in	many	models	of	mitochondrial	dysfunction	and	is	considered	to	be	a	hallmark	of	the	integrated	stress	response	(Khan	et	al.	2017,	Kuhl	 et	 al.	 2017).	 Surprisingly,	 both	 proteins	 are	 even	 reduced	 in	 abundance	 in	
SdhaMKO	muscles.			 	
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Assuming	 the	 NAD+-dependent	 increase	 in	 sirtuin	 activity	 is	 indeed	 true,	 the	deacetylation	of	histone	H3	by	SIRT6	(K9	and	K56)	and	SIRT7	(K18)	(Sebastian	et	al.	2012,	Shin	et	al.	2013)	and	histone	H4	(K16)	by	SIRT2	(Liu	et	al.	2013)	consequently	supress	c-MYC-dependent	gene	expression.	c-MYC	is	also	directly	regulated	by	SIRT1,	however,	 it	 is	still	under	debate	whether	this	represents	a	positive	(Menssen	et	al.	2012)	or	negative	regulation	(Yuan	et	al.	2009).	Furthermore,	c-MYC	targets	include	ribosomal	subunits	(Sebastian	et	al.	2012),	RNA	Polymerase	II	(Rahl	et	al.	2010)	and	nucleotide	 biogenesis	 (Liu	 et	 al.	 2008).	 These	 targets	 could	 potentially	 cause	 the	decrease	in	cytosolic	translation	and	nucleotide	levels	in	SdhaMKO	muscles.		In	addition	to	decreased	mRNA	translation	and	cell	proliferation,	the	repression	of	c-MYC-dependent	expression	of	Pycr1	could	finetune	energy	metabolism	to	conditions	with	low	ATP	and	high	NAD+	levels	via	the	proline	cycle	(Figure	4.4).	Cellular	proline	exists	in	a	reduced	(proline,	Pro)	and	in	an	oxidised	state	(pyrroline-5-carboxylate,	P5C).	Oxidation	and	reduction	of	the	amino	acid	is	catalysed	by	proline	dehydrogenase	(PRODH)	and	P5C	reductases	(PYCRs),	respectively.	While	PYCRs	are	located	in	the	mitochondrial	matrix	(PYCR1	and	2)	and	in	the	cytosol	(PYCR3),	PRODH	is	anchored	to	the	inner	mitochondrial	membrane	and	transfers	electrons	from	the	oxidation	of	proline	onto	ubiquinone.	The	cycle	between	oxidised	and	reduced	state	can	 therefore	 occur	 either	 within	 mitochondria	 or	 across	 the	 compartments,	depending	on	which	 reductases	 are	used.	As	 an	 alternative	 energy	 source,	 proline	oxidation	can	supply	electrons	to	the	respiratory	chain	and	the	metabolic	state	further	dictates	the	place	of	reduction.	When	ATP	and	NAD+	levels	are	low,	as	it	is	the	case	in	e.g.	 complex	 I-deficient	 cells	 (Figure	 4.4	 A),	 reduction	 of	 P5C	 is	 performed	 in	 the	matrix	using	NADH	as	 the	electron	donor.	Therefore,	NADH	can	be	oxidised	 in	 the	absence	of	complex	I,	albeit	at	a	lower	efficiency	due	to	less	proton	pumping.	Even	in	the	absence	of	major	parts	of	the	respiratory	chain,	such	as	in	the	mutator	or	Dars2HKO	mice,	 the	proline	 cycle	 can	at	 least	 replenish	NAD+	 levels	 for	nucleotide	 synthesis.	Consequently,	increased	Pycr1	expression	can	drive	a	mitochondrial	proline	cycle	to	use	mitochondrial	NADH	in	these	models	(Kuhl	et	al.	2017).	On	the	other	hand,	when	ATP	levels	are	low	but	NAD+	levels	are	high,	such	as	in	SdhaMKO	muscles	(Figure	4.4	B),	 no	 additional	 ATP	 could	 be	 generated	 by	 increased	 Pycr1	 expression.	 On	 the	contrary,	 low	levels	of	PYCR1	could	drive	a	proline	cycle	across	the	compartments	using	PYCR3	as	the	reductase,	which	has	a	higher	affinity	for	NADPH	(De	Ingeniis	et	
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al.	2012).	Although	NADPH	could	not	be	detected	using	metabolomic	quantification,	the	global	arrest	of	translation	and	anabolism	in	SdhaMKO	muscles	argue	for	increased	cytosolic	 NADPH.	 The	 cells	 could	 therefore	 be	 able	 to	 maximize	 ATP	 production,	depending	 on	 the	 metabolic	 environment	 via	 sirtuin-dependent	 c-MYC	 regulation	(Figure	4.4).		
	
Figure	4.4	Model	for	proline	cycle	regulation	during	complex	I	and	complex	II	deficiency	(A)	 During	 complex	 I	 deficiency,	 mitochondrial	 NADH	 accumulates	 and	 the	 mitochondrial	 P5C	reductases	 (PYCR1/2)	 are	 up-regulated.	 This	 causes	 the	 proline	 cycle	 to	 occur	 preferentially	 in	mitochondria,	in	which	PYCR1/2	use	NADH	to	reduce	P5C	into	proline.	Proline	is	oxidised	by	PRODH,	which	transfers	the	electrons	to	ubiquinone	(Ub)	to	drive	the	rest	of	the	respiratory	chain.	The	outcome	are	increased	respiration	and	NAD+	recycling.	(B)	During	complex	II	deficiency,	PYCR1/2	are	down-regulated,	causing	the	proline	cycle	to	run	across	the	mitochondrial	inner	membrane.	Here,	cytosolic	PYCR3	reduces	P5C	into	proline	using	cytosolic	NAD(P)H.	Proline	re-enters	the	mitochondrial	matrix,	where	it	is	oxidised	as	in	(A)	into	P5C,	which	exits	the	mitochondria	again	to	complete	the	cycle.	The	outcome	is	a	use	of	cytosolic	reducing	equivalents	to	increase	respiration.	(More)	active	reductases	are	depicted	in	colour.	Less	active	or	repressed	reductases	are	shown	in	greyscale.		 	
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4.1.3 What	is	the	primary	deficiency	in	SDHAMKO	muscles?	Loss	 of	 SDHA	 in	 skeletal	 muscles	 had	 a	 profound	 impact	 on	 muscle	 and	systemic	physiology	of	the	animal.	Furthermore,	multiple	response	pathways	where	engaged	and	numerous	secondary	effects	on	metabolism	and	gene	expression	could	be	observed.	However,	it	is	still	tempting	to	speculate	on	the	essential	changes	that	occur	in	the	tissue.	Undoubtedly,	the	primary	cause	starts	within	the	mitochondria	as	a	 clear	 SDH	 deficiency	 was	 observed,	 but	 TCA	 cycle	 function	 and	 respiration	 are	difficult	to	discriminate.	Nevertheless,	several	observations	indicate	that	a	direct	role	of	 SDH	 in	 ATP	 production	 through	 electron	 transfer	 is	 more	 important	 than	 its	metabolic	role	as	a	TCA	cycle	enzyme	and	its	production	of	NADH.		First	of	all,	mitochondria	are	able	to	completely	circumvent	SDH	in	vitro	within	the	TCA	cycle,	as	long	as	enough	pyruvate	and	malate	are	present,	because	oxoglutarate	can	be	exchanged	for	malate,	which	re-enters	the	cycle	after	SDH.	Thus,	half	of	the	TCA	cycle	can	technically	be	skipped.	Both	malate	and	pyruvate,	as	well	as	multiple	other	TCA	cycle	metabolites	were	unchanged	upon	the	loss	of	SDHA.	It	is	therefore	imaginable	 that	 the	 TCA	 cycle	 can	 still	 fulfil	 its	 function	 of	 providing	 metabolic	intermediates	and	NADH.	Furthermore,	 NADH	 levels	 were	 also	 not	 affected	 by	 the	 knockout.	 Since	 other	respiratory	chain	complexes	were	equally	present	and	able	to	respire	in	vitro,	it	would	be	difficult	to	understand	why	the	available	NADH	is	not	oxidised	through	complex	I,	especially	upon	ATP	depletion.	A	 possible	 explanation	 for	 this	 discrepancy	 could	 be	 that	 complex	 I-dependent	respiration	 is	 indeed	working	 normally	 in	 the	 absence	 of	 SDH.	 In	 vitro,	 wild	 type	muscle	mitochondria	had	an	increase	of	about	40%	in	respiration	when	succinate	was	added	to	complex	I-dependent	respiration.	Therefore,	SdhaMKO	muscles	should	lack	a	substantial	amount	of	maximal	respiration,	even	in	the	presence	of	sufficient	NADH.	It	 is	consequently	conceivable,	 that	 the	electrons	 transferred	via	SDH	considerably	add	to	respiration	and	oxidative	phosphorylation	in	vivo,	to	cause	the	observed	ATP	depletion	in	SdhaMKO	muscles	and	trigger	the	downstream	responses	(Figure	4.5).		 	
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Figure	4.5	Model	for	ATP	depletion	and	cellular	adaptations	upon	SDHA	deficiency	in	muscles	Loss	of	SDHA	(II)	results	in	a	functional	TCA	cycle	and	normal	complex	I-dependent	NADH	oxidation,	but	 disrupts	 electron	 flow	 from	 SDH	 to	 ubiquinone	 (Ub).	 The	 reduced	 electron	 transfer	 in	 turn	extenuates	 ATP	 production	 through	 OXPHOS.	 Low	 ATP	 levels	 activate	 AMPK	 signalling	 and	 NAD+	synthesis.	 This	 signalling	 is	 further	 enhanced	 by	 sirtuin-dependent	 deacetylation	 of	 PGC1a	 and	FOXO3A,	increasing	mitobiogenesis	and	atrophy,	respectively.	FOXO3A	is	further	stabilized	by	lower	ERK1/2	 and	 AKT	 activities,	 possibly	 because	 of	 reduced	 serum	 growth	 hormone	 (GH)	 levels.	Additionally,	 sirtuins	 inhibit	 HIF1a	 and	 c-MYC-dependent	 gene	 expression,	 attenuating	 hypoxic	induction	and	ISR	initiation.	Furthermore,	loss	of	SDH	causes	succinate	accumulation	that	represses	2-OG-dependent	dioxygenases	(PHDs,	TETs,	JMJCs).				 	
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4.1.4 Loss	of	SDHA	in	the	heart	triggers	the	ISR	and	pseudo-hypoxia	but	not	
AMPK	activation	The	striking	difference	between	SdhaMKO	and	other	models	for	mitochondrial	dysfunction	prompted	the	question,	whether	the	observations	are	unique	to	SDHA-deficiency	 or	 the	 combination	 of	 it	 and	 the	 investigated	 tissue.	 Although	 hepatic	metabolism	 has	 more	 profound	 differences	 in	 comparison	 to	 myocytes,	 the	embryonic	 lethality	 of	 SdhaLKO	 mice	 even	 with	 the	 Albumin	 promoter-driven	 Cre	expression	 excluded	 this	model	 for	 the	 study.	 This	 Cre	 line	was	 reported	 to	 have	incomplete	 recombination	 until	 the	 age	 of	 6	 weeks	 (Postic	 and	Magnuson	 2000),	although	another	study	reported	efficient	recombination	already	during	development	(Weisend	et	al.	2009).	In	either	case,	the	lethality	of	SdhaLKO	mice	points	towards	a	strong	dependency	of	hepatocytes	on	SDHA	early	on	that	could	be	addressed	using	inducible	knockout	models.		Instead,	 a	 cardiomyocyte-specific	 loss	 of	 function	model	 (SdhaHKO)	was	 employed,	which	is	of	similar	dependency	on	a	high	ATP	supply,	but	lacks	the	metabolic	plasticity	of	skeletal	muscles.	Cardiomyocytes	are	highly	dependent	on	fatty	acid	oxidation	and	use	 other	 nutrients	 only	 to	 limited	 extent	 (Grynberg	 and	 Demaison	 1996).	Accordingly,	SdhaHKO	mice	die	considerably	earlier	than	SdhaMKO	mice,	with	few	mice	reaching	3	weeks	of	age.	Conditional	knockouts	with	the	same	promoter	(Ckmm)	of	DARS2	or	TFAM	survive	up	 to	6	weeks	and	10	weeks,	 respectively	 (Hansson	et	al.	2004,	Dogan	et	al.	2014),	while	the	loss	of	Twinkle,	MTERF4	or	POLRMT	is	lethal	only	after	several	months	(Camara	et	al.	2011,	Ruzzenente	et	al.	2012,	Milenkovic	et	al.	2013).	 Although	 all	models	 ultimately	 affect	 oxidative	 phosphorylation	within	 the	heart	from	day	E13	(day	of	recombination)	on,	a	straight	forward	comparison	is	not	possible	for	multiple	reasons.	Most	 importantly,	 the	expression	 levels	of	each	protein	within	 the	 first	2	weeks	of	embryogenesis	 and	 their	 half-life	 after	 that	 are	 unknown.	 The	 development	 of	 a	phenotype	can	therefore	be	determined	by	the	time	the	protein	is	depleted	from	the	tissue.	Furthermore,	the	timepoint	of	the	“functional”	knockout	can	be	varying	as	well.	With	regard	to	DARS2,	the	functional	knockout	appears	once	the	loss	of	the	protein	actually	 affects	 mitochondrial	 protein	 translation	 and	 then	 the	 activity	 of	 the	respiratory	chain.	It	is	conceivable,	that	this	process	takes	less	time	compared	to	when	the	 loss	of	mitochondrial	DNA/transcription	affects	 the	same	process	 in	 the	TFAM	
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knockout,	 even	 if	 both	 proteins	 were	 lost	 simultaneously.	 Cardiac	 loss	 of	 SDHA	complicates	the	comparison	even	further:	While	SDHA	is	a	very	stable	housekeeping	protein,	SDHB	was	depleted	rather	quickly,	 leading	 to	 the	complete	 inactivation	of	complex	 II	 already	 at	 day	 11	 (and	 possibly	 earlier).	 The	 importance	 of	 protein	turnover	is	further	highlighted	by	the	finding	that	heart-specific	TFAM	knockout	mice	survived	 only	 2-4	weeks	 of	 age	when	 a	 different	 Ckmm-Cre	 line	was	 used	 for	 the	recombination	(Wang	et	al.	1999).	It	is	thus	not	always	possible	to	draw	conclusions	about	the	importance	of	a	protein	from	the	survival	of	its	knockout	mouse.	Despite	 the	 striking	 difference	 in	 survival,	 all	 of	 the	 aforementioned	 knockouts	eventually	develop	lethal	cardiomyopathy.	Furthermore,	they	were	recently	found	to	have	a	common	ISR	with	the	up-regulation	of	1C-metabolism	and	proline	conversion	as	common	markers	(Kuhl	et	al.	2017).	Surprisingly,	loss	of	SDHA	in	the	heart	causes	the	same	isolated	complex	II	deficiency	as	in	muscles,	but	the	ISR	is	only	engaged	in	the	heart.		This	 could	 be	 due	 to	 the	 lack	 of	 NAD+-dependent	 c-MYC	 regulation,	 as	 no	 AMPK	phosphorylation	or	NAD+	accumulation	was	observed	in	SdhaHKO	hearts	(Figure	4.6).		Although	 the	 differences	 in	 terms	 of	 stress	 response	 could	 be	 traced	 back	 to	 the	activation	of	AMPK,	or	the	absence	of	it,	respectively,	it	is	unclear	at	this	moment	why	the	loss	of	SDHA	in	cardiomyocytes	does	not	activate	AMPK.	The	possibility	of	AMPK	activation	during	energy	depletion	was	reported	in	the	heart	(Coven	et	al.	2003)	and	affects	glucose	uptake	and	fatty	acid	oxidation.	To	understand	the	molecular	reason	of	 this	 discrepancy,	 it	 is	 inevitable	 to	 perform	metabolome	 quantification	 also	 on	
SdhaHKO	hearts,	since	it	cannot	be	excluded	that	the	lack	of	certain	metabolites,	rather	than	ATP	depletion	causes	the	dysfunction.	Another	possibility	for	unchanged	AMPK	activity	could	be	the	age	of	the	animal.	Between	2	and	3	weeks	of	age,	the	mouse	heart	undergoes	drastic	remodelling	that	includes	hypertrophic	cell	expansion	and	strongly	increased	mitobiogenesis	(Piquereau	et	al.	2010),	along	with	increased	AMPK	activity	(Yatscoff	et	al.	2008).	It	is	therefore	possible	that	AMPK	is	fully	phosphorylated	during	this	time	and	cannot	be	further	activated	by	low	ATP	levels.	
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Figure	4.6	Model	for	tissue-specific	adaptations	to	SDHA	deficiency	(A)	 In	 skeletal	muscles,	 loss	 of	 SDHA	 causes	ATP	 depletion	 and	AMPK	phosphorylation.	 Increased	AMPK	activity	triggers	NAD+	synthesis,	which	leads	to	higher	sirtuin	activity.	Finally,	sirtuins	activate	PGC1a,	 while	 suppressing	 HIF1a	 and	 c-MYC	 target	 gene	 expression.	 (B)	 Loss	 of	 SDHA	 in	cardiomyocytes	does	not	increase	AMPK	phosphorylation	and	therefore	does	not	change	NAD+	levels	or	 sirtuin	 activity.	 Consequently,	 HIF1a	 and	 c-MYC-mediated	 gene	 expression	 is	 not	 inhibited	 and	PGC1a-dependent	mitobiogenesis	 is	 not	 augmented.	 (More)	 active	proteins	 are	depicted	 in	 colour.	Less	active	or	repressed	proteins	are	shown	in	greyscale.			In	summary,	the	cellular	responses	towards	the	loss	of	SDHA	are	tissue-specific	and	possibly	 dependent	 on	 the	 metabolic	 circumstances.	 The	 example	 of	 heart	 and	skeletal	muscles	shows	that	the	alternative	regulation	of	one	pathway	could	already	be	sufficient	to	evoke	dramatic	differences	in	the	elicited	response.	The	extension	of	this	work	to	other	tissues	could	therefore	give	further	insights	into	which	metabolic	changes	drive	the	malignant	transformations	in	SDH-deficient	cells	and	why	these	are	more	prone	to	become	cancer	cells	than	others.		 	
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4.2 Proteomic	 approaches	 to	 identify	 novel	 ClpXP	 substrates	 in	
vitro	and	in	vivo		 Mitochondrial	 protein	 homeostasis	 is	 the	 balance	 between	 protein	 synthesis	and	 protein	 degradation	 due	 to	 malfunction	 or	 overabundance	 and	 plays	 an	important	 role	 in	 cell	 function	 and	 viability.	 Thus,	 perturbations	 in	 the	 protein	surveillance	 machinery	 can	 have	 far-reaching	 consequences	 for	 human	 patients.	Mutations	 in	mitochondrial	 proteases	 often	manifest	 in	multisystemic	 phenotypes	that	 include	neurodegeneration,	hearing	 loss	or	ataxia	and	the	 identification	of	 the	underlying	 mutations	 with	 deep	 sequencing	 methods	 has	 greatly	 increased	 the	understanding	of	the	proteostasis	network.	Besides	the	quality	control	function,	the	focus	has	largely	shifted	towards	regulatory	functions	of	mitochondrial	proteases	and	several	 in	 vivo	 substrates	 have	 been	 identified	 for	 each	 of	 the	 ATP-dependent	proteases.	The	abundance	of	 these	substrates	needs	careful	regulation	and	aberrations	of	 the	default	state	can	significantly	affect	mitochondrial	 function.	To	date,	only	 few	such	substrates	 have	 been	 described	 for	 the	 protease	 ClpXP	 and	 the	 data	 indicate	 that	ClpXP	has	adopted	functions	that	deviate	strongly	from	other	species	such	as	E.	coli	or	C.	 elegans	 (Seiferling	 et	 al.	 2016).	 The	 identification	 of	 its	 substrates	 and	 their	control	is	therefore	of	continued	relevance	and	was	the	second	aim	of	this	work.		
4.2.1 Identification	of	new	bona	fide	ClpXP	substrates			 Using	a	classical	substrate	screen	and	the	recently	developed	quantification	of	the	N-terminome	(TAILS),	several	proteins	could	be	proposed	and	partially	confirmed	as	 ClpXP	 substrates.	 These	 proteins	 exhibited	 increased	 abundance	 on	 two	independent	proteomic	quantification	methods	and	on	western	blots,	increasing	the	likelihood	of	true	positives.	This	approach	is	particularly	useful,	as	“omics”	generate	large	datasets	and	a	simple	FDR	cut-off	analysis	either	retains	many	false	positives	or	loses	 the	 power	 to	 detect	 true	 substrates	 with	 minor	 changes	 in	 abundance.	Particularly,	TAILS	was	a	useful	addition	for	the	previously	published	LFQ	data	set,	however,	although	the	quantification	of	labelled	peptides	is	very	reproducible,	it	has	a	smaller	range	of	identified	proteins	compared	to	label-free	quantification	methods.	HSPA9	 and	 OAT	 were	 identified	 with	 TAILS	 and	 confirmed	 with	 additional	experiments	 to	 be	 ClpXP	 substrates.	 Additionally,	 they	 were	 also	 previously	 co-
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purified	with	a	substrate	screen	using	a	human	CLPP-TRAP	construct	in	P.	anserina	(Fischer	et	al.	2015).	The	overlap	with	previously	suggested	substrates	proves	 the	eligibility	 of	 the	 approach	 and	 facilitates	 the	 identification	 of	 true	 substrates.	Furthermore,	TAILS	provided	 strong	evidence	 for	 a	ClpXP	cleavage	 signature	with	arginine	at	 the	P1	position.	This	 is	 the	 first	description	of	a	mouse	ClpXP	cleavage	window	that	might	stem	from	an	evolutionary	conserved	function,	as	B.	subtilis	ClpCP	was	reported	to	degrade	the	heat	shock	response	regulator	CtsR	with	phosphorylated	arginine	 (P-Arg)	 (Trentini	 et	 al.	 2016).	 The	 phosphorylation	 of	 arginine	 or	 a	corresponding	kinase	was	not	described	 in	 eukaryotes	 so	 far,	 thus	 a	physiological	function	for	P-Arg	mediated	degradation	by	ClpXP	is	largely	speculative	at	this	point.	Although	TAILS	 and	 similarly	 operating	 labelling	 techniques	 for	 protein	N-termini	have	been	primarily	used	for	the	description	of	degradation	intermediates	(Prudova	et	al.	2016,	King	et	al.	2018),	this	work	clearly	establishes	TAILS	as	a	powerful	tool	to	detect	protease	substrates	along	with	other	proteomic	approaches.	It	is	therefore	very	promising	to	perform	the	experiment	in	other	tissues	of	Clpp-/-	mice	to	identify	tissue-specific	 substrates	 and	 to	 verify	 whether	 the	 cleavage	 motif	 is	 conserved	 across	different	cell	types.	The	 initial	 substrate	 screen	 performed	 in	 MEFs	 provided	 a	 considerable	 list	 of	putative	 ClpXP	 substrates	 and	 interacting	 partners,	 however,	 no	 confidence	 level	could	be	addressed	to	these	candidates,	as	an	isolated	experiment	was	performed	at	the	time.	To	obtain	quantitative	data	with	a	substrate	trapping	screen,	the	experiment	was	 repeated	 in	 triplicates	 in	 MEFs.	 However,	 the	 experiment	 could	 only	 be	performed	using	cell	lysates	instead	of	mitochondrial	purifications.	This	allows	for	a	manageable	 size	 and	 expense	 of	 the	 experiment,	 but	 at	 the	 cost	 of	 “diluting”	 low	abundant	mitochondrial	proteins	with	contaminations	from	the	cytosol.	The	resulting	list	was	thus	a	subset	of	the	first	screen	with	no	additional	candidates,	but	included	14	proteins	that	can	be	suggested	as	ClpXP	substrates	with	high	confidence.	 	
	 	 4	Discussion	
		 	 	 87	
POLDIP2	was	highly	enriched	in	TRAP-fractions	and	recently	identified	as	a	ClpXP-interacting	 protein	 in	 a	 cross-linking	 pulldown.	 Independently,	 it	 was	 further	suggested	to	be	a	CLPX-interacting	protein	that	regulates	the	degradation	of	ACSM1	(Paredes	et	al.	2018,	Fux	et	al.	2019).	As	the	CLPP-CLPX	interaction	appeared	to	be	stabilised	with	CLPP-TRAP	proteins,	it	thus	also	inherently	favours	the	pulldown	of	CLPX-interacting	proteins,	which	would	be	classified	as	ClpXP	substrates	instead	of	protease	interactors.	Further	investigation	of	the	interaction	is	necessary	as	LFQ	data	indicated	a	strong	accumulation	of	POLDIP2	in	Clpp-/-	hearts,	which	was	not	reported	in	the	publication	that	used	Clpp	siRNA.	Another	protein	that	strongly	interacted	with	CLPP-TRAP	was	 Coiled-coil-helix-coiled-coil-helix	 domain	 containing	 2	 (CHCHD2).	CHCHD2	showed	a	two-fold	accumulation	in	Clpp-/-	heart	mitochondria	(LFQ)	and	was	reported	to	interact	with	the	ClpXP	interactor	C1QBP	(Wei	et	al.	2015).	This	report	strongly	 suggests	 a	 ClpXP-mediated	 regulation	 and	 highlights	 the	 protein	 as	 a	promising	 ClpXP	 substrate	 with	 potential	 medical	 implications,	 as	 CHCH	 protein	complexes	are	associated	with	the	development	of	neurodegenerative	disorders	such	as	Parkinson’s	disease	(Imai	et	al.	2019).	Other	enriched	proteins	include	subunits	of	the	mitoribosome	and	therefore	may	result	from	the	stabilised	interaction	between	CLPP-TRAP	and	the	mitoribosome,	which	are	not	necessarily	true	substrates.	Further,	several	 proteins	 are	 not	 localized	 to	 mitochondria	 and	 likely	 represent	 artefacts	arising	during	cell	 lysis.	However,	since	the	interaction	is	nevertheless	stabilised,	a	certain	affinity	for	CLPP-TRAP	can	be	cautiously	postulated	for	the	proteins.	These	proteins	are	 involved	 in	RNA	or	calcium	binding,	both	of	which	were	addressed	to	C1QBP	(Yagi	et	al.	2012,	Yagi	et	al.	2017).	Although	this	evidence	is	circumstantial,	it	can	nevertheless	be	useful	for	the	identification	of	ClpXP	substrates	in	the	future.		 	
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4.2.2 UQCRC1,	 a	 non-canonical	 ClpXP	 substrate	 under	 cooperative	
degradation	surveillance	In	addition	to	the	bona	fide	substrate	candidates,	the	trapping	screen	and	data	on	the	N-terminome	revealed	UQCRC1	as	a	substrate	for	ClpXP	with	unaltered	steady	state	protein	levels	in	the	absence	of	CLPP.	The	first	and	rate-limiting	step	of	UQCRC1	degradation	appears	 to	be	 conducted	by	another	protease,	with	LonP1	or	AFG3L2	being	the	most	likely	candidates.	However,	ClpXP	is	able	to	eliminate	the,	albeit	low	abundant,	truncated	UQCRC1	proteoform	(Figure	4.7).	Similar	mechanisms	have	been	described	in	chloroplasts	(Kato	et	al.	2012)	and	the	cytosol	(Jang	et	al.	2000)	and	are	possibly	 also	present	 in	mitochondria.	 The	 impact	 of	 this	 cooperative	degradation	cannot	be	finally	concluded	at	this	point;	however,	the	effect	might	be	exacerbated	under	stress	conditions,	when	the	proteolytic	system	is	used	to	full	capacity	or	even	overloaded	 by	 unfolded	 or	 damaged	 proteins.	 It	 therefore	 suggests	 the	 very	interesting	 possibility	 to	 investigate	 degradation	 intermediates	 in	 Clpp-/-	 under	varying	 conditions	with	TAILS,	 as	ClpXP	and	other	proteases	 can	 adopt	 additional	functions	 under	 stress	 conditions	 such	 as	 heat-	 and	 oxidative	 stress	 in	 bacteria	(Gottesman	 1996,	 Michel	 et	 al.	 2006),	 light	 stress	 in	 plants	 (Kato	 et	 al.	 2012)	 or	oxidative-	and	unfolded	protein	stress	in	mitochondria	(Ngo	et	al.	2013,	Al-Furoukh	et	al.	2015,	Bezawork-Geleta	et	al.	2015,	Pareek	and	Pallanck	2018).		
	
Figure	4.7	Model	for	cooperative	degradation	of	UQCRC1	UQCRC1	abundance	is	regulated	by	an	unknown	protease,	which	cleaves	a	part	of	the	protein	from	the	N-terminus.	 This	 results	 in	 a	 truncated	 UQCRC1	 protein,	 that	 exhibits	 a	 degron	 (star)	 for	 ClpXP-mediated	proteolysis.	Peptides	released	from	ClpXP	preferentially	show	arginine	(R)	at	the	P1	position.		 	
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4.2.3 Generation	 of	 mice	 conditionally	 expressing	 CLPP-FLAG	 for	 substrate	
identification	in	vivo		 To	 date,	 the	 role	 of	 CLPP	 was	 described	 in	 the	 heart,	 liver,	 adipose	 and	reproductive	 tissue	as	well	 as	 several	 cancer	 cell	 lines	with	partially	 contradicting	results	(Gispert	et	al.	2013,	Cole	et	al.	2015,	Seiferling	et	al.	2016,	Szczepanowska	et	al.	2016,	Becker	et	al.	2018,	Bhaskaran	et	al.	2018,	Ishizawa	et	al.	2019).	The	most	plausible	 explanations	 for	 these	 results	 are	 that	 ClpXP	 has	 diverse	 regulatory	substrates	in	these	tissues	or	that	substrate	abundance/importance	differs	between	cell	types.	Both	possibilities	result	in	severe	limitations	for	the	substrate	identification	approaches	used	here	and	by	others,	as	the	employed	species	and	cell	 type	will	be	restrictive	 and	 only	 partially	 transferable.	 To	 overcome	 this	 obstacle,	 mice	conditionally	expressing	CLPP-FLAG	from	the	ROSA26	 locus	were	generated	with	a	CRISPR/Cas9-mediated	 knockin	 strategy	 in	 zygotes.	 Compared	 to	 the	 classical	recombination	approach	in	ES	cells,	this	method	has	a	higher	success	rate	of	germ	line	transmission	within	a	drastically	reduced	time	frame.		The	first	mice	analysed	proved	a	successful	integration	of	the	construct	and	a	strong	expression	 of	 CLPP-FLAG	 in	 the	 heart.	 CLPP-FLAG	 is	 imported	 into	mitochondria,	where	it	forms	oligomeric	structures	as	is	was	observed	with	transient	expressions	in	MEFs.	With	these	prerequisites	met,	the	mouse	line	ought	to	be	suitable	for	large-scale	affinity	purifications	with	high	purity,	as	sufficient	mitochondrial	extracts	from	hearts	are	not	rate-limiting.	Although	catalytically	active	CLPP	is	technically	suitable	for	the	identification	 of	 ClpXP	 substrates,	 the	 generation	 of	 CLPP-TRAP-FLAG	 expressing	mice	would	 further	 increase	 the	 efficiency	 and	 enable	 the	discrimination	between	substrates	and	interacting	proteins.	However,	due	to	a	low	viability	of	transplanted	embryos,	 no	 CLPP-TRAP-FLAG	 expressing	 mice	 could	 be	 generated	 after	 three	injections.	 Nevertheless,	 an	 increased	 in	 vitro	 fertilization	 efficiency	 with	 e.g.	electroporation	of	the	repair	template	into	zygotes	might	further	enhance	the	chances	of	positive	integration	and	viability	in	the	near	future.	 	
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Despite	that	CLPP-FLAG	is	expressed	at	several	folds	of	the	endogenous	CLPP	levels,	no	 changes	 were	 observed	 in	 substrate	 abundance,	 indicating	 that	 in	 heart	mitochondria,	CLPX	or	other	(adaptor-)	proteins	are	rate	limiting	for	the	recognition	and/or	degradation	of	substrates	as	it	was	proposed	before	(Lowth	et	al.	2012).	This	can	 be	 of	 advantage	 for	 substrate	 screens,	 as	 no	 detrimental	 effects	 mitigate	 the	expression	 or	 viability,	 but	 inevitably,	 the	 mouse	 line	 cannot	 be	 used	 as	 a	physiological	“over-expressor”	model.	Unfortunately,	these	mice	could	not	be	further	used	for	substrate	screens	and	must	serve	as	a	proof	of	concept	for	the	time	being.	In	conclusion,	the	combination	of	a	substrate	screen,	TAILS	and	the	verification	with	CLPP-deficient	tissues	and	cells	has	 led	to	the	discovery	or	confirmation	of	several	novel	ClpXP	substrates	implicated	in	various	mitochondrial	processes.	In	addition,	a	putative	 cleavage	 motif	 for	 murine	 ClpXP	 and	 a	 new	 cooperative	 degradation	mechanism	were	proposed.	Finally,	the	development	of	a	mouse	model	suitable	for	in	
vivo	substrate	screens	could	extent	the	discovery	of	substrates	to	so	far	unamenable	tissues	 and	 surge	 the	 understanding	 of	 Perrault	 syndrome’s	 unusual	 tissue-specificity.	
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